,sentenceid,sentence_text,drug_pair,ddi_label,drug1,drug2
0,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p0,0,abacavir,lamivudine
1,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p1,0,abacavir,zidovudine
2,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p2,0,abacavir,lamivudine
3,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p3,0,abacavir,zidovudine
4,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p4,0,lamivudine,zidovudine
5,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p5,0,lamivudine,lamivudine
6,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p6,0,lamivudine,zidovudine
7,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p7,0,zidovudine,lamivudine
8,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p8,0,zidovudine,zidovudine
9,DDI-DrugBank.d610.s0,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,DDI-DrugBank.d610.s0.p9,0,lamivudine,zidovudine
10,DDI-DrugBank.d610.s1,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,DDI-DrugBank.d610.s1.p0,0,lamivudine,zidovudine
11,DDI-DrugBank.d610.s1,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,DDI-DrugBank.d610.s1.p1,0,lamivudine,abacavir
12,DDI-DrugBank.d610.s1,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,DDI-DrugBank.d610.s1.p2,0,zidovudine,abacavir
13,DDI-DrugBank.d610.s2,Abacavir has no effect on the pharmacokinetic properties of ethanol. ,DDI-DrugBank.d610.s2.p0,0,Abacavir,ethanol
14,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p0,2,Ethanol,abacavir
15,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p1,0,Ethanol,methadone
16,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p2,0,Ethanol,abacavir
17,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p3,0,abacavir,methadone
18,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p4,0,abacavir,abacavir
19,DDI-DrugBank.d610.s3,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,DDI-DrugBank.d610.s3.p5,0,methadone,abacavir
20,DDI-DrugBank.d610.s4,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",DDI-DrugBank.d610.s4.p0,2,methadone,ZIAGEN
21,DDI-DrugBank.d610.s4,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",DDI-DrugBank.d610.s4.p1,0,methadone,methadone
22,DDI-DrugBank.d610.s4,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",DDI-DrugBank.d610.s4.p2,0,ZIAGEN,methadone
0,DDI-DrugBank.d572.s0,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,DDI-DrugBank.d572.s0.p0,0,Cholestyramine,cholestyramine
1,DDI-DrugBank.d572.s0,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,DDI-DrugBank.d572.s0.p1,0,Cholestyramine,ezetimibe
2,DDI-DrugBank.d572.s0,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,DDI-DrugBank.d572.s0.p2,2,cholestyramine,ezetimibe
3,DDI-DrugBank.d572.s1,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,DDI-DrugBank.d572.s1.p0,3,ezetimibe,cholestyramine
4,DDI-DrugBank.d572.s2,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,DDI-DrugBank.d572.s2.p0,0,Fibrates,ezetimibe
5,DDI-DrugBank.d572.s2,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,DDI-DrugBank.d572.s2.p1,0,Fibrates,fibrates
6,DDI-DrugBank.d572.s2,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,DDI-DrugBank.d572.s2.p2,0,ezetimibe,fibrates
7,DDI-DrugBank.d572.s5,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,DDI-DrugBank.d572.s5.p0,1,ZETIA,fibrates
8,DDI-DrugBank.d572.s6,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",DDI-DrugBank.d572.s6.p0,0,Fenofibrate,fenofibrate
9,DDI-DrugBank.d572.s6,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",DDI-DrugBank.d572.s6.p1,0,Fenofibrate,ezetimibe
10,DDI-DrugBank.d572.s6,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",DDI-DrugBank.d572.s6.p2,2,fenofibrate,ezetimibe
11,DDI-DrugBank.d572.s7,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",DDI-DrugBank.d572.s7.p0,0,Gemfibrozil,gemfibrozil
12,DDI-DrugBank.d572.s7,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",DDI-DrugBank.d572.s7.p1,0,Gemfibrozil,ezetimibe
13,DDI-DrugBank.d572.s7,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",DDI-DrugBank.d572.s7.p2,0,gemfibrozil,ezetimibe
14,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p0,0,HMG-CoA reductase inhibitors,ezetimibe
15,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p1,0,HMG-CoA reductase inhibitors,atorvastatin
16,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p2,0,HMG-CoA reductase inhibitors,simvastatin
17,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p3,0,HMG-CoA reductase inhibitors,pravastatin
18,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p4,0,HMG-CoA reductase inhibitors,lovastatin
19,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p5,0,HMG-CoA reductase inhibitors,fluvastatin
20,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p6,0,ezetimibe,atorvastatin
21,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p7,0,ezetimibe,simvastatin
22,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p8,0,ezetimibe,pravastatin
23,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p9,0,ezetimibe,lovastatin
24,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p10,0,ezetimibe,fluvastatin
25,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p11,0,atorvastatin,simvastatin
26,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p12,0,atorvastatin,pravastatin
27,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p13,0,atorvastatin,lovastatin
28,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p14,0,atorvastatin,fluvastatin
29,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p15,0,simvastatin,pravastatin
30,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p16,0,simvastatin,lovastatin
31,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p17,0,simvastatin,fluvastatin
32,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p18,0,pravastatin,lovastatin
33,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p19,0,pravastatin,fluvastatin
34,DDI-DrugBank.d572.s8,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",DDI-DrugBank.d572.s8.p20,0,lovastatin,fluvastatin
35,DDI-DrugBank.d572.s9,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",DDI-DrugBank.d572.s9.p0,0,Cyclosporine,ezetimibe
36,DDI-DrugBank.d572.s9,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",DDI-DrugBank.d572.s9.p1,0,Cyclosporine,cyclosporine
37,DDI-DrugBank.d572.s9,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",DDI-DrugBank.d572.s9.p2,2,ezetimibe,cyclosporine
38,DDI-DrugBank.d572.s10,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,DDI-DrugBank.d572.s10.p0,1,ezetimibe,cyclosporine
39,DDI-DrugBank.d572.s11,"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",DDI-DrugBank.d572.s11.p0,0,ezetimibe,ezetimibe
40,DDI-DrugBank.d572.s12,A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ,DDI-DrugBank.d572.s12.p0,0,ezetimibe,ezetimibe
41,DDI-DrugBank.d572.s17,"In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",DDI-DrugBank.d572.s17.p0,0,ezetimibe,ezetimibe
42,DDI-DrugBank.d572.s22,"In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",DDI-DrugBank.d572.s22.p0,0,ezetimibe,ezetimibe
43,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p0,0,ezetimibe,HMG-CoA reductase inhibitors
44,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p1,0,ezetimibe,statins
45,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p2,0,ezetimibe,ezetimibe
46,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p3,0,HMG-CoA reductase inhibitors,statins
47,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p4,0,HMG-CoA reductase inhibitors,ezetimibe
48,DDI-DrugBank.d572.s24,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,DDI-DrugBank.d572.s24.p5,0,statins,ezetimibe
49,DDI-DrugBank.d572.s27,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",DDI-DrugBank.d572.s27.p0,0,ZETIA,HMG-CoA reductase inhibitor
50,DDI-DrugBank.d572.s27,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",DDI-DrugBank.d572.s27.p1,0,ZETIA,HMG-CoA reductase inhibitor
51,DDI-DrugBank.d572.s27,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",DDI-DrugBank.d572.s27.p2,0,HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor
0,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p0,0,hypoglycemics,Coumarin-type anticoagulants
1,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p1,0,hypoglycemics,Phenytoin
2,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p2,0,hypoglycemics,Cyclosporine
3,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p3,0,hypoglycemics,Rifampin
4,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p4,0,hypoglycemics,Theophylline
5,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p5,0,hypoglycemics,Terfenadine
6,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p6,0,hypoglycemics,Cisapride
7,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p7,0,hypoglycemics,Astemizole
8,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p8,0,hypoglycemics,Rifabutin
9,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p9,0,hypoglycemics,Tacrolimus
10,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p10,0,hypoglycemics,Short-acting benzodiazepines
11,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p11,0,hypoglycemics,hypoglycemics
12,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p12,0,hypoglycemics,DIFLUCAN
13,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p13,0,hypoglycemics,hypoglycemic agents
14,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p14,0,Coumarin-type anticoagulants,Phenytoin
15,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p15,0,Coumarin-type anticoagulants,Cyclosporine
16,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p16,0,Coumarin-type anticoagulants,Rifampin
17,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p17,0,Coumarin-type anticoagulants,Theophylline
18,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p18,0,Coumarin-type anticoagulants,Terfenadine
19,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p19,0,Coumarin-type anticoagulants,Cisapride
20,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p20,0,Coumarin-type anticoagulants,Astemizole
21,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p21,0,Coumarin-type anticoagulants,Rifabutin
22,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p22,0,Coumarin-type anticoagulants,Tacrolimus
23,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p23,0,Coumarin-type anticoagulants,Short-acting benzodiazepines
24,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p24,0,Coumarin-type anticoagulants,hypoglycemics
25,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p25,0,Coumarin-type anticoagulants,DIFLUCAN
26,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p26,0,Coumarin-type anticoagulants,hypoglycemic agents
27,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p27,0,Phenytoin,Cyclosporine
28,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p28,0,Phenytoin,Rifampin
29,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p29,0,Phenytoin,Theophylline
30,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p30,0,Phenytoin,Terfenadine
31,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p31,0,Phenytoin,Cisapride
32,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p32,0,Phenytoin,Astemizole
33,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p33,0,Phenytoin,Rifabutin
34,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p34,0,Phenytoin,Tacrolimus
35,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p35,0,Phenytoin,Short-acting benzodiazepines
36,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p36,0,Phenytoin,hypoglycemics
37,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p37,0,Phenytoin,DIFLUCAN
38,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p38,0,Phenytoin,hypoglycemic agents
39,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p39,0,Cyclosporine,Rifampin
40,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p40,0,Cyclosporine,Theophylline
41,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p41,0,Cyclosporine,Terfenadine
42,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p42,0,Cyclosporine,Cisapride
43,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p43,0,Cyclosporine,Astemizole
44,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p44,0,Cyclosporine,Rifabutin
45,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p45,0,Cyclosporine,Tacrolimus
46,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p46,0,Cyclosporine,Short-acting benzodiazepines
47,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p47,0,Cyclosporine,hypoglycemics
48,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p48,0,Cyclosporine,DIFLUCAN
49,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p49,0,Cyclosporine,hypoglycemic agents
50,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p50,0,Rifampin,Theophylline
51,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p51,0,Rifampin,Terfenadine
52,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p52,0,Rifampin,Cisapride
53,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p53,0,Rifampin,Astemizole
54,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p54,0,Rifampin,Rifabutin
55,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p55,0,Rifampin,Tacrolimus
56,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p56,0,Rifampin,Short-acting benzodiazepines
57,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p57,0,Rifampin,hypoglycemics
58,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p58,0,Rifampin,DIFLUCAN
59,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p59,0,Rifampin,hypoglycemic agents
60,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p60,0,Theophylline,Terfenadine
61,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p61,0,Theophylline,Cisapride
62,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p62,0,Theophylline,Astemizole
63,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p63,0,Theophylline,Rifabutin
64,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p64,0,Theophylline,Tacrolimus
65,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p65,0,Theophylline,Short-acting benzodiazepines
66,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p66,0,Theophylline,hypoglycemics
67,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p67,0,Theophylline,DIFLUCAN
68,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p68,0,Theophylline,hypoglycemic agents
69,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p69,0,Terfenadine,Cisapride
70,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p70,0,Terfenadine,Astemizole
71,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p71,0,Terfenadine,Rifabutin
72,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p72,0,Terfenadine,Tacrolimus
73,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p73,0,Terfenadine,Short-acting benzodiazepines
74,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p74,0,Terfenadine,hypoglycemics
75,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p75,0,Terfenadine,DIFLUCAN
76,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p76,0,Terfenadine,hypoglycemic agents
77,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p77,0,Cisapride,Astemizole
78,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p78,0,Cisapride,Rifabutin
79,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p79,0,Cisapride,Tacrolimus
80,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p80,0,Cisapride,Short-acting benzodiazepines
81,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p81,0,Cisapride,hypoglycemics
82,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p82,0,Cisapride,DIFLUCAN
83,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p83,0,Cisapride,hypoglycemic agents
84,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p84,0,Astemizole,Rifabutin
85,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p85,0,Astemizole,Tacrolimus
86,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p86,0,Astemizole,Short-acting benzodiazepines
87,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p87,0,Astemizole,hypoglycemics
88,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p88,0,Astemizole,DIFLUCAN
89,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p89,0,Astemizole,hypoglycemic agents
90,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p90,0,Rifabutin,Tacrolimus
91,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p91,0,Rifabutin,Short-acting benzodiazepines
92,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p92,0,Rifabutin,hypoglycemics
93,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p93,0,Rifabutin,DIFLUCAN
94,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p94,0,Rifabutin,hypoglycemic agents
95,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p95,0,Tacrolimus,Short-acting benzodiazepines
96,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p96,0,Tacrolimus,hypoglycemics
97,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p97,0,Tacrolimus,DIFLUCAN
98,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p98,0,Tacrolimus,hypoglycemic agents
99,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p99,0,Short-acting benzodiazepines,hypoglycemics
100,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p100,0,Short-acting benzodiazepines,DIFLUCAN
101,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p101,0,Short-acting benzodiazepines,hypoglycemic agents
102,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p102,0,hypoglycemics,DIFLUCAN
103,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p103,0,hypoglycemics,hypoglycemic agents
104,DDI-DrugBank.d776.s2,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",DDI-DrugBank.d776.s2.p104,3,DIFLUCAN,hypoglycemic agents
105,DDI-DrugBank.d776.s3,one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. ,DDI-DrugBank.d776.s3.p0,3,DIFLUCAN,glyburide
106,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p0,2,DIFLUCAN,tolbutamide
107,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p1,2,DIFLUCAN,glyburide
108,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p2,2,DIFLUCAN,glipizide
109,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p3,0,tolbutamide,glyburide
110,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p4,0,tolbutamide,glipizide
111,DDI-DrugBank.d776.s4,"DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ",DDI-DrugBank.d776.s4.p5,0,glyburide,glipizide
112,DDI-DrugBank.d776.s5,"When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ",DDI-DrugBank.d776.s5.p0,1,DIFLUCAN,sulfonylurea oral hypoglycemic agents
113,DDI-DrugBank.d776.s5,"When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ",DDI-DrugBank.d776.s5.p1,0,DIFLUCAN,sulfonylurea
114,DDI-DrugBank.d776.s5,"When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ",DDI-DrugBank.d776.s5.p2,0,sulfonylurea oral hypoglycemic agents,sulfonylurea
115,DDI-DrugBank.d776.s6,Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. ,DDI-DrugBank.d776.s6.p0,0,Coumarin-type anticoagulants,DIFLUCAN
116,DDI-DrugBank.d776.s6,Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. ,DDI-DrugBank.d776.s6.p1,0,Coumarin-type anticoagulants,coumarin-type anticoagulants
117,DDI-DrugBank.d776.s6,Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. ,DDI-DrugBank.d776.s6.p2,3,DIFLUCAN,coumarin-type anticoagulants
118,DDI-DrugBank.d776.s7,"In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. ",DDI-DrugBank.d776.s7.p0,0,azole antifungals,fluconazole
119,DDI-DrugBank.d776.s7,"In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. ",DDI-DrugBank.d776.s7.p1,0,azole antifungals,warfarin
120,DDI-DrugBank.d776.s7,"In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. ",DDI-DrugBank.d776.s7.p2,3,fluconazole,warfarin
121,DDI-DrugBank.d776.s8,Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. ,DDI-DrugBank.d776.s8.p0,1,DIFLUCAN,coumarin-type anticoagulants
122,DDI-DrugBank.d776.s10,Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. ,DDI-DrugBank.d776.s10.p0,0,Phenytoin,DIFLUCAN
123,DDI-DrugBank.d776.s10,Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. ,DDI-DrugBank.d776.s10.p1,0,Phenytoin,phenytoin
124,DDI-DrugBank.d776.s10,Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. ,DDI-DrugBank.d776.s10.p2,2,DIFLUCAN,phenytoin
125,DDI-DrugBank.d776.s11,Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ,DDI-DrugBank.d776.s11.p0,0,phenytoin,DIFLUCAN
126,DDI-DrugBank.d776.s11,Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ,DDI-DrugBank.d776.s11.p1,0,phenytoin,phenytoin
127,DDI-DrugBank.d776.s11,Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ,DDI-DrugBank.d776.s11.p2,1,DIFLUCAN,phenytoin
128,DDI-DrugBank.d776.s13,Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ,DDI-DrugBank.d776.s13.p0,0,Cyclosporine,DIFLUCAN
129,DDI-DrugBank.d776.s13,Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ,DDI-DrugBank.d776.s13.p1,0,Cyclosporine,cyclosporine
130,DDI-DrugBank.d776.s13,Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ,DDI-DrugBank.d776.s13.p2,2,DIFLUCAN,cyclosporine
131,DDI-DrugBank.d776.s14,Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ,DDI-DrugBank.d776.s14.p0,0,cyclosporine,DIFLUCAN
132,DDI-DrugBank.d776.s14,Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ,DDI-DrugBank.d776.s14.p1,0,cyclosporine,cyclosporine
133,DDI-DrugBank.d776.s14,Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ,DDI-DrugBank.d776.s14.p2,1,DIFLUCAN,cyclosporine
134,DDI-DrugBank.d776.s16,Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ,DDI-DrugBank.d776.s16.p0,0,Rifampin,Rifampin
135,DDI-DrugBank.d776.s16,Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ,DDI-DrugBank.d776.s16.p1,0,Rifampin,DIFLUCAN
136,DDI-DrugBank.d776.s16,Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ,DDI-DrugBank.d776.s16.p2,2,Rifampin,DIFLUCAN
137,DDI-DrugBank.d776.s17,"Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. ",DDI-DrugBank.d776.s17.p0,1,DIFLUCAN,rifampin
138,DDI-DrugBank.d776.s18,Theophylline: DIFLUCAN increases the serum concentrations of theophylline. ,DDI-DrugBank.d776.s18.p0,0,Theophylline,DIFLUCAN
139,DDI-DrugBank.d776.s18,Theophylline: DIFLUCAN increases the serum concentrations of theophylline. ,DDI-DrugBank.d776.s18.p1,0,Theophylline,theophylline
140,DDI-DrugBank.d776.s18,Theophylline: DIFLUCAN increases the serum concentrations of theophylline. ,DDI-DrugBank.d776.s18.p2,2,DIFLUCAN,theophylline
141,DDI-DrugBank.d776.s19,Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ,DDI-DrugBank.d776.s19.p0,0,theophylline,DIFLUCAN
142,DDI-DrugBank.d776.s19,Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ,DDI-DrugBank.d776.s19.p1,0,theophylline,theophylline
143,DDI-DrugBank.d776.s19,Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ,DDI-DrugBank.d776.s19.p2,1,DIFLUCAN,theophylline
144,DDI-DrugBank.d776.s20,"Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. ",DDI-DrugBank.d776.s20.p0,0,Terfenadine,azole antifungals
145,DDI-DrugBank.d776.s20,"Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. ",DDI-DrugBank.d776.s20.p1,0,Terfenadine,terfenadine
146,DDI-DrugBank.d776.s20,"Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. ",DDI-DrugBank.d776.s20.p2,3,azole antifungals,terfenadine
147,DDI-DrugBank.d776.s22,Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ,DDI-DrugBank.d776.s22.p0,0,fluconazole,DIFLUCAN
148,DDI-DrugBank.d776.s22,Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ,DDI-DrugBank.d776.s22.p1,0,fluconazole,terfenadine
149,DDI-DrugBank.d776.s22,Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ,DDI-DrugBank.d776.s22.p2,2,DIFLUCAN,terfenadine
150,DDI-DrugBank.d776.s23,The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. ,DDI-DrugBank.d776.s23.p0,1,fluconazole,terfenadine
151,DDI-DrugBank.d776.s24,The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. ,DDI-DrugBank.d776.s24.p0,1,fluconazole,terfenadine
152,DDI-DrugBank.d776.s25,"Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. ",DDI-DrugBank.d776.s25.p0,0,Cisapride,fluconazole
153,DDI-DrugBank.d776.s25,"Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. ",DDI-DrugBank.d776.s25.p1,0,Cisapride,cisapride
154,DDI-DrugBank.d776.s25,"Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. ",DDI-DrugBank.d776.s25.p2,3,fluconazole,cisapride
155,DDI-DrugBank.d776.s26,A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.,DDI-DrugBank.d776.s26.p0,2,fluconazole,cisapride
156,DDI-DrugBank.d776.s26,A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.,DDI-DrugBank.d776.s26.p1,0,fluconazole,cisapride
157,DDI-DrugBank.d776.s26,A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.,DDI-DrugBank.d776.s26.p2,0,cisapride,cisapride
158,DDI-DrugBank.d776.s27,The combined use of fluconazole with cisapride is contraindicated. ,DDI-DrugBank.d776.s27.p0,1,fluconazole,cisapride
159,DDI-DrugBank.d776.s28,Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,DDI-DrugBank.d776.s28.p0,0,Astemizole,fluconazole
160,DDI-DrugBank.d776.s28,Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,DDI-DrugBank.d776.s28.p1,0,Astemizole,astemizole
161,DDI-DrugBank.d776.s28,Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,DDI-DrugBank.d776.s28.p2,2,fluconazole,astemizole
162,DDI-DrugBank.d776.s31,Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ,DDI-DrugBank.d776.s31.p0,0,Rifabutin,fluconazole
163,DDI-DrugBank.d776.s31,Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ,DDI-DrugBank.d776.s31.p1,0,Rifabutin,rifabutin
164,DDI-DrugBank.d776.s31,Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ,DDI-DrugBank.d776.s31.p2,3,fluconazole,rifabutin
165,DDI-DrugBank.d776.s32,Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. ,DDI-DrugBank.d776.s32.p0,1,rifabutin,fluconazole
166,DDI-DrugBank.d776.s33,Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. ,DDI-DrugBank.d776.s33.p0,0,Tacrolimus,fluconazole
167,DDI-DrugBank.d776.s33,Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. ,DDI-DrugBank.d776.s33.p1,0,Tacrolimus,tacrolimus
168,DDI-DrugBank.d776.s33,Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. ,DDI-DrugBank.d776.s33.p2,3,fluconazole,tacrolimus
169,DDI-DrugBank.d776.s34,Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. ,DDI-DrugBank.d776.s34.p0,1,tacrolimus,fluconazole
170,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p0,0,Short-acting Benzodiazepines,midazolam
171,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p1,0,Short-acting Benzodiazepines,fluconazole
172,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p2,0,Short-acting Benzodiazepines,midazolam
173,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p3,2,midazolam,fluconazole
174,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p4,0,midazolam,midazolam
175,DDI-DrugBank.d776.s35,"Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",DDI-DrugBank.d776.s35.p5,0,fluconazole,midazolam
176,DDI-DrugBank.d776.s36,This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ,DDI-DrugBank.d776.s36.p0,3,midazolam,fluconazole
177,DDI-DrugBank.d776.s36,This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ,DDI-DrugBank.d776.s36.p1,0,midazolam,fluconazole
178,DDI-DrugBank.d776.s36,This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ,DDI-DrugBank.d776.s36.p2,0,fluconazole,fluconazole
179,DDI-DrugBank.d776.s37,"If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ",DDI-DrugBank.d776.s37.p0,1,short-acting benzodiazepines,fluconazole
180,DDI-DrugBank.d776.s37,"If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ",DDI-DrugBank.d776.s37.p1,0,short-acting benzodiazepines,benzodiazepine
181,DDI-DrugBank.d776.s37,"If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ",DDI-DrugBank.d776.s37.p2,0,fluconazole,benzodiazepine
182,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p0,2,Fluconazole,ethinyl estradiol
183,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p1,2,Fluconazole,levonorgestrel
184,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p2,0,Fluconazole,contraceptives
185,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p3,0,Fluconazole,ethinyl estradiol
186,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p4,0,Fluconazole,levonorgestrel
187,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p5,0,ethinyl estradiol,levonorgestrel
188,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p6,0,ethinyl estradiol,contraceptives
189,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p7,0,ethinyl estradiol,ethinyl estradiol
190,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p8,0,ethinyl estradiol,levonorgestrel
191,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p9,0,levonorgestrel,contraceptives
192,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p10,0,levonorgestrel,ethinyl estradiol
193,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p11,0,levonorgestrel,levonorgestrel
194,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p12,0,contraceptives,ethinyl estradiol
195,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p13,0,contraceptives,levonorgestrel
196,DDI-DrugBank.d776.s38,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,DDI-DrugBank.d776.s38.p14,0,ethinyl estradiol,levonorgestrel
197,DDI-DrugBank.d776.s39,"however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. ",DDI-DrugBank.d776.s39.p0,0,ethinyl estradiol,levonorgestrel
198,DDI-DrugBank.d776.s40,The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ,DDI-DrugBank.d776.s40.p0,0,ethinyl estradiol,levonorgestrel
199,DDI-DrugBank.d776.s40,The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ,DDI-DrugBank.d776.s40.p1,0,ethinyl estradiol,fluconazole
200,DDI-DrugBank.d776.s40,The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ,DDI-DrugBank.d776.s40.p2,0,levonorgestrel,fluconazole
201,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p0,2,fluconazole,ethinyl estradiol
202,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p1,2,fluconazole,levonorgestrel
203,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p2,0,fluconazole,fluconazole
204,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p3,0,fluconazole,ethinyl estradiol
205,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p4,0,fluconazole,levonorgestrel
206,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p5,0,ethinyl estradiol,levonorgestrel
207,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p6,0,ethinyl estradiol,fluconazole
208,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p7,0,ethinyl estradiol,ethinyl estradiol
209,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p8,0,ethinyl estradiol,levonorgestrel
210,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p9,0,levonorgestrel,fluconazole
211,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p10,0,levonorgestrel,ethinyl estradiol
212,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p11,0,levonorgestrel,levonorgestrel
213,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p12,0,fluconazole,ethinyl estradiol
214,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p13,0,fluconazole,levonorgestrel
215,DDI-DrugBank.d776.s41,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",DDI-DrugBank.d776.s41.p14,0,ethinyl estradiol,levonorgestrel
0,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p0,1,mazindol,monoamine oxidase inhibitor
1,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p1,1,mazindol,MAOI
2,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p2,1,mazindol,isocarboxazid
3,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p3,1,mazindol,Marplan
4,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p4,1,mazindol,tranylcypromine
5,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p5,1,mazindol,Parnate
6,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p6,1,mazindol,phenelzine
7,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p7,1,mazindol,Nardil
8,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p8,0,monoamine oxidase inhibitor,MAOI
9,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p9,0,monoamine oxidase inhibitor,isocarboxazid
10,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p10,0,monoamine oxidase inhibitor,Marplan
11,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p11,0,monoamine oxidase inhibitor,tranylcypromine
12,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p12,0,monoamine oxidase inhibitor,Parnate
13,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p13,0,monoamine oxidase inhibitor,phenelzine
14,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p14,0,monoamine oxidase inhibitor,Nardil
15,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p15,0,MAOI,isocarboxazid
16,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p16,0,MAOI,Marplan
17,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p17,0,MAOI,tranylcypromine
18,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p18,0,MAOI,Parnate
19,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p19,0,MAOI,phenelzine
20,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p20,0,MAOI,Nardil
21,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p21,0,isocarboxazid,Marplan
22,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p22,0,isocarboxazid,tranylcypromine
23,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p23,0,isocarboxazid,Parnate
24,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p24,0,isocarboxazid,phenelzine
25,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p25,0,isocarboxazid,Nardil
26,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p26,0,Marplan,tranylcypromine
27,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p27,0,Marplan,Parnate
28,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p28,0,Marplan,phenelzine
29,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p29,0,Marplan,Nardil
30,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p30,0,tranylcypromine,Parnate
31,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p31,0,tranylcypromine,phenelzine
32,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p32,0,tranylcypromine,Nardil
33,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p33,0,Parnate,phenelzine
34,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p34,0,Parnate,Nardil
35,DDI-DrugBank.d716.s0,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",DDI-DrugBank.d716.s0.p35,0,phenelzine,Nardil
36,DDI-DrugBank.d716.s1,Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.,DDI-DrugBank.d716.s1.p0,1,insulin,mazindol
37,DDI-DrugBank.d716.s2,Mazindol may reduce the effects of guanethidine (Ismelin). ,DDI-DrugBank.d716.s2.p0,3,Mazindol,guanethidine
38,DDI-DrugBank.d716.s2,Mazindol may reduce the effects of guanethidine (Ismelin). ,DDI-DrugBank.d716.s2.p1,3,Mazindol,Ismelin
39,DDI-DrugBank.d716.s2,Mazindol may reduce the effects of guanethidine (Ismelin). ,DDI-DrugBank.d716.s2.p2,0,guanethidine,Ismelin
40,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p0,0,tricyclic antidepressant,amitriptyline
41,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p1,0,tricyclic antidepressant,Elavil
42,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p2,0,tricyclic antidepressant,amoxapine
43,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p3,0,tricyclic antidepressant,Asendin
44,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p4,0,tricyclic antidepressant,doxepin
45,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p5,0,tricyclic antidepressant,Sinequan
46,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p6,0,tricyclic antidepressant,nortriptyline
47,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p7,0,tricyclic antidepressant,Pamelor
48,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p8,0,tricyclic antidepressant,imipramine
49,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p9,0,tricyclic antidepressant,Tofranil
50,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p10,0,tricyclic antidepressant,clomipramine
51,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p11,0,tricyclic antidepressant,Anafranil
52,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p12,0,tricyclic antidepressant,protriptyline
53,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p13,0,tricyclic antidepressant,Vivactil
54,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p14,0,tricyclic antidepressant,desipramine
55,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p15,0,tricyclic antidepressant,Norpramin
56,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p16,0,amitriptyline,Elavil
57,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p17,0,amitriptyline,amoxapine
58,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p18,0,amitriptyline,Asendin
59,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p19,0,amitriptyline,doxepin
60,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p20,0,amitriptyline,Sinequan
61,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p21,0,amitriptyline,nortriptyline
62,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p22,0,amitriptyline,Pamelor
63,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p23,0,amitriptyline,imipramine
64,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p24,0,amitriptyline,Tofranil
65,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p25,0,amitriptyline,clomipramine
66,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p26,0,amitriptyline,Anafranil
67,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p27,0,amitriptyline,protriptyline
68,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p28,0,amitriptyline,Vivactil
69,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p29,0,amitriptyline,desipramine
70,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p30,0,amitriptyline,Norpramin
71,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p31,0,Elavil,amoxapine
72,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p32,0,Elavil,Asendin
73,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p33,0,Elavil,doxepin
74,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p34,0,Elavil,Sinequan
75,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p35,0,Elavil,nortriptyline
76,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p36,0,Elavil,Pamelor
77,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p37,0,Elavil,imipramine
78,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p38,0,Elavil,Tofranil
79,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p39,0,Elavil,clomipramine
80,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p40,0,Elavil,Anafranil
81,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p41,0,Elavil,protriptyline
82,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p42,0,Elavil,Vivactil
83,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p43,0,Elavil,desipramine
84,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p44,0,Elavil,Norpramin
85,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p45,0,amoxapine,Asendin
86,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p46,0,amoxapine,doxepin
87,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p47,0,amoxapine,Sinequan
88,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p48,0,amoxapine,nortriptyline
89,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p49,0,amoxapine,Pamelor
90,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p50,0,amoxapine,imipramine
91,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p51,0,amoxapine,Tofranil
92,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p52,0,amoxapine,clomipramine
93,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p53,0,amoxapine,Anafranil
94,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p54,0,amoxapine,protriptyline
95,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p55,0,amoxapine,Vivactil
96,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p56,0,amoxapine,desipramine
97,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p57,0,amoxapine,Norpramin
98,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p58,0,Asendin,doxepin
99,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p59,0,Asendin,Sinequan
100,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p60,0,Asendin,nortriptyline
101,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p61,0,Asendin,Pamelor
102,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p62,0,Asendin,imipramine
103,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p63,0,Asendin,Tofranil
104,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p64,0,Asendin,clomipramine
105,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p65,0,Asendin,Anafranil
106,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p66,0,Asendin,protriptyline
107,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p67,0,Asendin,Vivactil
108,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p68,0,Asendin,desipramine
109,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p69,0,Asendin,Norpramin
110,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p70,0,doxepin,Sinequan
111,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p71,0,doxepin,nortriptyline
112,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p72,0,doxepin,Pamelor
113,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p73,0,doxepin,imipramine
114,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p74,0,doxepin,Tofranil
115,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p75,0,doxepin,clomipramine
116,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p76,0,doxepin,Anafranil
117,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p77,0,doxepin,protriptyline
118,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p78,0,doxepin,Vivactil
119,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p79,0,doxepin,desipramine
120,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p80,0,doxepin,Norpramin
121,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p81,0,Sinequan,nortriptyline
122,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p82,0,Sinequan,Pamelor
123,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p83,0,Sinequan,imipramine
124,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p84,0,Sinequan,Tofranil
125,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p85,0,Sinequan,clomipramine
126,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p86,0,Sinequan,Anafranil
127,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p87,0,Sinequan,protriptyline
128,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p88,0,Sinequan,Vivactil
129,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p89,0,Sinequan,desipramine
130,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p90,0,Sinequan,Norpramin
131,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p91,0,nortriptyline,Pamelor
132,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p92,0,nortriptyline,imipramine
133,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p93,0,nortriptyline,Tofranil
134,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p94,0,nortriptyline,clomipramine
135,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p95,0,nortriptyline,Anafranil
136,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p96,0,nortriptyline,protriptyline
137,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p97,0,nortriptyline,Vivactil
138,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p98,0,nortriptyline,desipramine
139,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p99,0,nortriptyline,Norpramin
140,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p100,0,Pamelor,imipramine
141,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p101,0,Pamelor,Tofranil
142,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p102,0,Pamelor,clomipramine
143,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p103,0,Pamelor,Anafranil
144,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p104,0,Pamelor,protriptyline
145,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p105,0,Pamelor,Vivactil
146,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p106,0,Pamelor,desipramine
147,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p107,0,Pamelor,Norpramin
148,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p108,0,imipramine,Tofranil
149,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p109,0,imipramine,clomipramine
150,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p110,0,imipramine,Anafranil
151,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p111,0,imipramine,protriptyline
152,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p112,0,imipramine,Vivactil
153,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p113,0,imipramine,desipramine
154,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p114,0,imipramine,Norpramin
155,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p115,0,Tofranil,clomipramine
156,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p116,0,Tofranil,Anafranil
157,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p117,0,Tofranil,protriptyline
158,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p118,0,Tofranil,Vivactil
159,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p119,0,Tofranil,desipramine
160,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p120,0,Tofranil,Norpramin
161,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p121,0,clomipramine,Anafranil
162,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p122,0,clomipramine,protriptyline
163,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p123,0,clomipramine,Vivactil
164,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p124,0,clomipramine,desipramine
165,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p125,0,clomipramine,Norpramin
166,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p126,0,Anafranil,protriptyline
167,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p127,0,Anafranil,Vivactil
168,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p128,0,Anafranil,desipramine
169,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p129,0,Anafranil,Norpramin
170,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p130,0,protriptyline,Vivactil
171,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p131,0,protriptyline,desipramine
172,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p132,0,protriptyline,Norpramin
173,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p133,0,Vivactil,desipramine
174,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p134,0,Vivactil,Norpramin
175,DDI-DrugBank.d716.s5,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",DDI-DrugBank.d716.s5.p135,0,desipramine,Norpramin
0,DDI-DrugBank.d679.s0,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,DDI-DrugBank.d679.s0.p0,2,cimetidine,mebendazole
1,DDI-DrugBank.d679.s0,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,DDI-DrugBank.d679.s0.p1,0,cimetidine,mebendazole
2,DDI-DrugBank.d679.s0,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,DDI-DrugBank.d679.s0.p2,0,mebendazole,mebendazole
0,DDI-DrugBank.d579.s0,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,DDI-DrugBank.d579.s0.p0,0,antibiotics,sulfonamides
1,DDI-DrugBank.d579.s0,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,DDI-DrugBank.d579.s0.p1,1,antibiotics,ganglion blockers
2,DDI-DrugBank.d579.s0,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,DDI-DrugBank.d579.s0.p2,1,sulfonamides,ganglion blockers
3,DDI-DrugBank.d579.s1,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",DDI-DrugBank.d579.s1.p0,3,Mecamylamine,antihypertensive drugs
4,DDI-DrugBank.d579.s1,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",DDI-DrugBank.d579.s1.p1,3,Mecamylamine,alcohol
5,DDI-DrugBank.d579.s1,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",DDI-DrugBank.d579.s1.p2,0,antihypertensive drugs,alcohol
0,DDI-DrugBank.d623.s1,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,DDI-DrugBank.d623.s1.p0,2,Aminoglutethimide,depo-subQ provera 104
1,DDI-DrugBank.d623.s1,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,DDI-DrugBank.d623.s1.p1,0,Aminoglutethimide,MPA
2,DDI-DrugBank.d623.s1,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,DDI-DrugBank.d623.s1.p2,0,depo-subQ provera 104,MPA
0,DDI-DrugBank.d688.s0,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,DDI-DrugBank.d688.s0.p0,0,zidovudine,rifabutin
1,DDI-DrugBank.d688.s0,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,DDI-DrugBank.d688.s0.p1,0,zidovudine,megestrol acetate
2,DDI-DrugBank.d688.s0,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,DDI-DrugBank.d688.s0.p2,0,rifabutin,megestrol acetate
3,DDI-DrugBank.d688.s1,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,DDI-DrugBank.d688.s1.p0,2,megestrol acetate,indinavir
4,DDI-DrugBank.d688.s1,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,DDI-DrugBank.d688.s1.p1,0,megestrol acetate,indinavir
5,DDI-DrugBank.d688.s1,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,DDI-DrugBank.d688.s1.p2,0,indinavir,indinavir
6,DDI-DrugBank.d688.s2,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,DDI-DrugBank.d688.s2.p0,1,indinavir,megestrol acetate
7,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p0,0,indinavir,zidovudine
8,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p1,0,indinavir,rifabutin
9,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p2,0,indinavir,megestrol acetate
10,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p3,0,zidovudine,rifabutin
11,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p4,0,zidovudine,megestrol acetate
12,DDI-DrugBank.d688.s3,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",DDI-DrugBank.d688.s3.p5,0,rifabutin,megestrol acetate
0,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p0,4,Melatonin,aspirin
1,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p1,4,Melatonin,NSAIDs
2,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p2,0,Melatonin,melatonin
3,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p3,4,Melatonin,fluvoxamine
4,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p4,0,Melatonin,melatonin
5,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p5,4,Melatonin,beta blockers
6,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p6,0,Melatonin,melatonin
7,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p7,4,Melatonin,fluoxetine
8,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p8,4,Melatonin,progestin
9,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p9,0,Melatonin,melatonin
10,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p10,0,Melatonin,progestin
11,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p11,4,Melatonin,benzodiazepenes
12,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p12,4,Melatonin,corticosteroids
13,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p13,0,Melatonin,melatonin
14,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p14,0,Melatonin,corticosteroids
15,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p15,0,Melatonin,corticosteroids
16,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p16,0,aspirin,NSAIDs
17,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p17,0,aspirin,melatonin
18,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p18,0,aspirin,fluvoxamine
19,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p19,0,aspirin,melatonin
20,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p20,0,aspirin,beta blockers
21,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p21,0,aspirin,melatonin
22,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p22,0,aspirin,fluoxetine
23,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p23,0,aspirin,progestin
24,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p24,0,aspirin,melatonin
25,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p25,0,aspirin,progestin
26,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p26,0,aspirin,benzodiazepenes
27,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p27,0,aspirin,corticosteroids
28,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p28,0,aspirin,melatonin
29,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p29,0,aspirin,corticosteroids
30,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p30,0,aspirin,corticosteroids
31,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p31,0,NSAIDs,melatonin
32,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p32,0,NSAIDs,fluvoxamine
33,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p33,0,NSAIDs,melatonin
34,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p34,0,NSAIDs,beta blockers
35,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p35,0,NSAIDs,melatonin
36,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p36,0,NSAIDs,fluoxetine
37,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p37,0,NSAIDs,progestin
38,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p38,0,NSAIDs,melatonin
39,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p39,0,NSAIDs,progestin
40,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p40,0,NSAIDs,benzodiazepenes
41,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p41,0,NSAIDs,corticosteroids
42,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p42,0,NSAIDs,melatonin
43,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p43,0,NSAIDs,corticosteroids
44,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p44,0,NSAIDs,corticosteroids
45,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p45,0,melatonin,fluvoxamine
46,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p46,0,melatonin,melatonin
47,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p47,0,melatonin,beta blockers
48,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p48,0,melatonin,melatonin
49,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p49,0,melatonin,fluoxetine
50,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p50,0,melatonin,progestin
51,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p51,0,melatonin,melatonin
52,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p52,0,melatonin,progestin
53,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p53,0,melatonin,benzodiazepenes
54,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p54,0,melatonin,corticosteroids
55,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p55,0,melatonin,melatonin
56,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p56,0,melatonin,corticosteroids
57,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p57,0,melatonin,corticosteroids
58,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p58,0,fluvoxamine,melatonin
59,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p59,0,fluvoxamine,beta blockers
60,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p60,0,fluvoxamine,melatonin
61,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p61,0,fluvoxamine,fluoxetine
62,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p62,0,fluvoxamine,progestin
63,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p63,0,fluvoxamine,melatonin
64,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p64,0,fluvoxamine,progestin
65,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p65,0,fluvoxamine,benzodiazepenes
66,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p66,0,fluvoxamine,corticosteroids
67,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p67,0,fluvoxamine,melatonin
68,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p68,0,fluvoxamine,corticosteroids
69,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p69,0,fluvoxamine,corticosteroids
70,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p70,0,melatonin,beta blockers
71,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p71,0,melatonin,melatonin
72,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p72,0,melatonin,fluoxetine
73,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p73,0,melatonin,progestin
74,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p74,0,melatonin,melatonin
75,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p75,0,melatonin,progestin
76,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p76,0,melatonin,benzodiazepenes
77,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p77,0,melatonin,corticosteroids
78,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p78,0,melatonin,melatonin
79,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p79,0,melatonin,corticosteroids
80,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p80,0,melatonin,corticosteroids
81,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p81,0,beta blockers,melatonin
82,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p82,0,beta blockers,fluoxetine
83,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p83,0,beta blockers,progestin
84,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p84,0,beta blockers,melatonin
85,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p85,0,beta blockers,progestin
86,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p86,0,beta blockers,benzodiazepenes
87,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p87,0,beta blockers,corticosteroids
88,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p88,0,beta blockers,melatonin
89,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p89,0,beta blockers,corticosteroids
90,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p90,0,beta blockers,corticosteroids
91,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p91,0,melatonin,fluoxetine
92,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p92,0,melatonin,progestin
93,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p93,0,melatonin,melatonin
94,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p94,0,melatonin,progestin
95,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p95,0,melatonin,benzodiazepenes
96,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p96,0,melatonin,corticosteroids
97,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p97,0,melatonin,melatonin
98,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p98,0,melatonin,corticosteroids
99,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p99,0,melatonin,corticosteroids
100,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p100,0,fluoxetine,progestin
101,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p101,0,fluoxetine,melatonin
102,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p102,0,fluoxetine,progestin
103,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p103,0,fluoxetine,benzodiazepenes
104,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p104,0,fluoxetine,corticosteroids
105,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p105,0,fluoxetine,melatonin
106,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p106,0,fluoxetine,corticosteroids
107,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p107,0,fluoxetine,corticosteroids
108,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p108,0,progestin,melatonin
109,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p109,0,progestin,progestin
110,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p110,0,progestin,benzodiazepenes
111,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p111,0,progestin,corticosteroids
112,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p112,0,progestin,melatonin
113,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p113,0,progestin,corticosteroids
114,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p114,0,progestin,corticosteroids
115,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p115,3,melatonin,progestin
116,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p116,0,melatonin,benzodiazepenes
117,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p117,0,melatonin,corticosteroids
118,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p118,0,melatonin,melatonin
119,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p119,0,melatonin,corticosteroids
120,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p120,0,melatonin,corticosteroids
121,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p121,0,progestin,benzodiazepenes
122,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p122,0,progestin,corticosteroids
123,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p123,0,progestin,melatonin
124,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p124,0,progestin,corticosteroids
125,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p125,0,progestin,corticosteroids
126,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p126,0,benzodiazepenes,corticosteroids
127,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p127,0,benzodiazepenes,melatonin
128,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p128,0,benzodiazepenes,corticosteroids
129,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p129,0,benzodiazepenes,corticosteroids
130,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p130,0,corticosteroids,melatonin
131,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p131,0,corticosteroids,corticosteroids
132,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p132,0,corticosteroids,corticosteroids
133,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p133,3,melatonin,corticosteroids
134,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p134,0,melatonin,corticosteroids
135,DDI-DrugBank.d643.s0,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",DDI-DrugBank.d643.s0.p135,0,corticosteroids,corticosteroids
0,DDI-DrugBank.d597.s0,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,DDI-DrugBank.d597.s0.p0,0,ACE inhibitors,NSAIDs
1,DDI-DrugBank.d597.s0,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,DDI-DrugBank.d597.s0.p1,0,ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors
2,DDI-DrugBank.d597.s0,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,DDI-DrugBank.d597.s0.p2,3,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors
3,DDI-DrugBank.d597.s1,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,DDI-DrugBank.d597.s1.p0,1,NSAIDs,ACE inhibitors
4,DDI-DrugBank.d597.s2,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,DDI-DrugBank.d597.s2.p0,0,Aspirin,aspirin
5,DDI-DrugBank.d597.s2,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,DDI-DrugBank.d597.s2.p1,0,Aspirin,meloxicam
6,DDI-DrugBank.d597.s2,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,DDI-DrugBank.d597.s2.p2,2,aspirin,meloxicam
7,DDI-DrugBank.d597.s4,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",DDI-DrugBank.d597.s4.p0,0,NSAIDs,meloxicam
8,DDI-DrugBank.d597.s4,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",DDI-DrugBank.d597.s4.p1,1,NSAIDs,aspirin
9,DDI-DrugBank.d597.s4,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",DDI-DrugBank.d597.s4.p2,1,meloxicam,aspirin
10,DDI-DrugBank.d597.s5,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",DDI-DrugBank.d597.s5.p0,3,aspirin,MOBIC
11,DDI-DrugBank.d597.s5,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",DDI-DrugBank.d597.s5.p1,0,aspirin,MOBIC
12,DDI-DrugBank.d597.s5,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",DDI-DrugBank.d597.s5.p2,0,MOBIC,MOBIC
13,DDI-DrugBank.d597.s6,MOBIC is not a substitute for aspirin for cardiovascular prophylaxis. ,DDI-DrugBank.d597.s6.p0,0,MOBIC,aspirin
14,DDI-DrugBank.d597.s7,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,DDI-DrugBank.d597.s7.p0,0,Cholestyramine,cholestyramine
15,DDI-DrugBank.d597.s7,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,DDI-DrugBank.d597.s7.p1,0,Cholestyramine,meloxicam
16,DDI-DrugBank.d597.s7,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,DDI-DrugBank.d597.s7.p2,2,cholestyramine,meloxicam
17,DDI-DrugBank.d597.s11,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,DDI-DrugBank.d597.s11.p0,0,Cimetidine,cimetidine
18,DDI-DrugBank.d597.s11,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,DDI-DrugBank.d597.s11.p1,0,Cimetidine,meloxicam
19,DDI-DrugBank.d597.s11,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,DDI-DrugBank.d597.s11.p2,0,cimetidine,meloxicam
20,DDI-DrugBank.d597.s12,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,DDI-DrugBank.d597.s12.p0,0,Digoxin,Meloxicam
21,DDI-DrugBank.d597.s12,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,DDI-DrugBank.d597.s12.p1,0,Digoxin,digoxin
22,DDI-DrugBank.d597.s12,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,DDI-DrugBank.d597.s12.p2,0,Meloxicam,digoxin
23,DDI-DrugBank.d597.s13,In vitro testing found no protein binding drug interaction between digoxin and meloxicam. ,DDI-DrugBank.d597.s13.p0,0,digoxin,meloxicam
24,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p0,0,Furosemide,NSAIDs
25,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p1,0,Furosemide,furosemide
26,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p2,0,Furosemide,thiazide diuretics
27,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p3,3,NSAIDs,furosemide
28,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p4,3,NSAIDs,thiazide diuretics
29,DDI-DrugBank.d597.s14,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",DDI-DrugBank.d597.s14.p5,0,furosemide,thiazide diuretics
30,DDI-DrugBank.d597.s16,Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. ,DDI-DrugBank.d597.s16.p0,0,furosemide,meloxicam
31,DDI-DrugBank.d597.s17,Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. ,DDI-DrugBank.d597.s17.p0,0,Furosemide,meloxicam
32,DDI-DrugBank.d597.s18,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",DDI-DrugBank.d597.s18.p0,1,furosemide,MOBIC
33,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p0,0,Lithium,NSAIDs
34,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p1,0,Lithium,lithium
35,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p2,0,Lithium,lithium
36,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p3,2,NSAIDs,lithium
37,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p4,0,NSAIDs,lithium
38,DDI-DrugBank.d597.s19,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",DDI-DrugBank.d597.s19.p5,0,lithium,lithium
39,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p0,0,lithium,lithium
40,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p1,0,lithium,meloxicam
41,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p2,0,lithium,lithium
42,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p3,2,lithium,meloxicam
43,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p4,0,lithium,lithium
44,DDI-DrugBank.d597.s20,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",DDI-DrugBank.d597.s20.p5,0,meloxicam,lithium
45,DDI-DrugBank.d597.s22,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,DDI-DrugBank.d597.s22.p0,1,lithium,MOBIC
46,DDI-DrugBank.d597.s23,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,DDI-DrugBank.d597.s23.p0,0,Methotrexate,meloxicam
47,DDI-DrugBank.d597.s23,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,DDI-DrugBank.d597.s23.p1,0,Methotrexate,methotrexate
48,DDI-DrugBank.d597.s23,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,DDI-DrugBank.d597.s23.p2,0,meloxicam,methotrexate
49,DDI-DrugBank.d597.s24,Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. ,DDI-DrugBank.d597.s24.p0,0,Meloxicam,methotrexate
50,DDI-DrugBank.d597.s25,"In vitro, methotrexate did not displace meloxicam from its human serum binding sites. ",DDI-DrugBank.d597.s25.p0,0,methotrexate,meloxicam
51,DDI-DrugBank.d597.s26,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",DDI-DrugBank.d597.s26.p0,0,Warfarin,MOBIC
52,DDI-DrugBank.d597.s26,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",DDI-DrugBank.d597.s26.p1,0,Warfarin,warfarin
53,DDI-DrugBank.d597.s26,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",DDI-DrugBank.d597.s26.p2,1,MOBIC,warfarin
54,DDI-DrugBank.d597.s27,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,DDI-DrugBank.d597.s27.p0,0,meloxicam,warfarin
55,DDI-DrugBank.d597.s27,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,DDI-DrugBank.d597.s27.p1,0,meloxicam,warfarin
56,DDI-DrugBank.d597.s27,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,DDI-DrugBank.d597.s27.p2,0,warfarin,warfarin
57,DDI-DrugBank.d597.s28,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",DDI-DrugBank.d597.s28.p0,0,meloxicam,warfarin
58,DDI-DrugBank.d597.s28,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",DDI-DrugBank.d597.s28.p1,0,meloxicam,warfarin
59,DDI-DrugBank.d597.s28,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",DDI-DrugBank.d597.s28.p2,0,warfarin,warfarin
60,DDI-DrugBank.d597.s30,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,DDI-DrugBank.d597.s30.p0,1,MOBIC,warfarin
61,DDI-DrugBank.d597.s30,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,DDI-DrugBank.d597.s30.p1,0,MOBIC,warfarin
62,DDI-DrugBank.d597.s30,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,DDI-DrugBank.d597.s30.p2,0,warfarin,warfarin
0,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p0,0,ALKERAN,live organism vaccines
1,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p1,0,ALKERAN,Nalidixic acid
2,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p2,0,ALKERAN,melphalan
3,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p3,0,live organism vaccines,Nalidixic acid
4,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p4,0,live organism vaccines,melphalan
5,DDI-DrugBank.d625.s0,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,DDI-DrugBank.d625.s0.p5,3,Nalidixic acid,melphalan
6,DDI-DrugBank.d625.s1,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,DDI-DrugBank.d625.s1.p0,3,melphalan,cyclosporin
0,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p0,3,anticholinergic drugs,amantadine
1,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p1,3,anticholinergic drugs,antiarrhythmic agents of class I
2,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p2,3,anticholinergic drugs,quinidine
3,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p3,3,anticholinergic drugs,antihistamines
4,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p4,3,anticholinergic drugs,antipsychotic agents
5,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p5,3,anticholinergic drugs,phenothiazines
6,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p6,3,anticholinergic drugs,benzodiazepines
7,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p7,3,anticholinergic drugs,MAO inhibitors
8,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p8,3,anticholinergic drugs,narcotic analgesics
9,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p9,3,anticholinergic drugs,meperidine
10,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p10,3,anticholinergic drugs,nitrates
11,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p11,3,anticholinergic drugs,nitrites
12,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p12,3,anticholinergic drugs,sympathomimetic agents
13,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p13,3,anticholinergic drugs,tricyclic antidepressants
14,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p14,0,amantadine,antiarrhythmic agents of class I
15,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p15,0,amantadine,quinidine
16,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p16,0,amantadine,antihistamines
17,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p17,0,amantadine,antipsychotic agents
18,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p18,0,amantadine,phenothiazines
19,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p19,0,amantadine,benzodiazepines
20,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p20,0,amantadine,MAO inhibitors
21,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p21,0,amantadine,narcotic analgesics
22,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p22,0,amantadine,meperidine
23,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p23,0,amantadine,nitrates
24,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p24,0,amantadine,nitrites
25,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p25,0,amantadine,sympathomimetic agents
26,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p26,0,amantadine,tricyclic antidepressants
27,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p27,0,antiarrhythmic agents of class I,quinidine
28,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p28,0,antiarrhythmic agents of class I,antihistamines
29,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p29,0,antiarrhythmic agents of class I,antipsychotic agents
30,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p30,0,antiarrhythmic agents of class I,phenothiazines
31,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p31,0,antiarrhythmic agents of class I,benzodiazepines
32,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p32,0,antiarrhythmic agents of class I,MAO inhibitors
33,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p33,0,antiarrhythmic agents of class I,narcotic analgesics
34,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p34,0,antiarrhythmic agents of class I,meperidine
35,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p35,0,antiarrhythmic agents of class I,nitrates
36,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p36,0,antiarrhythmic agents of class I,nitrites
37,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p37,0,antiarrhythmic agents of class I,sympathomimetic agents
38,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p38,0,antiarrhythmic agents of class I,tricyclic antidepressants
39,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p39,0,quinidine,antihistamines
40,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p40,0,quinidine,antipsychotic agents
41,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p41,0,quinidine,phenothiazines
42,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p42,0,quinidine,benzodiazepines
43,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p43,0,quinidine,MAO inhibitors
44,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p44,0,quinidine,narcotic analgesics
45,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p45,0,quinidine,meperidine
46,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p46,0,quinidine,nitrates
47,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p47,0,quinidine,nitrites
48,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p48,0,quinidine,sympathomimetic agents
49,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p49,0,quinidine,tricyclic antidepressants
50,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p50,0,antihistamines,antipsychotic agents
51,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p51,0,antihistamines,phenothiazines
52,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p52,0,antihistamines,benzodiazepines
53,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p53,0,antihistamines,MAO inhibitors
54,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p54,0,antihistamines,narcotic analgesics
55,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p55,0,antihistamines,meperidine
56,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p56,0,antihistamines,nitrates
57,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p57,0,antihistamines,nitrites
58,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p58,0,antihistamines,sympathomimetic agents
59,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p59,0,antihistamines,tricyclic antidepressants
60,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p60,0,antipsychotic agents,phenothiazines
61,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p61,0,antipsychotic agents,benzodiazepines
62,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p62,0,antipsychotic agents,MAO inhibitors
63,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p63,0,antipsychotic agents,narcotic analgesics
64,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p64,0,antipsychotic agents,meperidine
65,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p65,0,antipsychotic agents,nitrates
66,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p66,0,antipsychotic agents,nitrites
67,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p67,0,antipsychotic agents,sympathomimetic agents
68,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p68,0,antipsychotic agents,tricyclic antidepressants
69,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p69,0,phenothiazines,benzodiazepines
70,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p70,0,phenothiazines,MAO inhibitors
71,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p71,0,phenothiazines,narcotic analgesics
72,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p72,0,phenothiazines,meperidine
73,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p73,0,phenothiazines,nitrates
74,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p74,0,phenothiazines,nitrites
75,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p75,0,phenothiazines,sympathomimetic agents
76,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p76,0,phenothiazines,tricyclic antidepressants
77,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p77,0,benzodiazepines,MAO inhibitors
78,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p78,0,benzodiazepines,narcotic analgesics
79,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p79,0,benzodiazepines,meperidine
80,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p80,0,benzodiazepines,nitrates
81,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p81,0,benzodiazepines,nitrites
82,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p82,0,benzodiazepines,sympathomimetic agents
83,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p83,0,benzodiazepines,tricyclic antidepressants
84,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p84,0,MAO inhibitors,narcotic analgesics
85,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p85,0,MAO inhibitors,meperidine
86,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p86,0,MAO inhibitors,nitrates
87,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p87,0,MAO inhibitors,nitrites
88,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p88,0,MAO inhibitors,sympathomimetic agents
89,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p89,0,MAO inhibitors,tricyclic antidepressants
90,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p90,0,narcotic analgesics,meperidine
91,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p91,0,narcotic analgesics,nitrates
92,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p92,0,narcotic analgesics,nitrites
93,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p93,0,narcotic analgesics,sympathomimetic agents
94,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p94,0,narcotic analgesics,tricyclic antidepressants
95,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p95,0,meperidine,nitrates
96,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p96,0,meperidine,nitrites
97,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p97,0,meperidine,sympathomimetic agents
98,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p98,0,meperidine,tricyclic antidepressants
99,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p99,0,nitrates,nitrites
100,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p100,0,nitrates,sympathomimetic agents
101,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p101,0,nitrates,tricyclic antidepressants
102,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p102,0,nitrites,sympathomimetic agents
103,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p103,0,nitrites,tricyclic antidepressants
104,DDI-DrugBank.d585.s0,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",DDI-DrugBank.d585.s0.p104,0,sympathomimetic agents,tricyclic antidepressants
105,DDI-DrugBank.d585.s1,Anticholinergics antagonize the effects of antiglaucoma agents. ,DDI-DrugBank.d585.s1.p0,3,Anticholinergics,antiglaucoma agents
106,DDI-DrugBank.d585.s2,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,DDI-DrugBank.d585.s2.p0,3,Anticholinergic drugs,corticosteroids
107,DDI-DrugBank.d585.s3,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",DDI-DrugBank.d585.s3.p0,2,Anticholinergic agents,digoxin
108,DDI-DrugBank.d585.s5,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",DDI-DrugBank.d585.s5.p0,3,Anticholinergic drugs,metoclopramide
109,DDI-DrugBank.d585.s6,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",DDI-DrugBank.d585.s6.p0,2,antacids,anticholinergic agents
0,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p0,0,Central Nervous System Depressants,MEPERIDINE
1,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p1,0,Central Nervous System Depressants,NARCOTIC ANALGESICS
2,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p2,0,Central Nervous System Depressants,ANESTHETICS
3,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p3,0,Central Nervous System Depressants,PHENOTHIAZINES
4,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p4,0,Central Nervous System Depressants,TRANQUILIZERS
5,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p5,0,Central Nervous System Depressants,SEDATIVE-HYPNOTICS
6,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p6,0,Central Nervous System Depressants,BARBITURATES
7,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p7,0,Central Nervous System Depressants,TRICYCLIC ANTIDEPRESSANTS
8,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p8,0,Central Nervous System Depressants,CNS DEPRESSANTS
9,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p9,0,Central Nervous System Depressants,ALCOHOL
10,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p10,1,MEPERIDINE,NARCOTIC ANALGESICS
11,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p11,1,MEPERIDINE,ANESTHETICS
12,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p12,1,MEPERIDINE,PHENOTHIAZINES
13,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p13,1,MEPERIDINE,TRANQUILIZERS
14,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p14,1,MEPERIDINE,SEDATIVE-HYPNOTICS
15,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p15,1,MEPERIDINE,BARBITURATES
16,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p16,1,MEPERIDINE,TRICYCLIC ANTIDEPRESSANTS
17,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p17,1,MEPERIDINE,CNS DEPRESSANTS
18,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p18,1,MEPERIDINE,ALCOHOL
19,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p19,0,NARCOTIC ANALGESICS,ANESTHETICS
20,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p20,0,NARCOTIC ANALGESICS,PHENOTHIAZINES
21,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p21,0,NARCOTIC ANALGESICS,TRANQUILIZERS
22,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p22,0,NARCOTIC ANALGESICS,SEDATIVE-HYPNOTICS
23,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p23,0,NARCOTIC ANALGESICS,BARBITURATES
24,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p24,0,NARCOTIC ANALGESICS,TRICYCLIC ANTIDEPRESSANTS
25,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p25,0,NARCOTIC ANALGESICS,CNS DEPRESSANTS
26,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p26,0,NARCOTIC ANALGESICS,ALCOHOL
27,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p27,0,ANESTHETICS,PHENOTHIAZINES
28,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p28,0,ANESTHETICS,TRANQUILIZERS
29,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p29,0,ANESTHETICS,SEDATIVE-HYPNOTICS
30,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p30,0,ANESTHETICS,BARBITURATES
31,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p31,0,ANESTHETICS,TRICYCLIC ANTIDEPRESSANTS
32,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p32,0,ANESTHETICS,CNS DEPRESSANTS
33,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p33,0,ANESTHETICS,ALCOHOL
34,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p34,0,PHENOTHIAZINES,TRANQUILIZERS
35,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p35,0,PHENOTHIAZINES,SEDATIVE-HYPNOTICS
36,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p36,0,PHENOTHIAZINES,BARBITURATES
37,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p37,0,PHENOTHIAZINES,TRICYCLIC ANTIDEPRESSANTS
38,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p38,0,PHENOTHIAZINES,CNS DEPRESSANTS
39,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p39,0,PHENOTHIAZINES,ALCOHOL
40,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p40,0,TRANQUILIZERS,SEDATIVE-HYPNOTICS
41,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p41,0,TRANQUILIZERS,BARBITURATES
42,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p42,0,TRANQUILIZERS,TRICYCLIC ANTIDEPRESSANTS
43,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p43,0,TRANQUILIZERS,CNS DEPRESSANTS
44,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p44,0,TRANQUILIZERS,ALCOHOL
45,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p45,0,SEDATIVE-HYPNOTICS,BARBITURATES
46,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p46,0,SEDATIVE-HYPNOTICS,TRICYCLIC ANTIDEPRESSANTS
47,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p47,0,SEDATIVE-HYPNOTICS,CNS DEPRESSANTS
48,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p48,0,SEDATIVE-HYPNOTICS,ALCOHOL
49,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p49,0,BARBITURATES,TRICYCLIC ANTIDEPRESSANTS
50,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p50,0,BARBITURATES,CNS DEPRESSANTS
51,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p51,0,BARBITURATES,ALCOHOL
52,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p52,0,TRICYCLIC ANTIDEPRESSANTS,CNS DEPRESSANTS
53,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p53,0,TRICYCLIC ANTIDEPRESSANTS,ALCOHOL
54,DDI-DrugBank.d703.s0,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",DDI-DrugBank.d703.s0.p54,0,CNS DEPRESSANTS,ALCOHOL
0,DDI-DrugBank.d636.s0,Some anticonvulsants may interact with Mephenytoin. ,DDI-DrugBank.d636.s0.p0,4,anticonvulsants,Mephenytoin
1,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p0,0,anticonvulsants,divalproex sodium
2,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p1,0,anticonvulsants,valproic acid
3,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p2,0,anticonvulsants,phenobarbital
4,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p3,0,divalproex sodium,valproic acid
5,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p4,0,divalproex sodium,phenobarbital
6,DDI-DrugBank.d636.s2,"Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. ",DDI-DrugBank.d636.s2.p5,0,valproic acid,phenobarbital
7,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p0,3,Mephenytoin,steroid medications
8,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p1,3,Mephenytoin,warfarin
9,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p2,3,Mephenytoin,anti-infective medicines
10,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p3,3,Mephenytoin,furosemide
11,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p4,3,Mephenytoin,theophylline
12,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p5,0,Mephenytoin,Mephenytoin
13,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p6,0,steroid medications,warfarin
14,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p7,0,steroid medications,anti-infective medicines
15,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p8,0,steroid medications,furosemide
16,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p9,0,steroid medications,theophylline
17,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p10,0,steroid medications,Mephenytoin
18,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p11,0,warfarin,anti-infective medicines
19,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p12,0,warfarin,furosemide
20,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p13,0,warfarin,theophylline
21,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p14,0,warfarin,Mephenytoin
22,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p15,0,anti-infective medicines,furosemide
23,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p16,0,anti-infective medicines,theophylline
24,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p17,0,anti-infective medicines,Mephenytoin
25,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p18,0,furosemide,theophylline
26,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p19,0,furosemide,Mephenytoin
27,DDI-DrugBank.d636.s3,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",DDI-DrugBank.d636.s3.p20,0,theophylline,Mephenytoin
0,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p0,4,Mequitazine,CNS depressant
1,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p1,4,Mequitazine,antichlolinergic
2,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p2,4,Mequitazine,TCA
3,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p3,4,Mequitazine,MAOIs
4,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p4,4,Mequitazine,alcohol
5,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p5,0,CNS depressant,antichlolinergic
6,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p6,0,CNS depressant,TCA
7,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p7,0,CNS depressant,MAOIs
8,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p8,0,CNS depressant,alcohol
9,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p9,0,antichlolinergic,TCA
10,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p10,0,antichlolinergic,MAOIs
11,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p11,0,antichlolinergic,alcohol
12,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p12,0,TCA,MAOIs
13,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p13,0,TCA,alcohol
14,DDI-DrugBank.d699.s0,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.",DDI-DrugBank.d699.s0.p14,0,MAOIs,alcohol
0,DDI-DrugBank.d762.s0,Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. ,DDI-DrugBank.d762.s0.p0,2,Probenecid,meropenem
1,DDI-DrugBank.d762.s0,Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. ,DDI-DrugBank.d762.s0.p1,0,Probenecid,meropenem
2,DDI-DrugBank.d762.s0,Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. ,DDI-DrugBank.d762.s0.p2,0,meropenem,meropenem
3,DDI-DrugBank.d762.s2,"Therefore, the coadministration of probenecid with meropenem is not recommended. ",DDI-DrugBank.d762.s2.p0,1,probenecid,meropenem
4,DDI-DrugBank.d762.s3,There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).,DDI-DrugBank.d762.s3.p0,2,meropenem,valproic acid
5,DDI-DrugBank.d762.s3,There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).,DDI-DrugBank.d762.s3.p1,0,meropenem,valproate
6,DDI-DrugBank.d762.s3,There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).,DDI-DrugBank.d762.s3.p2,0,valproic acid,valproate
0,DDI-DrugBank.d746.s0,"ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. ",DDI-DrugBank.d746.s0.p0,0,ARAMINE,digitalis
1,DDI-DrugBank.d746.s0,"ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. ",DDI-DrugBank.d746.s0.p1,0,ARAMINE,sympathomimetic amines
2,DDI-DrugBank.d746.s0,"ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. ",DDI-DrugBank.d746.s0.p2,3,digitalis,sympathomimetic amines
3,DDI-DrugBank.d746.s1,Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. ,DDI-DrugBank.d746.s1.p0,0,Monoamine oxidase inhibitors,tricyclic antidepressants
4,DDI-DrugBank.d746.s1,Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. ,DDI-DrugBank.d746.s1.p1,3,Monoamine oxidase inhibitors,sympathomimetic amines
5,DDI-DrugBank.d746.s1,Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. ,DDI-DrugBank.d746.s1.p2,3,tricyclic antidepressants,sympathomimetic amines
0,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p0,3,SKELAXIN,alcohol
1,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p1,3,SKELAXIN,barbiturates
2,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p2,3,SKELAXIN,CNS depressants
3,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p3,0,alcohol,barbiturates
4,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p4,0,alcohol,CNS depressants
5,DDI-DrugBank.d605.s0,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",DDI-DrugBank.d605.s0.p5,0,barbiturates,CNS depressants
0,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p0,1,aspirin,methazolamide
1,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p1,0,aspirin,aspirin
2,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p2,0,aspirin,carbonic anhydrase inhibitors
3,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p3,0,methazolamide,aspirin
4,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p4,0,methazolamide,carbonic anhydrase inhibitors
5,DDI-DrugBank.d630.s1,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",DDI-DrugBank.d630.s1.p5,3,aspirin,carbonic anhydrase inhibitors
0,DDI-DrugBank.d634.s0,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,DDI-DrugBank.d634.s0.p0,0,Anticoagulants,anticoagulants
1,DDI-DrugBank.d634.s0,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,DDI-DrugBank.d634.s0.p1,0,Anticoagulants,methimazole
2,DDI-DrugBank.d634.s0,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,DDI-DrugBank.d634.s0.p2,3,anticoagulants,methimazole
3,DDI-DrugBank.d634.s3,Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; ,DDI-DrugBank.d634.s3.p0,0,Digitalis glycosides,digitalis glycoside
4,DDI-DrugBank.d634.s5,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,DDI-DrugBank.d634.s5.p0,0,Theophylline,Theophylline
5,DDI-DrugBank.d634.s5,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,DDI-DrugBank.d634.s5.p1,0,Theophylline,theophylline
6,DDI-DrugBank.d634.s5,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,DDI-DrugBank.d634.s5.p2,0,Theophylline,theophylline
0,DDI-DrugBank.d756.s0,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",DDI-DrugBank.d756.s0.p0,3,opioids,levomepromazine
1,DDI-DrugBank.d756.s0,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",DDI-DrugBank.d756.s0.p1,0,opioids,opioids
2,DDI-DrugBank.d756.s0,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",DDI-DrugBank.d756.s0.p2,3,levomepromazine,opioids
3,DDI-DrugBank.d756.s1,Combination with tramadol (Ultram) is associated with increased risk of seizures. ,DDI-DrugBank.d756.s1.p0,0,tramadol,Ultram
4,DDI-DrugBank.d756.s2,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,DDI-DrugBank.d756.s2.p0,3,levomepromazine,benzodiazepines
5,DDI-DrugBank.d756.s2,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,DDI-DrugBank.d756.s2.p1,3,levomepromazine,barbiturates
6,DDI-DrugBank.d756.s2,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,DDI-DrugBank.d756.s2.p2,0,benzodiazepines,barbiturates
7,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p0,1,levomepromazine,anticholinergic drugs
8,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p1,1,levomepromazine,tricyclic antidepressants
9,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p2,1,levomepromazine,antiparkinsonian-agents
10,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p3,0,anticholinergic drugs,tricyclic antidepressants
11,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p4,0,anticholinergic drugs,antiparkinsonian-agents
12,DDI-DrugBank.d756.s4,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",DDI-DrugBank.d756.s4.p5,0,tricyclic antidepressants,antiparkinsonian-agents
13,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p0,0,Caffeine,ephedrine
14,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p1,0,Caffeine,amphetamine
15,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p2,3,Caffeine,levomepromazine
16,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p3,0,ephedrine,amphetamine
17,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p4,3,ephedrine,levomepromazine
18,DDI-DrugBank.d756.s7,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,DDI-DrugBank.d756.s7.p5,3,amphetamine,levomepromazine
0,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p0,0,Celontin,methsuximide
1,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p1,1,Celontin,antiepileptic drugs
2,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p2,0,Celontin,methsuximide
3,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p3,0,Celontin,phenytoin
4,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p4,0,Celontin,phenobarbital
5,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p5,1,methsuximide,antiepileptic drugs
6,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p6,0,methsuximide,methsuximide
7,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p7,0,methsuximide,phenytoin
8,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p8,0,methsuximide,phenobarbital
9,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p9,0,antiepileptic drugs,methsuximide
10,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p10,0,antiepileptic drugs,phenytoin
11,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p11,0,antiepileptic drugs,phenobarbital
12,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p12,2,methsuximide,phenytoin
13,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p13,2,methsuximide,phenobarbital
14,DDI-DrugBank.d587.s0,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",DDI-DrugBank.d587.s0.p14,0,phenytoin,phenobarbital
0,DDI-DrugBank.d736.s1,Hypokalemia may develop during concomitant use of steroids or ACTH. ,DDI-DrugBank.d736.s1.p0,0,steroids,ACTH
1,DDI-DrugBank.d736.s3,Thiazides may decrease arterial responsiveness to norepinephrine. ,DDI-DrugBank.d736.s3.p0,3,Thiazides,norepinephrine
2,DDI-DrugBank.d736.s5,Thiazide drugs may increase the responsiveness of tubocurarine. ,DDI-DrugBank.d736.s5.p0,3,Thiazide drugs,tubocurarine
3,DDI-DrugBank.d736.s6,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",DDI-DrugBank.d736.s6.p0,2,Lithium,thiazides
4,DDI-DrugBank.d736.s6,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",DDI-DrugBank.d736.s6.p1,0,Lithium,lithium
5,DDI-DrugBank.d736.s6,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",DDI-DrugBank.d736.s6.p2,0,thiazides,lithium
6,DDI-DrugBank.d736.s7,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,DDI-DrugBank.d736.s7.p0,3,Thiazides,antihypertensive drugs
7,DDI-DrugBank.d736.s8,Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.,DDI-DrugBank.d736.s8.p0,0,ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs
0,DDI-DrugBank.d779.s0,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",DDI-DrugBank.d779.s0.p0,3,methyldopa,antihypertensive drugs
1,DDI-DrugBank.d779.s2,Patients may require reduced doses of anesthetics when on methyldopa. ,DDI-DrugBank.d779.s2.p0,1,anesthetics,methyldopa
2,DDI-DrugBank.d779.s5,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,DDI-DrugBank.d779.s5.p0,1,methyldopa,lithium
3,DDI-DrugBank.d779.s5,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,DDI-DrugBank.d779.s5.p1,0,methyldopa,lithium
4,DDI-DrugBank.d779.s5,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,DDI-DrugBank.d779.s5.p2,0,lithium,lithium
5,DDI-DrugBank.d779.s7,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,DDI-DrugBank.d779.s7.p0,2,methyldopa,ferrous sulfate
6,DDI-DrugBank.d779.s7,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,DDI-DrugBank.d779.s7.p1,2,methyldopa,ferrous gluconate
7,DDI-DrugBank.d779.s7,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,DDI-DrugBank.d779.s7.p2,0,ferrous sulfate,ferrous gluconate
8,DDI-DrugBank.d779.s9,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,DDI-DrugBank.d779.s9.p0,1,methyldopa,ferrous sulfate
9,DDI-DrugBank.d779.s9,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,DDI-DrugBank.d779.s9.p1,1,methyldopa,ferrous gluconate
10,DDI-DrugBank.d779.s9,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,DDI-DrugBank.d779.s9.p2,0,ferrous sulfate,ferrous gluconate
11,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p0,0,Methyldopa,VMA
12,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p1,0,Methyldopa,vanillylmandelic acid
13,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p2,0,Methyldopa,VMA
14,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p3,0,Methyldopa,vanillin
15,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p4,0,VMA,vanillylmandelic acid
16,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p5,0,VMA,VMA
17,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p6,0,VMA,vanillin
18,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p7,0,vanillylmandelic acid,VMA
19,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p8,0,vanillylmandelic acid,vanillin
20,DDI-DrugBank.d779.s16,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",DDI-DrugBank.d779.s16.p9,0,VMA,vanillin
0,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p0,0,Macrolide Antibiotics,Protease Inhibitors
1,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p1,0,Macrolide Antibiotics,ergot alkaloid drugs
2,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p2,0,Macrolide Antibiotics,dihydroergotamine
3,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p3,0,Macrolide Antibiotics,ergotamine
4,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p4,0,Protease Inhibitors,ergot alkaloid drugs
5,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p5,0,Protease Inhibitors,dihydroergotamine
6,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p6,0,Protease Inhibitors,ergotamine
7,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p7,0,ergot alkaloid drugs,dihydroergotamine
8,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p8,0,ergot alkaloid drugs,ergotamine
9,DDI-DrugBank.d675.s0,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",DDI-DrugBank.d675.s0.p9,0,dihydroergotamine,ergotamine
10,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p0,0,macrolide antibiotics,erythromycin
11,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p1,0,macrolide antibiotics,troleandomycin
12,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p2,0,macrolide antibiotics,clarithromycin
13,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p3,0,macrolide antibiotics,HIV protease inhibitors
14,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p4,0,macrolide antibiotics,reverse transcriptase inhibitors
15,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p5,0,macrolide antibiotics,ritonavir
16,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p6,0,macrolide antibiotics,indinavir
17,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p7,0,macrolide antibiotics,nelfinavir
18,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p8,0,macrolide antibiotics,delavirdine
19,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p9,0,macrolide antibiotics,azole antifungals
20,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p10,0,macrolide antibiotics,ketoconazole
21,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p11,0,macrolide antibiotics,itraconazole
22,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p12,0,macrolide antibiotics,voriconazole
23,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p13,0,erythromycin,troleandomycin
24,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p14,0,erythromycin,clarithromycin
25,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p15,0,erythromycin,HIV protease inhibitors
26,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p16,0,erythromycin,reverse transcriptase inhibitors
27,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p17,0,erythromycin,ritonavir
28,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p18,0,erythromycin,indinavir
29,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p19,0,erythromycin,nelfinavir
30,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p20,0,erythromycin,delavirdine
31,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p21,0,erythromycin,azole antifungals
32,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p22,0,erythromycin,ketoconazole
33,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p23,0,erythromycin,itraconazole
34,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p24,0,erythromycin,voriconazole
35,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p25,0,troleandomycin,clarithromycin
36,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p26,0,troleandomycin,HIV protease inhibitors
37,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p27,0,troleandomycin,reverse transcriptase inhibitors
38,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p28,0,troleandomycin,ritonavir
39,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p29,0,troleandomycin,indinavir
40,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p30,0,troleandomycin,nelfinavir
41,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p31,0,troleandomycin,delavirdine
42,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p32,0,troleandomycin,azole antifungals
43,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p33,0,troleandomycin,ketoconazole
44,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p34,0,troleandomycin,itraconazole
45,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p35,0,troleandomycin,voriconazole
46,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p36,0,clarithromycin,HIV protease inhibitors
47,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p37,0,clarithromycin,reverse transcriptase inhibitors
48,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p38,0,clarithromycin,ritonavir
49,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p39,0,clarithromycin,indinavir
50,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p40,0,clarithromycin,nelfinavir
51,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p41,0,clarithromycin,delavirdine
52,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p42,0,clarithromycin,azole antifungals
53,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p43,0,clarithromycin,ketoconazole
54,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p44,0,clarithromycin,itraconazole
55,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p45,0,clarithromycin,voriconazole
56,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p46,0,HIV protease inhibitors,reverse transcriptase inhibitors
57,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p47,0,HIV protease inhibitors,ritonavir
58,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p48,0,HIV protease inhibitors,indinavir
59,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p49,0,HIV protease inhibitors,nelfinavir
60,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p50,0,HIV protease inhibitors,delavirdine
61,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p51,0,HIV protease inhibitors,azole antifungals
62,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p52,0,HIV protease inhibitors,ketoconazole
63,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p53,0,HIV protease inhibitors,itraconazole
64,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p54,0,HIV protease inhibitors,voriconazole
65,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p55,0,reverse transcriptase inhibitors,ritonavir
66,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p56,0,reverse transcriptase inhibitors,indinavir
67,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p57,0,reverse transcriptase inhibitors,nelfinavir
68,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p58,0,reverse transcriptase inhibitors,delavirdine
69,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p59,0,reverse transcriptase inhibitors,azole antifungals
70,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p60,0,reverse transcriptase inhibitors,ketoconazole
71,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p61,0,reverse transcriptase inhibitors,itraconazole
72,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p62,0,reverse transcriptase inhibitors,voriconazole
73,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p63,0,ritonavir,indinavir
74,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p64,0,ritonavir,nelfinavir
75,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p65,0,ritonavir,delavirdine
76,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p66,0,ritonavir,azole antifungals
77,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p67,0,ritonavir,ketoconazole
78,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p68,0,ritonavir,itraconazole
79,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p69,0,ritonavir,voriconazole
80,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p70,0,indinavir,nelfinavir
81,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p71,0,indinavir,delavirdine
82,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p72,0,indinavir,azole antifungals
83,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p73,0,indinavir,ketoconazole
84,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p74,0,indinavir,itraconazole
85,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p75,0,indinavir,voriconazole
86,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p76,0,nelfinavir,delavirdine
87,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p77,0,nelfinavir,azole antifungals
88,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p78,0,nelfinavir,ketoconazole
89,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p79,0,nelfinavir,itraconazole
90,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p80,0,nelfinavir,voriconazole
91,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p81,0,delavirdine,azole antifungals
92,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p82,0,delavirdine,ketoconazole
93,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p83,0,delavirdine,itraconazole
94,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p84,0,delavirdine,voriconazole
95,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p85,0,azole antifungals,ketoconazole
96,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p86,0,azole antifungals,itraconazole
97,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p87,0,azole antifungals,voriconazole
98,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p88,0,ketoconazole,itraconazole
99,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p89,0,ketoconazole,voriconazole
100,DDI-DrugBank.d675.s2,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",DDI-DrugBank.d675.s2.p90,0,itraconazole,voriconazole
101,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p0,0,saquinavir,nefazodone
102,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p1,0,saquinavir,fluconazole
103,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p2,0,saquinavir,fluoxetine
104,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p3,0,saquinavir,fluvoxamine
105,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p4,0,saquinavir,zileuton
106,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p5,0,saquinavir,clotrimazole
107,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p6,0,nefazodone,fluconazole
108,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p7,0,nefazodone,fluoxetine
109,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p8,0,nefazodone,fluvoxamine
110,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p9,0,nefazodone,zileuton
111,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p10,0,nefazodone,clotrimazole
112,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p11,0,fluconazole,fluoxetine
113,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p12,0,fluconazole,fluvoxamine
114,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p13,0,fluconazole,zileuton
115,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p14,0,fluconazole,clotrimazole
116,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p15,0,fluoxetine,fluvoxamine
117,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p16,0,fluoxetine,zileuton
118,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p17,0,fluoxetine,clotrimazole
119,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p18,0,fluvoxamine,zileuton
120,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p19,0,fluvoxamine,clotrimazole
121,DDI-DrugBank.d675.s4,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",DDI-DrugBank.d675.s4.p20,0,zileuton,clotrimazole
122,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p0,0,Methergine,methylergonovine maleate
123,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p1,1,Methergine,vasoconstrictors
124,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p2,1,Methergine,ergot alkaloids
125,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p3,1,methylergonovine maleate,vasoconstrictors
126,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p4,0,methylergonovine maleate,ergot alkaloids
127,DDI-DrugBank.d675.s7,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,DDI-DrugBank.d675.s7.p5,0,vasoconstrictors,ergot alkaloids
0,DDI-DrugBank.d638.s0,Ritalin may decrease the hypotensive effect of guanethidine. ,DDI-DrugBank.d638.s0.p0,3,Ritalin,guanethidine
1,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p0,2,Ritalin,coumarin anticoagulants
2,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p1,2,Ritalin,anticonvulsants
3,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p2,2,Ritalin,phenobarbital
4,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p3,2,Ritalin,diphenylhydantoin
5,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p4,2,Ritalin,primidone
6,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p5,2,Ritalin,phenylbutazone
7,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p6,2,Ritalin,tricyclic drugs
8,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p7,2,Ritalin,imipramine
9,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p8,2,Ritalin,clomipramine
10,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p9,2,Ritalin,desipramine
11,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p10,0,coumarin anticoagulants,anticonvulsants
12,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p11,0,coumarin anticoagulants,phenobarbital
13,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p12,0,coumarin anticoagulants,diphenylhydantoin
14,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p13,0,coumarin anticoagulants,primidone
15,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p14,0,coumarin anticoagulants,phenylbutazone
16,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p15,0,coumarin anticoagulants,tricyclic drugs
17,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p16,0,coumarin anticoagulants,imipramine
18,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p17,0,coumarin anticoagulants,clomipramine
19,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p18,0,coumarin anticoagulants,desipramine
20,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p19,0,anticonvulsants,phenobarbital
21,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p20,0,anticonvulsants,diphenylhydantoin
22,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p21,0,anticonvulsants,primidone
23,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p22,0,anticonvulsants,phenylbutazone
24,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p23,0,anticonvulsants,tricyclic drugs
25,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p24,0,anticonvulsants,imipramine
26,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p25,0,anticonvulsants,clomipramine
27,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p26,0,anticonvulsants,desipramine
28,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p27,0,phenobarbital,diphenylhydantoin
29,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p28,0,phenobarbital,primidone
30,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p29,0,phenobarbital,phenylbutazone
31,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p30,0,phenobarbital,tricyclic drugs
32,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p31,0,phenobarbital,imipramine
33,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p32,0,phenobarbital,clomipramine
34,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p33,0,phenobarbital,desipramine
35,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p34,0,diphenylhydantoin,primidone
36,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p35,0,diphenylhydantoin,phenylbutazone
37,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p36,0,diphenylhydantoin,tricyclic drugs
38,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p37,0,diphenylhydantoin,imipramine
39,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p38,0,diphenylhydantoin,clomipramine
40,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p39,0,diphenylhydantoin,desipramine
41,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p40,0,primidone,phenylbutazone
42,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p41,0,primidone,tricyclic drugs
43,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p42,0,primidone,imipramine
44,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p43,0,primidone,clomipramine
45,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p44,0,primidone,desipramine
46,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p45,0,phenylbutazone,tricyclic drugs
47,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p46,0,phenylbutazone,imipramine
48,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p47,0,phenylbutazone,clomipramine
49,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p48,0,phenylbutazone,desipramine
50,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p49,0,tricyclic drugs,imipramine
51,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p50,0,tricyclic drugs,clomipramine
52,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p51,0,tricyclic drugs,desipramine
53,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p52,0,imipramine,clomipramine
54,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p53,0,imipramine,desipramine
55,DDI-DrugBank.d638.s2,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",DDI-DrugBank.d638.s2.p54,0,clomipramine,desipramine
56,DDI-DrugBank.d638.s5,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,DDI-DrugBank.d638.s5.p0,0,methylphenidate,clonidine
57,DDI-DrugBank.d638.s5,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,DDI-DrugBank.d638.s5.p1,0,methylphenidate,alpha-2 agonists
58,DDI-DrugBank.d638.s5,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,DDI-DrugBank.d638.s5.p2,0,clonidine,alpha-2 agonists
0,DDI-DrugBank.d578.s1,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,DDI-DrugBank.d578.s1.p0,2,cyclosporin,methylprednisolone
1,DDI-DrugBank.d578.s3,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,DDI-DrugBank.d578.s3.p0,3,methylprednisolone,cyclosporin
2,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p0,0,phenobarbital,phenytoin
3,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p1,0,phenobarbital,rifampin
4,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p2,2,phenobarbital,methylprednisolone
5,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p3,1,phenobarbital,methylprednisolone
6,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p4,0,phenytoin,rifampin
7,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p5,2,phenytoin,methylprednisolone
8,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p6,1,phenytoin,methylprednisolone
9,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p7,2,rifampin,methylprednisolone
10,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p8,1,rifampin,methylprednisolone
11,DDI-DrugBank.d578.s4,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",DDI-DrugBank.d578.s4.p9,0,methylprednisolone,methylprednisolone
12,DDI-DrugBank.d578.s5,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,DDI-DrugBank.d578.s5.p0,0,troleandomycin,ketoconazole
13,DDI-DrugBank.d578.s5,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,DDI-DrugBank.d578.s5.p1,2,troleandomycin,methylprednisolone
14,DDI-DrugBank.d578.s5,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,DDI-DrugBank.d578.s5.p2,2,ketoconazole,methylprednisolone
15,DDI-DrugBank.d578.s7,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,DDI-DrugBank.d578.s7.p0,2,Methylprednisolone,aspirin
16,DDI-DrugBank.d578.s8,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,DDI-DrugBank.d578.s8.p0,0,salicylate,salicylate
17,DDI-DrugBank.d578.s8,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,DDI-DrugBank.d578.s8.p1,0,salicylate,methylprednisolone
18,DDI-DrugBank.d578.s8,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,DDI-DrugBank.d578.s8.p2,3,salicylate,methylprednisolone
19,DDI-DrugBank.d578.s9,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,DDI-DrugBank.d578.s9.p0,1,Aspirin,corticosteroids
20,DDI-DrugBank.d578.s10,The effect of methylprednisolone on oral anticoagulants is variable. ,DDI-DrugBank.d578.s10.p0,0,methylprednisolone,anticoagulants
21,DDI-DrugBank.d578.s11,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,DDI-DrugBank.d578.s11.p0,3,anticoagulant,corticosteroids
0,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p0,0,Methscopolamine,antidepressants
1,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p1,4,Methscopolamine,tricyclic
2,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p2,4,Methscopolamine,MAO inhibitors
3,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p3,4,Methscopolamine,phenelzine
4,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p4,4,Methscopolamine,linezolid
5,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p5,4,Methscopolamine,tranylcypromine
6,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p6,4,Methscopolamine,isocarboxazid
7,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p7,4,Methscopolamine,selegiline
8,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p8,4,Methscopolamine,furazolidone
9,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p9,4,Methscopolamine,quinidine
10,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p10,4,Methscopolamine,amantadine
11,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p11,4,Methscopolamine,antihistamines
12,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p12,4,Methscopolamine,diphenhydramine
13,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p13,4,Methscopolamine,anticholinergics
14,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p14,4,Methscopolamine,potassium chloride
15,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p15,4,Methscopolamine,antacids
16,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p16,4,Methscopolamine,absorbent-type anti-diarrhea medicines
17,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p17,4,Methscopolamine,kaolin
18,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p18,4,Methscopolamine,pectin
19,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p19,4,Methscopolamine,phenothiazines
20,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p20,4,Methscopolamine,chlorpromazine
21,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p21,4,Methscopolamine,promethazine
22,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p22,0,antidepressants,tricyclic
23,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p23,0,antidepressants,MAO inhibitors
24,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p24,0,antidepressants,phenelzine
25,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p25,0,antidepressants,linezolid
26,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p26,0,antidepressants,tranylcypromine
27,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p27,0,antidepressants,isocarboxazid
28,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p28,0,antidepressants,selegiline
29,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p29,0,antidepressants,furazolidone
30,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p30,0,antidepressants,quinidine
31,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p31,0,antidepressants,amantadine
32,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p32,0,antidepressants,antihistamines
33,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p33,0,antidepressants,diphenhydramine
34,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p34,0,antidepressants,anticholinergics
35,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p35,0,antidepressants,potassium chloride
36,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p36,0,antidepressants,antacids
37,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p37,0,antidepressants,absorbent-type anti-diarrhea medicines
38,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p38,0,antidepressants,kaolin
39,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p39,0,antidepressants,pectin
40,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p40,0,antidepressants,phenothiazines
41,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p41,0,antidepressants,chlorpromazine
42,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p42,0,antidepressants,promethazine
43,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p43,0,tricyclic,MAO inhibitors
44,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p44,0,tricyclic,phenelzine
45,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p45,0,tricyclic,linezolid
46,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p46,0,tricyclic,tranylcypromine
47,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p47,0,tricyclic,isocarboxazid
48,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p48,0,tricyclic,selegiline
49,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p49,0,tricyclic,furazolidone
50,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p50,0,tricyclic,quinidine
51,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p51,0,tricyclic,amantadine
52,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p52,0,tricyclic,antihistamines
53,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p53,0,tricyclic,diphenhydramine
54,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p54,0,tricyclic,anticholinergics
55,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p55,0,tricyclic,potassium chloride
56,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p56,0,tricyclic,antacids
57,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p57,0,tricyclic,absorbent-type anti-diarrhea medicines
58,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p58,0,tricyclic,kaolin
59,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p59,0,tricyclic,pectin
60,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p60,0,tricyclic,phenothiazines
61,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p61,0,tricyclic,chlorpromazine
62,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p62,0,tricyclic,promethazine
63,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p63,0,MAO inhibitors,phenelzine
64,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p64,0,MAO inhibitors,linezolid
65,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p65,0,MAO inhibitors,tranylcypromine
66,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p66,0,MAO inhibitors,isocarboxazid
67,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p67,0,MAO inhibitors,selegiline
68,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p68,0,MAO inhibitors,furazolidone
69,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p69,0,MAO inhibitors,quinidine
70,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p70,0,MAO inhibitors,amantadine
71,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p71,0,MAO inhibitors,antihistamines
72,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p72,0,MAO inhibitors,diphenhydramine
73,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p73,0,MAO inhibitors,anticholinergics
74,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p74,0,MAO inhibitors,potassium chloride
75,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p75,0,MAO inhibitors,antacids
76,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p76,0,MAO inhibitors,absorbent-type anti-diarrhea medicines
77,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p77,0,MAO inhibitors,kaolin
78,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p78,0,MAO inhibitors,pectin
79,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p79,0,MAO inhibitors,phenothiazines
80,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p80,0,MAO inhibitors,chlorpromazine
81,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p81,0,MAO inhibitors,promethazine
82,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p82,0,phenelzine,linezolid
83,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p83,0,phenelzine,tranylcypromine
84,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p84,0,phenelzine,isocarboxazid
85,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p85,0,phenelzine,selegiline
86,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p86,0,phenelzine,furazolidone
87,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p87,0,phenelzine,quinidine
88,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p88,0,phenelzine,amantadine
89,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p89,0,phenelzine,antihistamines
90,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p90,0,phenelzine,diphenhydramine
91,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p91,0,phenelzine,anticholinergics
92,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p92,0,phenelzine,potassium chloride
93,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p93,0,phenelzine,antacids
94,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p94,0,phenelzine,absorbent-type anti-diarrhea medicines
95,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p95,0,phenelzine,kaolin
96,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p96,0,phenelzine,pectin
97,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p97,0,phenelzine,phenothiazines
98,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p98,0,phenelzine,chlorpromazine
99,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p99,0,phenelzine,promethazine
100,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p100,0,linezolid,tranylcypromine
101,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p101,0,linezolid,isocarboxazid
102,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p102,0,linezolid,selegiline
103,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p103,0,linezolid,furazolidone
104,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p104,0,linezolid,quinidine
105,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p105,0,linezolid,amantadine
106,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p106,0,linezolid,antihistamines
107,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p107,0,linezolid,diphenhydramine
108,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p108,0,linezolid,anticholinergics
109,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p109,0,linezolid,potassium chloride
110,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p110,0,linezolid,antacids
111,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p111,0,linezolid,absorbent-type anti-diarrhea medicines
112,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p112,0,linezolid,kaolin
113,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p113,0,linezolid,pectin
114,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p114,0,linezolid,phenothiazines
115,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p115,0,linezolid,chlorpromazine
116,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p116,0,linezolid,promethazine
117,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p117,0,tranylcypromine,isocarboxazid
118,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p118,0,tranylcypromine,selegiline
119,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p119,0,tranylcypromine,furazolidone
120,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p120,0,tranylcypromine,quinidine
121,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p121,0,tranylcypromine,amantadine
122,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p122,0,tranylcypromine,antihistamines
123,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p123,0,tranylcypromine,diphenhydramine
124,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p124,0,tranylcypromine,anticholinergics
125,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p125,0,tranylcypromine,potassium chloride
126,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p126,0,tranylcypromine,antacids
127,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p127,0,tranylcypromine,absorbent-type anti-diarrhea medicines
128,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p128,0,tranylcypromine,kaolin
129,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p129,0,tranylcypromine,pectin
130,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p130,0,tranylcypromine,phenothiazines
131,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p131,0,tranylcypromine,chlorpromazine
132,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p132,0,tranylcypromine,promethazine
133,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p133,0,isocarboxazid,selegiline
134,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p134,0,isocarboxazid,furazolidone
135,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p135,0,isocarboxazid,quinidine
136,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p136,0,isocarboxazid,amantadine
137,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p137,0,isocarboxazid,antihistamines
138,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p138,0,isocarboxazid,diphenhydramine
139,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p139,0,isocarboxazid,anticholinergics
140,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p140,0,isocarboxazid,potassium chloride
141,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p141,0,isocarboxazid,antacids
142,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p142,0,isocarboxazid,absorbent-type anti-diarrhea medicines
143,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p143,0,isocarboxazid,kaolin
144,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p144,0,isocarboxazid,pectin
145,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p145,0,isocarboxazid,phenothiazines
146,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p146,0,isocarboxazid,chlorpromazine
147,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p147,0,isocarboxazid,promethazine
148,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p148,0,selegiline,furazolidone
149,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p149,0,selegiline,quinidine
150,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p150,0,selegiline,amantadine
151,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p151,0,selegiline,antihistamines
152,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p152,0,selegiline,diphenhydramine
153,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p153,0,selegiline,anticholinergics
154,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p154,0,selegiline,potassium chloride
155,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p155,0,selegiline,antacids
156,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p156,0,selegiline,absorbent-type anti-diarrhea medicines
157,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p157,0,selegiline,kaolin
158,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p158,0,selegiline,pectin
159,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p159,0,selegiline,phenothiazines
160,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p160,0,selegiline,chlorpromazine
161,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p161,0,selegiline,promethazine
162,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p162,0,furazolidone,quinidine
163,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p163,0,furazolidone,amantadine
164,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p164,0,furazolidone,antihistamines
165,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p165,0,furazolidone,diphenhydramine
166,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p166,0,furazolidone,anticholinergics
167,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p167,0,furazolidone,potassium chloride
168,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p168,0,furazolidone,antacids
169,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p169,0,furazolidone,absorbent-type anti-diarrhea medicines
170,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p170,0,furazolidone,kaolin
171,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p171,0,furazolidone,pectin
172,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p172,0,furazolidone,phenothiazines
173,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p173,0,furazolidone,chlorpromazine
174,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p174,0,furazolidone,promethazine
175,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p175,0,quinidine,amantadine
176,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p176,0,quinidine,antihistamines
177,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p177,0,quinidine,diphenhydramine
178,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p178,0,quinidine,anticholinergics
179,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p179,0,quinidine,potassium chloride
180,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p180,0,quinidine,antacids
181,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p181,0,quinidine,absorbent-type anti-diarrhea medicines
182,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p182,0,quinidine,kaolin
183,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p183,0,quinidine,pectin
184,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p184,0,quinidine,phenothiazines
185,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p185,0,quinidine,chlorpromazine
186,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p186,0,quinidine,promethazine
187,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p187,0,amantadine,antihistamines
188,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p188,0,amantadine,diphenhydramine
189,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p189,0,amantadine,anticholinergics
190,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p190,0,amantadine,potassium chloride
191,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p191,0,amantadine,antacids
192,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p192,0,amantadine,absorbent-type anti-diarrhea medicines
193,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p193,0,amantadine,kaolin
194,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p194,0,amantadine,pectin
195,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p195,0,amantadine,phenothiazines
196,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p196,0,amantadine,chlorpromazine
197,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p197,0,amantadine,promethazine
198,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p198,0,antihistamines,diphenhydramine
199,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p199,0,antihistamines,anticholinergics
200,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p200,0,antihistamines,potassium chloride
201,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p201,0,antihistamines,antacids
202,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p202,0,antihistamines,absorbent-type anti-diarrhea medicines
203,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p203,0,antihistamines,kaolin
204,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p204,0,antihistamines,pectin
205,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p205,0,antihistamines,phenothiazines
206,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p206,0,antihistamines,chlorpromazine
207,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p207,0,antihistamines,promethazine
208,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p208,0,diphenhydramine,anticholinergics
209,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p209,0,diphenhydramine,potassium chloride
210,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p210,0,diphenhydramine,antacids
211,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p211,0,diphenhydramine,absorbent-type anti-diarrhea medicines
212,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p212,0,diphenhydramine,kaolin
213,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p213,0,diphenhydramine,pectin
214,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p214,0,diphenhydramine,phenothiazines
215,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p215,0,diphenhydramine,chlorpromazine
216,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p216,0,diphenhydramine,promethazine
217,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p217,0,anticholinergics,potassium chloride
218,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p218,0,anticholinergics,antacids
219,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p219,0,anticholinergics,absorbent-type anti-diarrhea medicines
220,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p220,0,anticholinergics,kaolin
221,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p221,0,anticholinergics,pectin
222,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p222,0,anticholinergics,phenothiazines
223,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p223,0,anticholinergics,chlorpromazine
224,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p224,0,anticholinergics,promethazine
225,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p225,0,potassium chloride,antacids
226,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p226,0,potassium chloride,absorbent-type anti-diarrhea medicines
227,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p227,0,potassium chloride,kaolin
228,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p228,0,potassium chloride,pectin
229,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p229,0,potassium chloride,phenothiazines
230,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p230,0,potassium chloride,chlorpromazine
231,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p231,0,potassium chloride,promethazine
232,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p232,0,antacids,absorbent-type anti-diarrhea medicines
233,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p233,0,antacids,kaolin
234,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p234,0,antacids,pectin
235,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p235,0,antacids,phenothiazines
236,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p236,0,antacids,chlorpromazine
237,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p237,0,antacids,promethazine
238,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p238,0,absorbent-type anti-diarrhea medicines,kaolin
239,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p239,0,absorbent-type anti-diarrhea medicines,pectin
240,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p240,0,absorbent-type anti-diarrhea medicines,phenothiazines
241,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p241,0,absorbent-type anti-diarrhea medicines,chlorpromazine
242,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p242,0,absorbent-type anti-diarrhea medicines,promethazine
243,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p243,0,kaolin,pectin
244,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p244,0,kaolin,phenothiazines
245,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p245,0,kaolin,chlorpromazine
246,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p246,0,kaolin,promethazine
247,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p247,0,pectin,phenothiazines
248,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p248,0,pectin,chlorpromazine
249,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p249,0,pectin,promethazine
250,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p250,0,phenothiazines,chlorpromazine
251,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p251,0,phenothiazines,promethazine
252,DDI-DrugBank.d655.s0,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",DDI-DrugBank.d655.s0.p252,0,chlorpromazine,promethazine
0,DDI-DrugBank.d600.s1,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,DDI-DrugBank.d600.s1.p0,0,alcohol,CNS depression-producing drugs
1,DDI-DrugBank.d600.s1,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,DDI-DrugBank.d600.s1.p1,3,alcohol,methyprylon
2,DDI-DrugBank.d600.s1,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,DDI-DrugBank.d600.s1.p2,3,CNS depression-producing drugs,methyprylon
0,DDI-DrugBank.d696.s0,Methysergide may reverse the analgesic activity of narcotic analgesics. ,DDI-DrugBank.d696.s0.p0,3,Methysergide,narcotic analgesics
1,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p0,0,vasoconstrictor agents,ergot alkaloids
2,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p1,0,vasoconstrictor agents,sumatriptan
3,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p2,0,vasoconstrictor agents,nicotine
4,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p3,0,ergot alkaloids,sumatriptan
5,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p4,0,ergot alkaloids,nicotine
6,DDI-DrugBank.d696.s1,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",DDI-DrugBank.d696.s1.p5,0,sumatriptan,nicotine
0,DDI-DrugBank.d652.s0,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,DDI-DrugBank.d652.s0.p0,3,metoclopramide,anticholinergic drugs
1,DDI-DrugBank.d652.s0,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,DDI-DrugBank.d652.s0.p1,3,metoclopramide,narcotic analgesics
2,DDI-DrugBank.d652.s0,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,DDI-DrugBank.d652.s0.p2,0,anticholinergic drugs,narcotic analgesics
3,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p0,3,metoclopramide,alcohol
4,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p1,3,metoclopramide,sedatives
5,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p2,3,metoclopramide,hypnotics
6,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p3,3,metoclopramide,narcotics
7,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p4,3,metoclopramide,tranquilizers
8,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p5,0,alcohol,sedatives
9,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p6,0,alcohol,hypnotics
10,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p7,0,alcohol,narcotics
11,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p8,0,alcohol,tranquilizers
12,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p9,0,sedatives,hypnotics
13,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p10,0,sedatives,narcotics
14,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p11,0,sedatives,tranquilizers
15,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p12,0,hypnotics,narcotics
16,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p13,0,hypnotics,tranquilizers
17,DDI-DrugBank.d652.s1,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",DDI-DrugBank.d652.s1.p14,0,narcotics,tranquilizers
18,DDI-DrugBank.d652.s2,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",DDI-DrugBank.d652.s2.p0,1,metoclopramide,monoamine oxi-dase inhibitors
19,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p0,2,digoxin,metoclopramide
20,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p1,0,digoxin,acetaminophen
21,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p2,0,digoxin,tetracycline
22,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p3,0,digoxin,levodopa
23,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p4,0,digoxin,ethanol
24,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p5,0,digoxin,cyclosporine
25,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p6,2,metoclopramide,acetaminophen
26,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p7,0,metoclopramide,tetracycline
27,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p8,0,metoclopramide,levodopa
28,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p9,0,metoclopramide,ethanol
29,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p10,0,metoclopramide,cyclosporine
30,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p11,0,acetaminophen,tetracycline
31,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p12,0,acetaminophen,levodopa
32,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p13,0,acetaminophen,ethanol
33,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p14,0,acetaminophen,cyclosporine
34,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p15,0,tetracycline,levodopa
35,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p16,0,tetracycline,ethanol
36,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p17,0,tetracycline,cyclosporine
37,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p18,0,levodopa,ethanol
38,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p19,0,levodopa,cyclosporine
39,DDI-DrugBank.d652.s3,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",DDI-DrugBank.d652.s3.p20,0,ethanol,cyclosporine
40,DDI-DrugBank.d652.s6,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",DDI-DrugBank.d652.s6.p0,1,metoclopramide,insulin
0,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p0,0,Diuretics,Furosemide
1,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p1,0,Diuretics,loop diuretics
2,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p2,0,Diuretics,metolazone
3,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p3,0,Furosemide,loop diuretics
4,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p4,3,Furosemide,metolazone
5,DDI-DrugBank.d588.s0,Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,DDI-DrugBank.d588.s0.p5,3,loop diuretics,metolazone
6,DDI-DrugBank.d588.s1,"Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ",DDI-DrugBank.d588.s1.p0,0,Antihypertensives,MYKROX
7,DDI-DrugBank.d588.s1,"Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ",DDI-DrugBank.d588.s1.p1,0,Antihypertensives,antihypertensive drugs
8,DDI-DrugBank.d588.s1,"Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ",DDI-DrugBank.d588.s1.p2,1,MYKROX,antihypertensive drugs
9,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p0,0,Alcohol,Barbiturates
10,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p1,0,Alcohol,Narcotics
11,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p2,0,Alcohol,metolazone
12,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p3,0,Barbiturates,Narcotics
13,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p4,0,Barbiturates,metolazone
14,DDI-DrugBank.d588.s3,"Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",DDI-DrugBank.d588.s3.p5,0,Narcotics,metolazone
15,DDI-DrugBank.d588.s4,Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ,DDI-DrugBank.d588.s4.p0,0,Digitalis Glycosides,Diuretic
16,DDI-DrugBank.d588.s4,Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ,DDI-DrugBank.d588.s4.p1,0,Digitalis Glycosides,digitalis
17,DDI-DrugBank.d588.s4,Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ,DDI-DrugBank.d588.s4.p2,3,Diuretic,digitalis
18,DDI-DrugBank.d588.s6,Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention. ,DDI-DrugBank.d588.s6.p0,0,Corticosteroids,ACTH
19,DDI-DrugBank.d588.s7,Lithium: Serum lithium levels may increase. ,DDI-DrugBank.d588.s7.p0,0,Lithium,lithium
20,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p0,0,Curariform Drugs,Diuretic
21,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p1,0,Curariform Drugs,curariform drugs
22,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p2,0,Curariform Drugs,tubocurarine
23,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p3,3,Diuretic,curariform drugs
24,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p4,3,Diuretic,tubocurarine
25,DDI-DrugBank.d588.s8,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,DDI-DrugBank.d588.s8.p5,0,curariform drugs,tubocurarine
26,DDI-DrugBank.d588.s10,Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. ,DDI-DrugBank.d588.s10.p0,0,Salicylates,Non-Steroidal Anti-Inflammatory Drugs
27,DDI-DrugBank.d588.s10,Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. ,DDI-DrugBank.d588.s10.p1,3,Salicylates,MYKROX
28,DDI-DrugBank.d588.s10,Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. ,DDI-DrugBank.d588.s10.p2,3,Non-Steroidal Anti-Inflammatory Drugs,MYKROX
29,DDI-DrugBank.d588.s11,"Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",DDI-DrugBank.d588.s11.p0,0,Sympathomimetics,Metolazone
30,DDI-DrugBank.d588.s11,"Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",DDI-DrugBank.d588.s11.p1,0,Sympathomimetics,norepinephrine
31,DDI-DrugBank.d588.s11,"Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",DDI-DrugBank.d588.s11.p2,3,Metolazone,norepinephrine
32,DDI-DrugBank.d588.s12,Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone. ,DDI-DrugBank.d588.s12.p0,3,Methenamine,metolazone
33,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p0,0,Anticoagulants,Metolazone
34,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p1,0,Anticoagulants,thiazide-like diuretics
35,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p2,0,Anticoagulants,anticoagulants
36,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p3,0,Metolazone,thiazide-like diuretics
37,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p4,3,Metolazone,anticoagulants
38,DDI-DrugBank.d588.s13,"Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",DDI-DrugBank.d588.s13.p5,0,thiazide-like diuretics,anticoagulants
0,DDI-DrugBank.d706.s0,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",DDI-DrugBank.d706.s0.p0,3,reserpine,beta-blocking agents
0,DDI-DrugBank.d629.s0,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",DDI-DrugBank.d629.s0.p0,3,metronidazole,coumarin
1,DDI-DrugBank.d629.s0,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",DDI-DrugBank.d629.s0.p1,3,metronidazole,warfarin
2,DDI-DrugBank.d629.s0,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",DDI-DrugBank.d629.s0.p2,0,coumarin,warfarin
3,DDI-DrugBank.d629.s1,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",DDI-DrugBank.d629.s1.p0,0,METROGEL,metronidazole
4,DDI-DrugBank.d629.s1,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",DDI-DrugBank.d629.s1.p1,0,METROGEL,metronidazole
5,DDI-DrugBank.d629.s1,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",DDI-DrugBank.d629.s1.p2,0,metronidazole,metronidazole
0,DDI-DrugBank.d678.s1,The metabolism of Metopirone is accelerated by phenytoin; ,DDI-DrugBank.d678.s1.p0,2,Metopirone,phenytoin
1,DDI-DrugBank.d678.s4,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,DDI-DrugBank.d678.s4.p0,2,Metopirone,acetaminophen
2,DDI-DrugBank.d678.s4,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,DDI-DrugBank.d678.s4.p1,3,Metopirone,acetaminophen
3,DDI-DrugBank.d678.s4,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,DDI-DrugBank.d678.s4.p2,0,acetaminophen,acetaminophen
0,DDI-DrugBank.d715.s0,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DDI-DrugBank.d715.s0.p0,1,DEMSER,phenothiazines
1,DDI-DrugBank.d715.s0,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DDI-DrugBank.d715.s0.p1,1,DEMSER,haloperidol
2,DDI-DrugBank.d715.s0,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DDI-DrugBank.d715.s0.p2,0,phenothiazines,haloperidol
3,DDI-DrugBank.d715.s1,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DDI-DrugBank.d715.s1.p0,3,DEMSER,alcohol
4,DDI-DrugBank.d715.s1,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DDI-DrugBank.d715.s1.p1,3,DEMSER,CNS depressants
5,DDI-DrugBank.d715.s1,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DDI-DrugBank.d715.s1.p2,0,alcohol,CNS depressants
0,DDI-DrugBank.d633.s0,"Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. ",DDI-DrugBank.d633.s0.p0,0,MEXITIL,mexiletine
1,DDI-DrugBank.d633.s1,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",DDI-DrugBank.d633.s1.p0,2,mexiletine,fluvoxamine
2,DDI-DrugBank.d633.s2,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. ",DDI-DrugBank.d633.s2.p0,0,propafenone,mexiletine
3,DDI-DrugBank.d633.s4,"In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. ",DDI-DrugBank.d633.s4.p0,0,propafenone,mexiletine
4,DDI-DrugBank.d633.s5,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",DDI-DrugBank.d633.s5.p0,0,mexiletine,propafenone
5,DDI-DrugBank.d633.s5,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",DDI-DrugBank.d633.s5.p1,0,mexiletine,propafenone
6,DDI-DrugBank.d633.s5,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",DDI-DrugBank.d633.s5.p2,0,propafenone,propafenone
7,DDI-DrugBank.d633.s6,"When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect. ",DDI-DrugBank.d633.s6.p0,0,mexiletine,mexiletine
8,DDI-DrugBank.d633.s7,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",DDI-DrugBank.d633.s7.p0,0,Mexitil,antihypertensive
9,DDI-DrugBank.d633.s7,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",DDI-DrugBank.d633.s7.p1,0,Mexitil,anticoagulant drugs
10,DDI-DrugBank.d633.s7,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",DDI-DrugBank.d633.s7.p2,0,antihypertensive,anticoagulant drugs
11,DDI-DrugBank.d633.s8,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",DDI-DrugBank.d633.s8.p0,0,antiarrhythmics,quinidine
12,DDI-DrugBank.d633.s8,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",DDI-DrugBank.d633.s8.p1,0,antiarrhythmics,propranolol
13,DDI-DrugBank.d633.s8,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",DDI-DrugBank.d633.s8.p2,0,quinidine,propranolol
14,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p0,0,phenytoin,rifampin
15,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p1,0,phenytoin,phenobarbital
16,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p2,2,phenytoin,Mexitil
17,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p3,0,phenytoin,Mexitil
18,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p4,0,rifampin,phenobarbital
19,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p5,2,rifampin,Mexitil
20,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p6,0,rifampin,Mexitil
21,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p7,2,phenobarbital,Mexitil
22,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p8,0,phenobarbital,Mexitil
23,DDI-DrugBank.d633.s9,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",DDI-DrugBank.d633.s9.p9,0,Mexitil,Mexitil
24,DDI-DrugBank.d633.s11,"In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations. ",DDI-DrugBank.d633.s11.p0,0,benzodiazepines,Mexitil
25,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p0,0,Mexitil,digoxin
26,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p1,0,Mexitil,diuretics
27,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p2,0,Mexitil,propranolol
28,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p3,0,digoxin,diuretics
29,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p4,0,digoxin,propranolol
30,DDI-DrugBank.d633.s12,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",DDI-DrugBank.d633.s12.p5,0,diuretics,propranolol
31,DDI-DrugBank.d633.s13,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",DDI-DrugBank.d633.s13.p0,2,cimetidine,Mexitil
32,DDI-DrugBank.d633.s13,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",DDI-DrugBank.d633.s13.p1,0,cimetidine,Mexitil
33,DDI-DrugBank.d633.s13,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",DDI-DrugBank.d633.s13.p2,0,Mexitil,Mexitil
34,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p0,0,Mexitil,digoxin
35,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p1,0,Mexitil,magnesium-aluminum hydroxide
36,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p2,0,Mexitil,Mexitil
37,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p3,0,Mexitil,digoxin
38,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p4,0,digoxin,magnesium-aluminum hydroxide
39,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p5,0,digoxin,Mexitil
40,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p6,0,digoxin,digoxin
41,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p7,0,magnesium-aluminum hydroxide,Mexitil
42,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p8,2,magnesium-aluminum hydroxide,digoxin
43,DDI-DrugBank.d633.s15,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",DDI-DrugBank.d633.s15.p9,0,Mexitil,digoxin
44,DDI-DrugBank.d633.s16,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,DDI-DrugBank.d633.s16.p0,2,Mexitil,theophylline
45,DDI-DrugBank.d633.s16,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,DDI-DrugBank.d633.s16.p1,0,Mexitil,theophylline
46,DDI-DrugBank.d633.s16,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,DDI-DrugBank.d633.s16.p2,0,theophylline,theophylline
47,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p0,0,Mexitil,Theophylline
48,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p1,0,Mexitil,Mexitil
49,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p2,0,Mexitil,Mexitil
50,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p3,0,Mexitil,Mexitil
51,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p4,0,Mexitil,theophylline
52,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p5,0,Mexitil,theophylline
53,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p6,0,Mexitil,Mexitil
54,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p7,0,Theophylline,Mexitil
55,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p8,2,Theophylline,Mexitil
56,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p9,0,Theophylline,Mexitil
57,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p10,0,Theophylline,theophylline
58,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p11,0,Theophylline,theophylline
59,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p12,0,Theophylline,Mexitil
60,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p13,0,Mexitil,Mexitil
61,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p14,0,Mexitil,Mexitil
62,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p15,0,Mexitil,theophylline
63,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p16,0,Mexitil,theophylline
64,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p17,0,Mexitil,Mexitil
65,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p18,0,Mexitil,Mexitil
66,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p19,0,Mexitil,theophylline
67,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p20,0,Mexitil,theophylline
68,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p21,0,Mexitil,Mexitil
69,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p22,1,Mexitil,theophylline
70,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p23,0,Mexitil,theophylline
71,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p24,0,Mexitil,Mexitil
72,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p25,0,theophylline,theophylline
73,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p26,0,theophylline,Mexitil
74,DDI-DrugBank.d633.s18,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",DDI-DrugBank.d633.s18.p27,0,theophylline,Mexitil
75,DDI-DrugBank.d633.s20,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",DDI-DrugBank.d633.s20.p0,2,caffeine,Mexitil
0,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p0,2,Posicor,terfenadine
1,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p1,2,Posicor,astemizole
2,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p2,2,Posicor,cisapride
3,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p3,2,Posicor,cyclosporine
4,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p4,2,Posicor,tricyclic antidepressants
5,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p5,0,terfenadine,astemizole
6,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p6,0,terfenadine,cisapride
7,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p7,0,terfenadine,cyclosporine
8,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p8,0,terfenadine,tricyclic antidepressants
9,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p9,0,astemizole,cisapride
10,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p10,0,astemizole,cyclosporine
11,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p11,0,astemizole,tricyclic antidepressants
12,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p12,0,cisapride,cyclosporine
13,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p13,0,cisapride,tricyclic antidepressants
14,DDI-DrugBank.d783.s0,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",DDI-DrugBank.d783.s0.p14,0,cyclosporine,tricyclic antidepressants
0,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p0,0,MYCAMINE,mycophenolate mofetil
1,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p1,0,MYCAMINE,cyclosporine
2,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p2,0,MYCAMINE,tacrolimus
3,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p3,0,MYCAMINE,prednisolone
4,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p4,0,MYCAMINE,sirolimus
5,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p5,0,MYCAMINE,nifedipine
6,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p6,0,MYCAMINE,fluconazole
7,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p7,0,MYCAMINE,ritonavir
8,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p8,0,MYCAMINE,rifampin
9,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p9,0,mycophenolate mofetil,cyclosporine
10,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p10,0,mycophenolate mofetil,tacrolimus
11,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p11,0,mycophenolate mofetil,prednisolone
12,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p12,0,mycophenolate mofetil,sirolimus
13,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p13,0,mycophenolate mofetil,nifedipine
14,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p14,0,mycophenolate mofetil,fluconazole
15,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p15,0,mycophenolate mofetil,ritonavir
16,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p16,0,mycophenolate mofetil,rifampin
17,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p17,0,cyclosporine,tacrolimus
18,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p18,0,cyclosporine,prednisolone
19,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p19,0,cyclosporine,sirolimus
20,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p20,0,cyclosporine,nifedipine
21,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p21,0,cyclosporine,fluconazole
22,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p22,0,cyclosporine,ritonavir
23,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p23,0,cyclosporine,rifampin
24,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p24,0,tacrolimus,prednisolone
25,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p25,0,tacrolimus,sirolimus
26,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p26,0,tacrolimus,nifedipine
27,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p27,0,tacrolimus,fluconazole
28,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p28,0,tacrolimus,ritonavir
29,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p29,0,tacrolimus,rifampin
30,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p30,0,prednisolone,sirolimus
31,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p31,0,prednisolone,nifedipine
32,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p32,0,prednisolone,fluconazole
33,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p33,0,prednisolone,ritonavir
34,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p34,0,prednisolone,rifampin
35,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p35,0,sirolimus,nifedipine
36,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p36,0,sirolimus,fluconazole
37,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p37,0,sirolimus,ritonavir
38,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p38,0,sirolimus,rifampin
39,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p39,0,nifedipine,fluconazole
40,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p40,0,nifedipine,ritonavir
41,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p41,0,nifedipine,rifampin
42,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p42,0,fluconazole,ritonavir
43,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p43,0,fluconazole,rifampin
44,DDI-DrugBank.d735.s0,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",DDI-DrugBank.d735.s0.p44,0,ritonavir,rifampin
45,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p0,0,MYCAMINE,mycophenolate mofetil
46,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p1,0,MYCAMINE,cyclosporine
47,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p2,0,MYCAMINE,tacrolimus
48,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p3,0,MYCAMINE,prednisolone
49,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p4,0,MYCAMINE,fluconazole
50,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p5,0,mycophenolate mofetil,cyclosporine
51,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p6,0,mycophenolate mofetil,tacrolimus
52,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p7,0,mycophenolate mofetil,prednisolone
53,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p8,0,mycophenolate mofetil,fluconazole
54,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p9,0,cyclosporine,tacrolimus
55,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p10,0,cyclosporine,prednisolone
56,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p11,0,cyclosporine,fluconazole
57,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p12,0,tacrolimus,prednisolone
58,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p13,0,tacrolimus,fluconazole
59,DDI-DrugBank.d735.s2,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",DDI-DrugBank.d735.s2.p14,0,prednisolone,fluconazole
60,DDI-DrugBank.d735.s3,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,DDI-DrugBank.d735.s3.p0,2,Sirolimus,MYCAMINE
61,DDI-DrugBank.d735.s3,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,DDI-DrugBank.d735.s3.p1,0,Sirolimus,sirolimus
62,DDI-DrugBank.d735.s3,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,DDI-DrugBank.d735.s3.p2,0,MYCAMINE,sirolimus
63,DDI-DrugBank.d735.s4,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",DDI-DrugBank.d735.s4.p0,2,Nifedipine,MYCAMINE
64,DDI-DrugBank.d735.s4,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",DDI-DrugBank.d735.s4.p1,0,Nifedipine,nifedipine
65,DDI-DrugBank.d735.s4,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",DDI-DrugBank.d735.s4.p2,0,MYCAMINE,nifedipine
66,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p0,0,sirolimus,nifedipine
67,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p1,1,sirolimus,MYCAMINE
68,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p2,0,sirolimus,sirolimus
69,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p3,0,sirolimus,nifedipine
70,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p4,0,sirolimus,sirolimus
71,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p5,0,sirolimus,nifedipine
72,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p6,1,nifedipine,MYCAMINE
73,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p7,0,nifedipine,sirolimus
74,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p8,0,nifedipine,nifedipine
75,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p9,0,nifedipine,sirolimus
76,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p10,0,nifedipine,nifedipine
77,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p11,0,MYCAMINE,sirolimus
78,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p12,0,MYCAMINE,nifedipine
79,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p13,0,MYCAMINE,sirolimus
80,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p14,0,MYCAMINE,nifedipine
81,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p15,0,sirolimus,nifedipine
82,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p16,0,sirolimus,sirolimus
83,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p17,0,sirolimus,nifedipine
84,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p18,0,nifedipine,sirolimus
85,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p19,0,nifedipine,nifedipine
86,DDI-DrugBank.d735.s5,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,DDI-DrugBank.d735.s5.p20,0,sirolimus,nifedipine
0,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p0,1,midazolam,azole antimycotics
1,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p1,1,midazolam,protease inhibitors
2,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p2,1,midazolam,calcium channel antagonists
3,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p3,1,midazolam,macrolide antibiotics
4,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p4,0,azole antimycotics,protease inhibitors
5,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p5,0,azole antimycotics,calcium channel antagonists
6,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p6,0,azole antimycotics,macrolide antibiotics
7,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p7,0,protease inhibitors,calcium channel antagonists
8,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p8,0,protease inhibitors,macrolide antibiotics
9,DDI-DrugBank.d752.s0,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",DDI-DrugBank.d752.s0.p9,0,calcium channel antagonists,macrolide antibiotics
10,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p0,0,erythromycin,diltiazem
11,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p1,0,erythromycin,verapamil
12,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p2,0,erythromycin,ketoconazole
13,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p3,0,erythromycin,fluconazole
14,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p4,0,erythromycin,itraconazole
15,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p5,2,erythromycin,midazolam
16,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p6,0,diltiazem,verapamil
17,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p7,0,diltiazem,ketoconazole
18,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p8,0,diltiazem,fluconazole
19,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p9,0,diltiazem,itraconazole
20,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p10,2,diltiazem,midazolam
21,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p11,0,verapamil,ketoconazole
22,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p12,0,verapamil,fluconazole
23,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p13,0,verapamil,itraconazole
24,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p14,2,verapamil,midazolam
25,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p15,0,ketoconazole,fluconazole
26,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p16,0,ketoconazole,itraconazole
27,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p17,2,ketoconazole,midazolam
28,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p18,0,fluconazole,itraconazole
29,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p19,2,fluconazole,midazolam
30,DDI-DrugBank.d752.s1,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",DDI-DrugBank.d752.s1.p20,2,itraconazole,midazolam
31,DDI-DrugBank.d752.s3,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",DDI-DrugBank.d752.s3.p0,0,ritonavir,nelfinavir
32,DDI-DrugBank.d752.s3,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",DDI-DrugBank.d752.s3.p1,2,ritonavir,midazolam
33,DDI-DrugBank.d752.s3,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",DDI-DrugBank.d752.s3.p2,2,nelfinavir,midazolam
34,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p0,0,rifampin,carbamazepine
35,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p1,0,rifampin,phenytoin
36,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p2,2,rifampin,midazolam
37,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p3,0,carbamazepine,phenytoin
38,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p4,2,carbamazepine,midazolam
39,DDI-DrugBank.d752.s6,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",DDI-DrugBank.d752.s6.p5,2,phenytoin,midazolam
40,DDI-DrugBank.d752.s9,The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate. ,DDI-DrugBank.d752.s9.p0,0,sedatives,methylphenidate
41,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p0,3,VERSED Syrup,narcotics
42,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p1,3,VERSED Syrup,morphine
43,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p2,3,VERSED Syrup,meperidine
44,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p3,3,VERSED Syrup,fentanyl
45,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p4,3,VERSED Syrup,propofol
46,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p5,3,VERSED Syrup,ketamine
47,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p6,3,VERSED Syrup,nitrous oxide
48,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p7,3,VERSED Syrup,secobarbital
49,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p8,3,VERSED Syrup,droperidol
50,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p9,0,narcotics,morphine
51,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p10,0,narcotics,meperidine
52,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p11,0,narcotics,fentanyl
53,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p12,0,narcotics,propofol
54,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p13,0,narcotics,ketamine
55,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p14,0,narcotics,nitrous oxide
56,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p15,0,narcotics,secobarbital
57,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p16,0,narcotics,droperidol
58,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p17,0,morphine,meperidine
59,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p18,0,morphine,fentanyl
60,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p19,0,morphine,propofol
61,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p20,0,morphine,ketamine
62,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p21,0,morphine,nitrous oxide
63,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p22,0,morphine,secobarbital
64,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p23,0,morphine,droperidol
65,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p24,0,meperidine,fentanyl
66,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p25,0,meperidine,propofol
67,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p26,0,meperidine,ketamine
68,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p27,0,meperidine,nitrous oxide
69,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p28,0,meperidine,secobarbital
70,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p29,0,meperidine,droperidol
71,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p30,0,fentanyl,propofol
72,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p31,0,fentanyl,ketamine
73,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p32,0,fentanyl,nitrous oxide
74,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p33,0,fentanyl,secobarbital
75,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p34,0,fentanyl,droperidol
76,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p35,0,propofol,ketamine
77,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p36,0,propofol,nitrous oxide
78,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p37,0,propofol,secobarbital
79,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p38,0,propofol,droperidol
80,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p39,0,ketamine,nitrous oxide
81,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p40,0,ketamine,secobarbital
82,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p41,0,ketamine,droperidol
83,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p42,0,nitrous oxide,secobarbital
84,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p43,0,nitrous oxide,droperidol
85,DDI-DrugBank.d752.s10,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",DDI-DrugBank.d752.s10.p44,0,secobarbital,droperidol
86,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p0,0,atropine,scopolamine
87,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p1,0,atropine,glycopyrrolate
88,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p2,0,atropine,diazepam
89,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p3,0,atropine,hydroxyzine
90,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p4,0,atropine,muscle relaxants
91,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p5,0,atropine,anesthetics
92,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p6,0,scopolamine,glycopyrrolate
93,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p7,0,scopolamine,diazepam
94,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p8,0,scopolamine,hydroxyzine
95,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p9,0,scopolamine,muscle relaxants
96,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p10,0,scopolamine,anesthetics
97,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p11,0,glycopyrrolate,diazepam
98,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p12,0,glycopyrrolate,hydroxyzine
99,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p13,0,glycopyrrolate,muscle relaxants
100,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p14,0,glycopyrrolate,anesthetics
101,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p15,0,diazepam,hydroxyzine
102,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p16,0,diazepam,muscle relaxants
103,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p17,0,diazepam,anesthetics
104,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p18,0,hydroxyzine,muscle relaxants
105,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p19,0,hydroxyzine,anesthetics
106,DDI-DrugBank.d752.s12,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",DDI-DrugBank.d752.s12.p20,0,muscle relaxants,anesthetics
0,DDI-DrugBank.d603.s0,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",DDI-DrugBank.d603.s0.p0,3,ProAmatine,cardiac glycosides
1,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p0,0,phenylephrine,pseudoephedrine
2,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p1,0,phenylephrine,ephedrine
3,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p2,0,phenylephrine,phenylpropanolamine
4,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p3,0,phenylephrine,dihydroergotamine
5,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p4,3,phenylephrine,ProAmatine
6,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p5,0,phenylephrine,ProAmatine
7,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p6,0,pseudoephedrine,ephedrine
8,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p7,0,pseudoephedrine,phenylpropanolamine
9,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p8,0,pseudoephedrine,dihydroergotamine
10,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p9,3,pseudoephedrine,ProAmatine
11,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p10,0,pseudoephedrine,ProAmatine
12,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p11,0,ephedrine,phenylpropanolamine
13,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p12,0,ephedrine,dihydroergotamine
14,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p13,3,ephedrine,ProAmatine
15,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p14,0,ephedrine,ProAmatine
16,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p15,0,phenylpropanolamine,dihydroergotamine
17,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p16,3,phenylpropanolamine,ProAmatine
18,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p17,0,phenylpropanolamine,ProAmatine
19,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p18,3,dihydroergotamine,ProAmatine
20,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p19,0,dihydroergotamine,ProAmatine
21,DDI-DrugBank.d603.s2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",DDI-DrugBank.d603.s2.p20,0,ProAmatine,ProAmatine
22,DDI-DrugBank.d603.s3,"ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. ",DDI-DrugBank.d603.s3.p0,0,ProAmatine,fludrocortisone acetate
23,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p0,0,ProAmatine,Alpha-adrenergic blocking agents
24,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p1,0,ProAmatine,prazosin
25,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p2,0,ProAmatine,terazosin
26,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p3,0,ProAmatine,doxazosin
27,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p4,0,ProAmatine,ProAmatine
28,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p5,0,ProAmatine,desglymidodrine
29,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p6,0,ProAmatine,metformin
30,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p7,0,ProAmatine,cimetidine
31,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p8,0,ProAmatine,ranitidine
32,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p9,0,ProAmatine,procainamide
33,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p10,0,ProAmatine,triamterene
34,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p11,0,ProAmatine,flecainide
35,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p12,0,ProAmatine,quinidine
36,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p13,0,Alpha-adrenergic blocking agents,prazosin
37,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p14,0,Alpha-adrenergic blocking agents,terazosin
38,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p15,0,Alpha-adrenergic blocking agents,doxazosin
39,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p16,3,Alpha-adrenergic blocking agents,ProAmatine
40,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p17,0,Alpha-adrenergic blocking agents,desglymidodrine
41,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p18,0,Alpha-adrenergic blocking agents,metformin
42,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p19,0,Alpha-adrenergic blocking agents,cimetidine
43,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p20,0,Alpha-adrenergic blocking agents,ranitidine
44,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p21,0,Alpha-adrenergic blocking agents,procainamide
45,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p22,0,Alpha-adrenergic blocking agents,triamterene
46,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p23,0,Alpha-adrenergic blocking agents,flecainide
47,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p24,0,Alpha-adrenergic blocking agents,quinidine
48,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p25,0,prazosin,terazosin
49,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p26,0,prazosin,doxazosin
50,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p27,3,prazosin,ProAmatine
51,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p28,0,prazosin,desglymidodrine
52,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p29,0,prazosin,metformin
53,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p30,0,prazosin,cimetidine
54,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p31,0,prazosin,ranitidine
55,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p32,0,prazosin,procainamide
56,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p33,0,prazosin,triamterene
57,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p34,0,prazosin,flecainide
58,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p35,0,prazosin,quinidine
59,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p36,0,terazosin,doxazosin
60,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p37,3,terazosin,ProAmatine
61,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p38,0,terazosin,desglymidodrine
62,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p39,0,terazosin,metformin
63,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p40,0,terazosin,cimetidine
64,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p41,0,terazosin,ranitidine
65,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p42,0,terazosin,procainamide
66,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p43,0,terazosin,triamterene
67,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p44,0,terazosin,flecainide
68,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p45,0,terazosin,quinidine
69,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p46,3,doxazosin,ProAmatine
70,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p47,0,doxazosin,desglymidodrine
71,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p48,0,doxazosin,metformin
72,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p49,0,doxazosin,cimetidine
73,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p50,0,doxazosin,ranitidine
74,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p51,0,doxazosin,procainamide
75,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p52,0,doxazosin,triamterene
76,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p53,0,doxazosin,flecainide
77,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p54,0,doxazosin,quinidine
78,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p55,0,ProAmatine,desglymidodrine
79,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p56,0,ProAmatine,metformin
80,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p57,0,ProAmatine,cimetidine
81,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p58,0,ProAmatine,ranitidine
82,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p59,0,ProAmatine,procainamide
83,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p60,0,ProAmatine,triamterene
84,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p61,0,ProAmatine,flecainide
85,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p62,0,ProAmatine,quinidine
86,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p63,2,desglymidodrine,metformin
87,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p64,2,desglymidodrine,cimetidine
88,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p65,2,desglymidodrine,ranitidine
89,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p66,2,desglymidodrine,procainamide
90,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p67,2,desglymidodrine,triamterene
91,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p68,2,desglymidodrine,flecainide
92,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p69,2,desglymidodrine,quinidine
93,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p70,0,metformin,cimetidine
94,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p71,0,metformin,ranitidine
95,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p72,0,metformin,procainamide
96,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p73,0,metformin,triamterene
97,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p74,0,metformin,flecainide
98,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p75,0,metformin,quinidine
99,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p76,0,cimetidine,ranitidine
100,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p77,0,cimetidine,procainamide
101,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p78,0,cimetidine,triamterene
102,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p79,0,cimetidine,flecainide
103,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p80,0,cimetidine,quinidine
104,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p81,0,ranitidine,procainamide
105,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p82,0,ranitidine,triamterene
106,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p83,0,ranitidine,flecainide
107,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p84,0,ranitidine,quinidine
108,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p85,0,procainamide,triamterene
109,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p86,0,procainamide,flecainide
110,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p87,0,procainamide,quinidine
111,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p88,0,triamterene,flecainide
112,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p89,0,triamterene,quinidine
113,DDI-DrugBank.d603.s5,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",DDI-DrugBank.d603.s5.p90,0,flecainide,quinidine
0,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p0,0,mifepristone,ketoconazole
1,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p1,0,mifepristone,itraconazole
2,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p2,0,mifepristone,erythromycin
3,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p3,0,mifepristone,mifepristone
4,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p4,0,ketoconazole,itraconazole
5,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p5,0,ketoconazole,erythromycin
6,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p6,2,ketoconazole,mifepristone
7,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p7,0,itraconazole,erythromycin
8,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p8,2,itraconazole,mifepristone
9,DDI-DrugBank.d668.s0,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",DDI-DrugBank.d668.s0.p9,2,erythromycin,mifepristone
10,DDI-DrugBank.d668.s1,"Furthermore, rifampin, dexamethasone, St. ",DDI-DrugBank.d668.s1.p0,0,rifampin,dexamethasone
11,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p0,0,anticonvulsants,phenytoin
12,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p1,0,anticonvulsants,phenobarbital
13,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p2,0,anticonvulsants,carbamazepine
14,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p3,2,anticonvulsants,mifepristone
15,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p4,0,anticonvulsants,mifepristone
16,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p5,0,phenytoin,phenobarbital
17,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p6,0,phenytoin,carbamazepine
18,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p7,2,phenytoin,mifepristone
19,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p8,0,phenytoin,mifepristone
20,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p9,0,phenobarbital,carbamazepine
21,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p10,2,phenobarbital,mifepristone
22,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p11,0,phenobarbital,mifepristone
23,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p12,2,carbamazepine,mifepristone
24,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p13,0,carbamazepine,mifepristone
25,DDI-DrugBank.d668.s2,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",DDI-DrugBank.d668.s2.p14,0,mifepristone,mifepristone
0,DDI-DrugBank.d695.s0,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",DDI-DrugBank.d695.s0.p0,2,ZAVESCA,Cerezyme
1,DDI-DrugBank.d695.s0,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",DDI-DrugBank.d695.s0.p1,0,ZAVESCA,Cerezyme
2,DDI-DrugBank.d695.s0,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",DDI-DrugBank.d695.s0.p2,0,Cerezyme,Cerezyme
3,DDI-DrugBank.d695.s1,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,DDI-DrugBank.d695.s1.p0,0,Cerezyme,imiglucerase
4,DDI-DrugBank.d695.s1,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,DDI-DrugBank.d695.s1.p1,1,Cerezyme,ZAVESCA
5,DDI-DrugBank.d695.s1,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,DDI-DrugBank.d695.s1.p2,1,imiglucerase,ZAVESCA
0,DDI-DrugBank.d711.s0,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",DDI-DrugBank.d711.s0.p0,1,tetracyclines,anticoagulant
1,DDI-DrugBank.d711.s0,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",DDI-DrugBank.d711.s0.p1,0,tetracyclines,anticoagulant
2,DDI-DrugBank.d711.s0,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",DDI-DrugBank.d711.s0.p2,0,anticoagulant,anticoagulant
3,DDI-DrugBank.d711.s1,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",DDI-DrugBank.d711.s1.p0,0,penicillin,tetracycline class drugs
4,DDI-DrugBank.d711.s1,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",DDI-DrugBank.d711.s1.p1,0,penicillin,penicillin
5,DDI-DrugBank.d711.s1,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",DDI-DrugBank.d711.s1.p2,1,tetracycline class drugs,penicillin
6,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p0,0,tetracyclines,antacids
7,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p1,2,tetracyclines,aluminum
8,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p2,2,tetracyclines,calcium
9,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p3,2,tetracyclines,magnesium
10,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p4,2,tetracyclines,iron
11,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p5,0,antacids,aluminum
12,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p6,0,antacids,calcium
13,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p7,0,antacids,magnesium
14,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p8,0,antacids,iron
15,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p9,0,aluminum,calcium
16,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p10,0,aluminum,magnesium
17,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p11,0,aluminum,iron
18,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p12,0,calcium,magnesium
19,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p13,0,calcium,iron
20,DDI-DrugBank.d711.s2,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",DDI-DrugBank.d711.s2.p14,0,magnesium,iron
21,DDI-DrugBank.d711.s3,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,DDI-DrugBank.d711.s3.p0,3,tetracycline,methoxyflurane
22,DDI-DrugBank.d711.s4,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,DDI-DrugBank.d711.s4.p0,3,tetracyclines,contraceptives
23,DDI-DrugBank.d711.s4,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,DDI-DrugBank.d711.s4.p1,0,tetracyclines,contraceptives
24,DDI-DrugBank.d711.s4,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,DDI-DrugBank.d711.s4.p2,0,contraceptives,contraceptives
0,DDI-DrugBank.d573.s0,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",DDI-DrugBank.d573.s0.p0,0,Guanethidine,minoxidil
1,DDI-DrugBank.d573.s0,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",DDI-DrugBank.d573.s0.p1,0,Guanethidine,guanethidine
2,DDI-DrugBank.d573.s0,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",DDI-DrugBank.d573.s0.p2,3,minoxidil,guanethidine
3,DDI-DrugBank.d573.s1,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,DDI-DrugBank.d573.s1.p0,1,guanethidine,minoxidil
0,DDI-DrugBank.d742.s2,Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. ,DDI-DrugBank.d742.s2.p0,0,REMERON SolTab,mirtazapine
1,DDI-DrugBank.d742.s5,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",DDI-DrugBank.d742.s5.p0,0,mirtazapine,mirtazapine
2,DDI-DrugBank.d742.s5,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",DDI-DrugBank.d742.s5.p1,0,mirtazapine,REMERON SolTab
3,DDI-DrugBank.d742.s5,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",DDI-DrugBank.d742.s5.p2,0,mirtazapine,REMERON SolTab
4,DDI-DrugBank.d742.s7,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,DDI-DrugBank.d742.s7.p0,0,Alcohol,alcohol
5,DDI-DrugBank.d742.s7,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,DDI-DrugBank.d742.s7.p1,0,Alcohol,mirtazapine
6,DDI-DrugBank.d742.s7,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,DDI-DrugBank.d742.s7.p2,2,alcohol,mirtazapine
7,DDI-DrugBank.d742.s8,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",DDI-DrugBank.d742.s8.p0,3,REMERON,alcohol
8,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p0,1,alcohol,REMERON SolTab
9,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p1,0,alcohol,Diazepam
10,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p2,0,alcohol,diazepam
11,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p3,0,alcohol,mirtazapine
12,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p4,0,REMERON SolTab,Diazepam
13,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p5,0,REMERON SolTab,diazepam
14,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p6,0,REMERON SolTab,mirtazapine
15,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p7,0,Diazepam,diazepam
16,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p8,0,Diazepam,mirtazapine
17,DDI-DrugBank.d742.s9,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",DDI-DrugBank.d742.s9.p9,2,diazepam,mirtazapine
18,DDI-DrugBank.d742.s10,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",DDI-DrugBank.d742.s10.p0,3,REMERON,diazepam
19,DDI-DrugBank.d742.s11,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",DDI-DrugBank.d742.s11.p0,1,diazepam,REMERON SolTab
0,DDI-DrugBank.d717.s0,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",DDI-DrugBank.d717.s0.p0,2,Mitotane,warfarin
1,DDI-DrugBank.d717.s0,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",DDI-DrugBank.d717.s0.p1,0,Mitotane,warfarin
2,DDI-DrugBank.d717.s0,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",DDI-DrugBank.d717.s0.p2,0,warfarin,warfarin
3,DDI-DrugBank.d717.s1,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",DDI-DrugBank.d717.s1.p0,0,anticoagulant,Mitotane
4,DDI-DrugBank.d717.s1,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",DDI-DrugBank.d717.s1.p1,0,anticoagulant,coumarin-type anticoagulants
5,DDI-DrugBank.d717.s1,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",DDI-DrugBank.d717.s1.p2,1,Mitotane,coumarin-type anticoagulants
0,DDI-DrugBank.d775.s0,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",DDI-DrugBank.d775.s0.p0,0,MIVACRON,MIVACRON
1,DDI-DrugBank.d775.s0,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",DDI-DrugBank.d775.s0.p1,0,MIVACRON,succinylcholine
2,DDI-DrugBank.d775.s0,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",DDI-DrugBank.d775.s0.p2,0,MIVACRON,succinylcholine
3,DDI-DrugBank.d775.s1,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,DDI-DrugBank.d775.s1.p0,3,succinylcholine,nondepolarizing agents
4,DDI-DrugBank.d775.s2,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,DDI-DrugBank.d775.s2.p0,1,succinylcholine,MIVACRON
5,DDI-DrugBank.d775.s3,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,DDI-DrugBank.d775.s3.p0,0,MIVACRON,succinylcholine
6,DDI-DrugBank.d775.s3,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,DDI-DrugBank.d775.s3.p1,0,MIVACRON,succinylcholine
7,DDI-DrugBank.d775.s3,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,DDI-DrugBank.d775.s3.p2,0,succinylcholine,succinylcholine
8,DDI-DrugBank.d775.s4,There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents. ,DDI-DrugBank.d775.s4.p0,0,MIVACRON,nondepolarizing neuromuscular blocking agents
9,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p0,0,Isoflurane,enflurane
10,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p1,0,Isoflurane,nitrous oxide
11,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p2,0,Isoflurane,oxygen
12,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p3,0,enflurane,nitrous oxide
13,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p4,0,enflurane,oxygen
14,DDI-DrugBank.d775.s5,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,DDI-DrugBank.d775.s5.p5,0,nitrous oxide,oxygen
15,DDI-DrugBank.d775.s8,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,DDI-DrugBank.d775.s8.p0,0,MIVACRON,enflurane
16,DDI-DrugBank.d775.s8,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,DDI-DrugBank.d775.s8.p1,0,MIVACRON,isoflurane
17,DDI-DrugBank.d775.s8,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,DDI-DrugBank.d775.s8.p2,0,enflurane,isoflurane
18,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p0,0,nondepolarizing agents,MIVACRON
19,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p1,4,nondepolarizing agents,antibiotics
20,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p2,4,nondepolarizing agents,aminoglycosides
21,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p3,4,nondepolarizing agents,tetracyclines
22,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p4,4,nondepolarizing agents,bacitracin
23,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p5,4,nondepolarizing agents,polymyxins
24,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p6,4,nondepolarizing agents,lincomycin
25,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p7,4,nondepolarizing agents,clindamycin
26,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p8,4,nondepolarizing agents,colistin
27,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p9,4,nondepolarizing agents,sodium colistimethate
28,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p10,4,nondepolarizing agents,magnesium
29,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p11,4,nondepolarizing agents,lithium
30,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p12,4,nondepolarizing agents,anesthetics
31,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p13,4,nondepolarizing agents,procainamide
32,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p14,4,nondepolarizing agents,quinidine
33,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p15,4,MIVACRON,antibiotics
34,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p16,4,MIVACRON,aminoglycosides
35,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p17,4,MIVACRON,tetracyclines
36,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p18,4,MIVACRON,bacitracin
37,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p19,4,MIVACRON,polymyxins
38,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p20,4,MIVACRON,lincomycin
39,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p21,4,MIVACRON,clindamycin
40,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p22,4,MIVACRON,colistin
41,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p23,4,MIVACRON,sodium colistimethate
42,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p24,4,MIVACRON,magnesium
43,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p25,4,MIVACRON,lithium
44,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p26,4,MIVACRON,anesthetics
45,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p27,4,MIVACRON,procainamide
46,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p28,4,MIVACRON,quinidine
47,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p29,0,antibiotics,aminoglycosides
48,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p30,0,antibiotics,tetracyclines
49,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p31,0,antibiotics,bacitracin
50,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p32,0,antibiotics,polymyxins
51,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p33,0,antibiotics,lincomycin
52,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p34,0,antibiotics,clindamycin
53,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p35,0,antibiotics,colistin
54,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p36,0,antibiotics,sodium colistimethate
55,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p37,0,antibiotics,magnesium
56,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p38,0,antibiotics,lithium
57,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p39,0,antibiotics,anesthetics
58,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p40,0,antibiotics,procainamide
59,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p41,0,antibiotics,quinidine
60,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p42,0,aminoglycosides,tetracyclines
61,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p43,0,aminoglycosides,bacitracin
62,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p44,0,aminoglycosides,polymyxins
63,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p45,0,aminoglycosides,lincomycin
64,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p46,0,aminoglycosides,clindamycin
65,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p47,0,aminoglycosides,colistin
66,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p48,0,aminoglycosides,sodium colistimethate
67,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p49,0,aminoglycosides,magnesium
68,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p50,0,aminoglycosides,lithium
69,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p51,0,aminoglycosides,anesthetics
70,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p52,0,aminoglycosides,procainamide
71,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p53,0,aminoglycosides,quinidine
72,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p54,0,tetracyclines,bacitracin
73,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p55,0,tetracyclines,polymyxins
74,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p56,0,tetracyclines,lincomycin
75,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p57,0,tetracyclines,clindamycin
76,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p58,0,tetracyclines,colistin
77,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p59,0,tetracyclines,sodium colistimethate
78,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p60,0,tetracyclines,magnesium
79,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p61,0,tetracyclines,lithium
80,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p62,0,tetracyclines,anesthetics
81,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p63,0,tetracyclines,procainamide
82,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p64,0,tetracyclines,quinidine
83,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p65,0,bacitracin,polymyxins
84,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p66,0,bacitracin,lincomycin
85,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p67,0,bacitracin,clindamycin
86,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p68,0,bacitracin,colistin
87,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p69,0,bacitracin,sodium colistimethate
88,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p70,0,bacitracin,magnesium
89,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p71,0,bacitracin,lithium
90,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p72,0,bacitracin,anesthetics
91,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p73,0,bacitracin,procainamide
92,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p74,0,bacitracin,quinidine
93,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p75,0,polymyxins,lincomycin
94,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p76,0,polymyxins,clindamycin
95,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p77,0,polymyxins,colistin
96,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p78,0,polymyxins,sodium colistimethate
97,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p79,0,polymyxins,magnesium
98,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p80,0,polymyxins,lithium
99,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p81,0,polymyxins,anesthetics
100,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p82,0,polymyxins,procainamide
101,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p83,0,polymyxins,quinidine
102,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p84,0,lincomycin,clindamycin
103,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p85,0,lincomycin,colistin
104,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p86,0,lincomycin,sodium colistimethate
105,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p87,0,lincomycin,magnesium
106,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p88,0,lincomycin,lithium
107,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p89,0,lincomycin,anesthetics
108,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p90,0,lincomycin,procainamide
109,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p91,0,lincomycin,quinidine
110,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p92,0,clindamycin,colistin
111,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p93,0,clindamycin,sodium colistimethate
112,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p94,0,clindamycin,magnesium
113,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p95,0,clindamycin,lithium
114,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p96,0,clindamycin,anesthetics
115,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p97,0,clindamycin,procainamide
116,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p98,0,clindamycin,quinidine
117,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p99,0,colistin,sodium colistimethate
118,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p100,0,colistin,magnesium
119,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p101,0,colistin,lithium
120,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p102,0,colistin,anesthetics
121,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p103,0,colistin,procainamide
122,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p104,0,colistin,quinidine
123,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p105,0,sodium colistimethate,magnesium
124,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p106,0,sodium colistimethate,lithium
125,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p107,0,sodium colistimethate,anesthetics
126,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p108,0,sodium colistimethate,procainamide
127,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p109,0,sodium colistimethate,quinidine
128,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p110,0,magnesium,lithium
129,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p111,0,magnesium,anesthetics
130,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p112,0,magnesium,procainamide
131,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p113,0,magnesium,quinidine
132,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p114,0,lithium,anesthetics
133,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p115,0,lithium,procainamide
134,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p116,0,lithium,quinidine
135,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p117,0,anesthetics,procainamide
136,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p118,0,anesthetics,quinidine
137,DDI-DrugBank.d775.s10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",DDI-DrugBank.d775.s10.p119,0,procainamide,quinidine
138,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p0,3,MIVACRON,contraceptives
139,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p1,3,MIVACRON,glucocorticoids
140,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p2,3,MIVACRON,monoamine oxidase inhibitors
141,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p3,0,MIVACRON,neuromuscular blocking agents
142,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p4,0,MIVACRON,phenytoin
143,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p5,0,MIVACRON,carbamazepine
144,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p6,0,contraceptives,glucocorticoids
145,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p7,0,contraceptives,monoamine oxidase inhibitors
146,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p8,0,contraceptives,neuromuscular blocking agents
147,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p9,0,contraceptives,phenytoin
148,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p10,0,contraceptives,carbamazepine
149,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p11,0,glucocorticoids,monoamine oxidase inhibitors
150,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p12,0,glucocorticoids,neuromuscular blocking agents
151,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p13,0,glucocorticoids,phenytoin
152,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p14,0,glucocorticoids,carbamazepine
153,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p15,0,monoamine oxidase inhibitors,neuromuscular blocking agents
154,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p16,0,monoamine oxidase inhibitors,phenytoin
155,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p17,0,monoamine oxidase inhibitors,carbamazepine
156,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p18,3,neuromuscular blocking agents,phenytoin
157,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p19,3,neuromuscular blocking agents,carbamazepine
158,DDI-DrugBank.d775.s11,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",DDI-DrugBank.d775.s11.p20,0,phenytoin,carbamazepine
159,DDI-DrugBank.d775.s12,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",DDI-DrugBank.d775.s12.p0,0,phenytoin,carbamazepine
160,DDI-DrugBank.d775.s12,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",DDI-DrugBank.d775.s12.p1,3,phenytoin,MIVACRON
161,DDI-DrugBank.d775.s12,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",DDI-DrugBank.d775.s12.p2,3,carbamazepine,MIVACRON
162,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p0,0,corticosteroids,phenytoin
163,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p1,0,corticosteroids,carbamazepine
164,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p2,0,corticosteroids,antibiotics
165,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p3,0,corticosteroids,cisplatin
166,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p4,0,corticosteroids,edrophonium
167,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p5,0,corticosteroids,neostigmine
168,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p6,0,corticosteroids,polymyxin B
169,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p7,0,corticosteroids,bacitracin
170,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p8,0,corticosteroids,anesthetics
171,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p9,0,corticosteroids,procaine
172,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p10,0,corticosteroids,anesthetics
173,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p11,0,corticosteroids,succinylcholine
174,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p12,0,corticosteroids,muscle relaxants
175,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p13,0,phenytoin,carbamazepine
176,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p14,0,phenytoin,antibiotics
177,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p15,0,phenytoin,cisplatin
178,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p16,0,phenytoin,edrophonium
179,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p17,0,phenytoin,neostigmine
180,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p18,0,phenytoin,polymyxin B
181,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p19,0,phenytoin,bacitracin
182,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p20,0,phenytoin,anesthetics
183,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p21,0,phenytoin,procaine
184,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p22,0,phenytoin,anesthetics
185,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p23,0,phenytoin,succinylcholine
186,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p24,0,phenytoin,muscle relaxants
187,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p25,0,carbamazepine,antibiotics
188,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p26,0,carbamazepine,cisplatin
189,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p27,0,carbamazepine,edrophonium
190,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p28,0,carbamazepine,neostigmine
191,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p29,0,carbamazepine,polymyxin B
192,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p30,0,carbamazepine,bacitracin
193,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p31,0,carbamazepine,anesthetics
194,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p32,0,carbamazepine,procaine
195,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p33,0,carbamazepine,anesthetics
196,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p34,0,carbamazepine,succinylcholine
197,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p35,0,carbamazepine,muscle relaxants
198,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p36,0,antibiotics,cisplatin
199,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p37,0,antibiotics,edrophonium
200,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p38,0,antibiotics,neostigmine
201,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p39,0,antibiotics,polymyxin B
202,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p40,0,antibiotics,bacitracin
203,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p41,0,antibiotics,anesthetics
204,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p42,0,antibiotics,procaine
205,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p43,0,antibiotics,anesthetics
206,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p44,0,antibiotics,succinylcholine
207,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p45,0,antibiotics,muscle relaxants
208,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p46,0,cisplatin,edrophonium
209,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p47,0,cisplatin,neostigmine
210,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p48,0,cisplatin,polymyxin B
211,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p49,0,cisplatin,bacitracin
212,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p50,0,cisplatin,anesthetics
213,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p51,0,cisplatin,procaine
214,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p52,0,cisplatin,anesthetics
215,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p53,0,cisplatin,succinylcholine
216,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p54,0,cisplatin,muscle relaxants
217,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p55,0,edrophonium,neostigmine
218,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p56,0,edrophonium,polymyxin B
219,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p57,0,edrophonium,bacitracin
220,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p58,0,edrophonium,anesthetics
221,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p59,0,edrophonium,procaine
222,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p60,0,edrophonium,anesthetics
223,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p61,0,edrophonium,succinylcholine
224,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p62,0,edrophonium,muscle relaxants
225,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p63,0,neostigmine,polymyxin B
226,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p64,0,neostigmine,bacitracin
227,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p65,0,neostigmine,anesthetics
228,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p66,0,neostigmine,procaine
229,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p67,0,neostigmine,anesthetics
230,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p68,0,neostigmine,succinylcholine
231,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p69,0,neostigmine,muscle relaxants
232,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p70,0,polymyxin B,bacitracin
233,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p71,0,polymyxin B,anesthetics
234,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p72,0,polymyxin B,procaine
235,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p73,0,polymyxin B,anesthetics
236,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p74,0,polymyxin B,succinylcholine
237,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p75,0,polymyxin B,muscle relaxants
238,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p76,0,bacitracin,anesthetics
239,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p77,0,bacitracin,procaine
240,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p78,0,bacitracin,anesthetics
241,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p79,0,bacitracin,succinylcholine
242,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p80,0,bacitracin,muscle relaxants
243,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p81,0,anesthetics,procaine
244,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p82,0,anesthetics,anesthetics
245,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p83,0,anesthetics,succinylcholine
246,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p84,0,anesthetics,muscle relaxants
247,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p85,0,procaine,anesthetics
248,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p86,0,procaine,succinylcholine
249,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p87,0,procaine,muscle relaxants
250,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p88,0,anesthetics,succinylcholine
251,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p89,0,anesthetics,muscle relaxants
252,DDI-DrugBank.d775.s13,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,DDI-DrugBank.d775.s13.p90,0,succinylcholine,muscle relaxants
0,DDI-DrugBank.d640.s0,Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. ,DDI-DrugBank.d640.s0.p0,0,Diuretics,ACE inhibitors
1,DDI-DrugBank.d640.s1,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",DDI-DrugBank.d640.s1.p0,0,UNIVASC,UNIVASC
2,DDI-DrugBank.d640.s1,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",DDI-DrugBank.d640.s1.p1,0,UNIVASC,moexpril
3,DDI-DrugBank.d640.s1,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",DDI-DrugBank.d640.s1.p2,0,UNIVASC,moexpril
4,DDI-DrugBank.d640.s2,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,DDI-DrugBank.d640.s2.p0,0,Potassium,Potassium-Sparing Diuretics
5,DDI-DrugBank.d640.s2,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,DDI-DrugBank.d640.s2.p1,0,Potassium,UNIVASC
6,DDI-DrugBank.d640.s2,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,DDI-DrugBank.d640.s2.p2,0,Potassium-Sparing Diuretics,UNIVASC
7,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p0,0,potassium-sparing diuretics,spironolactone
8,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p1,0,potassium-sparing diuretics,triamterene
9,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p2,0,potassium-sparing diuretics,amiloride
10,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p3,0,potassium-sparing diuretics,potassium
11,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p4,3,potassium-sparing diuretics,ACE inhibitors
12,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p5,0,spironolactone,triamterene
13,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p6,0,spironolactone,amiloride
14,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p7,0,spironolactone,potassium
15,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p8,3,spironolactone,ACE inhibitors
16,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p9,0,triamterene,amiloride
17,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p10,0,triamterene,potassium
18,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p11,3,triamterene,ACE inhibitors
19,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p12,0,amiloride,potassium
20,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p13,3,amiloride,ACE inhibitors
21,DDI-DrugBank.d640.s3,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",DDI-DrugBank.d640.s3.p14,3,potassium,ACE inhibitors
22,DDI-DrugBank.d640.s5,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,DDI-DrugBank.d640.s5.p0,0,Anticoagulants,warfarin
23,DDI-DrugBank.d640.s5,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,DDI-DrugBank.d640.s5.p1,0,Anticoagulants,anticoagulant
24,DDI-DrugBank.d640.s5,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,DDI-DrugBank.d640.s5.p2,0,warfarin,anticoagulant
25,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p0,0,Lithium,lithium
26,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p1,0,Lithium,lithium
27,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p2,0,Lithium,ACE inhibitors
28,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p3,0,Lithium,lithium
29,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p4,0,lithium,lithium
30,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p5,0,lithium,ACE inhibitors
31,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p6,0,lithium,lithium
32,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p7,0,lithium,ACE inhibitors
33,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p8,0,lithium,lithium
34,DDI-DrugBank.d640.s6,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,DDI-DrugBank.d640.s6.p9,3,ACE inhibitors,lithium
35,DDI-DrugBank.d640.s8,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",DDI-DrugBank.d640.s8.p0,3,diuretic,lithium
36,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p0,0,UNIVASC,hydrochlorothiazide
37,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p1,0,UNIVASC,digoxin
38,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p2,0,UNIVASC,cimetidine
39,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p3,0,hydrochlorothiazide,digoxin
40,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p4,0,hydrochlorothiazide,cimetidine
41,DDI-DrugBank.d640.s9,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",DDI-DrugBank.d640.s9.p5,0,digoxin,cimetidine
42,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p0,0,UNIVASC,calcium-channel-blocking agents
43,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p1,0,UNIVASC,diuretics
44,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p2,0,UNIVASC,H2 blockers
45,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p3,0,UNIVASC,digoxin
46,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p4,0,UNIVASC,hypoglycemic agents
47,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p5,0,calcium-channel-blocking agents,diuretics
48,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p6,0,calcium-channel-blocking agents,H2 blockers
49,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p7,0,calcium-channel-blocking agents,digoxin
50,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p8,0,calcium-channel-blocking agents,hypoglycemic agents
51,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p9,0,diuretics,H2 blockers
52,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p10,0,diuretics,digoxin
53,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p11,0,diuretics,hypoglycemic agents
54,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p12,0,H2 blockers,digoxin
55,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p13,0,H2 blockers,hypoglycemic agents
56,DDI-DrugBank.d640.s10,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",DDI-DrugBank.d640.s10.p14,0,digoxin,hypoglycemic agents
0,DDI-DrugBank.d580.s1,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",DDI-DrugBank.d580.s1.p0,2,ketoconazole,mometasone furoate
0,DDI-DrugBank.d739.s0,Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate). ,DDI-DrugBank.d739.s0.p0,0,Montelukast,theophylline
1,DDI-DrugBank.d739.s1,- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). ,DDI-DrugBank.d739.s1.p0,0,warfarin,warfarin
2,DDI-DrugBank.d739.s3,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",DDI-DrugBank.d739.s3.p0,0,terfenadine,fexofenadine
3,DDI-DrugBank.d739.s3,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",DDI-DrugBank.d739.s3.p1,0,terfenadine,terfenadine
4,DDI-DrugBank.d739.s3,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",DDI-DrugBank.d739.s3.p2,0,fexofenadine,terfenadine
5,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p0,0,Montelukast,contraceptive
6,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p1,0,Montelukast,norethindrone
7,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p2,0,Montelukast,estradiol
8,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p3,0,contraceptive,norethindrone
9,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p4,0,contraceptive,estradiol
10,DDI-DrugBank.d739.s4,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,DDI-DrugBank.d739.s4.p5,0,norethindrone,estradiol
11,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p0,0,prednisone,prednisolone
12,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p1,0,prednisone,prednisone
13,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p2,0,prednisone,prednisolone
14,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p3,0,prednisolone,prednisone
15,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p4,0,prednisolone,prednisolone
16,DDI-DrugBank.d739.s5,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,DDI-DrugBank.d739.s5.p5,0,prednisone,prednisolone
17,DDI-DrugBank.d739.s6,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s6.p0,0,Phenobarbital,montelukast
18,DDI-DrugBank.d739.s6,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s6.p1,0,Phenobarbital,montelukast
19,DDI-DrugBank.d739.s6,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s6.p2,0,montelukast,montelukast
20,DDI-DrugBank.d739.s8,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",DDI-DrugBank.d739.s8.p0,0,phenobarbital,rifampin
21,DDI-DrugBank.d739.s8,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",DDI-DrugBank.d739.s8.p1,1,phenobarbital,montelukast
22,DDI-DrugBank.d739.s8,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",DDI-DrugBank.d739.s8.p2,1,rifampin,montelukast
23,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p0,0,montelukast,theophylline
24,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p1,0,montelukast,prednisone
25,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p2,0,montelukast,prednisolone
26,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p3,0,montelukast,contraceptives
27,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p4,0,montelukast,norethindrone
28,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p5,0,montelukast,ethinyl estradiol
29,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p6,0,montelukast,terfenadine
30,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p7,0,montelukast,digoxin
31,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p8,0,montelukast,warfarin
32,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p9,0,theophylline,prednisone
33,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p10,0,theophylline,prednisolone
34,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p11,0,theophylline,contraceptives
35,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p12,0,theophylline,norethindrone
36,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p13,0,theophylline,ethinyl estradiol
37,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p14,0,theophylline,terfenadine
38,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p15,0,theophylline,digoxin
39,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p16,0,theophylline,warfarin
40,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p17,0,prednisone,prednisolone
41,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p18,0,prednisone,contraceptives
42,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p19,0,prednisone,norethindrone
43,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p20,0,prednisone,ethinyl estradiol
44,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p21,0,prednisone,terfenadine
45,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p22,0,prednisone,digoxin
46,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p23,0,prednisone,warfarin
47,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p24,0,prednisolone,contraceptives
48,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p25,0,prednisolone,norethindrone
49,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p26,0,prednisolone,ethinyl estradiol
50,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p27,0,prednisolone,terfenadine
51,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p28,0,prednisolone,digoxin
52,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p29,0,prednisolone,warfarin
53,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p30,0,contraceptives,norethindrone
54,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p31,0,contraceptives,ethinyl estradiol
55,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p32,0,contraceptives,terfenadine
56,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p33,0,contraceptives,digoxin
57,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p34,0,contraceptives,warfarin
58,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p35,0,norethindrone,ethinyl estradiol
59,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p36,0,norethindrone,terfenadine
60,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p37,0,norethindrone,digoxin
61,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p38,0,norethindrone,warfarin
62,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p39,0,ethinyl estradiol,terfenadine
63,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p40,0,ethinyl estradiol,digoxin
64,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p41,0,ethinyl estradiol,warfarin
65,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p42,0,terfenadine,digoxin
66,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p43,0,terfenadine,warfarin
67,DDI-DrugBank.d739.s10,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",DDI-DrugBank.d739.s10.p44,0,digoxin,warfarin
68,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p0,0,thyroid hormones,sedative hypnotics
69,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p1,0,thyroid hormones,non-steroidal anti-inflammatory agents
70,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p2,0,thyroid hormones,benzodiazepines
71,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p3,0,thyroid hormones,decongestants
72,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p4,0,sedative hypnotics,non-steroidal anti-inflammatory agents
73,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p5,0,sedative hypnotics,benzodiazepines
74,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p6,0,sedative hypnotics,decongestants
75,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p7,0,non-steroidal anti-inflammatory agents,benzodiazepines
76,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p8,0,non-steroidal anti-inflammatory agents,decongestants
77,DDI-DrugBank.d739.s12,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",DDI-DrugBank.d739.s12.p9,0,benzodiazepines,decongestants
78,DDI-DrugBank.d739.s13,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s13.p0,0,Phenobarbital,montelukast
79,DDI-DrugBank.d739.s13,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s13.p1,0,Phenobarbital,montelukast
80,DDI-DrugBank.d739.s13,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",DDI-DrugBank.d739.s13.p2,0,montelukast,montelukast
81,DDI-DrugBank.d739.s15,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",DDI-DrugBank.d739.s15.p0,0,phenobarbital,rifampin
82,DDI-DrugBank.d739.s15,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",DDI-DrugBank.d739.s15.p1,1,phenobarbital,montelukast
83,DDI-DrugBank.d739.s15,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",DDI-DrugBank.d739.s15.p2,1,rifampin,montelukast
0,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p0,0,Central Nervous System Depressants,morphine
1,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p1,0,Central Nervous System Depressants,CNS depressants
2,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p2,0,Central Nervous System Depressants,alcohol
3,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p3,0,Central Nervous System Depressants,sedatives
4,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p4,0,Central Nervous System Depressants,antihistaminics
5,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p5,0,Central Nervous System Depressants,psychotropic drugs
6,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p6,3,morphine,CNS depressants
7,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p7,3,morphine,alcohol
8,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p8,3,morphine,sedatives
9,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p9,3,morphine,antihistaminics
10,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p10,3,morphine,psychotropic drugs
11,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p11,0,CNS depressants,alcohol
12,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p12,0,CNS depressants,sedatives
13,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p13,0,CNS depressants,antihistaminics
14,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p14,0,CNS depressants,psychotropic drugs
15,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p15,0,alcohol,sedatives
16,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p16,0,alcohol,antihistaminics
17,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p17,0,alcohol,psychotropic drugs
18,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p18,0,sedatives,antihistaminics
19,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p19,0,sedatives,psychotropic drugs
20,DDI-DrugBank.d637.s0,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",DDI-DrugBank.d637.s0.p20,0,antihistaminics,psychotropic drugs
21,DDI-DrugBank.d637.s1,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",DDI-DrugBank.d637.s1.p0,3,neuroleptics,morphine
22,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p0,0,Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics
23,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p1,0,Mixed Agonist/Antagonist Opioid Analgesics,pentazocine
24,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p2,0,Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine
25,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p3,0,Mixed Agonist/Antagonist Opioid Analgesics,butorphanol
26,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p4,0,Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine
27,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p5,0,Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic
28,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p6,0,Agonist/antagonist analgesics,pentazocine
29,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p7,0,Agonist/antagonist analgesics,nalbuphine
30,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p8,0,Agonist/antagonist analgesics,butorphanol
31,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p9,0,Agonist/antagonist analgesics,buprenorphine
32,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p10,1,Agonist/antagonist analgesics,opioid agonist analgesic
33,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p11,0,pentazocine,nalbuphine
34,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p12,0,pentazocine,butorphanol
35,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p13,0,pentazocine,buprenorphine
36,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p14,1,pentazocine,opioid agonist analgesic
37,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p15,0,nalbuphine,butorphanol
38,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p16,0,nalbuphine,buprenorphine
39,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p17,1,nalbuphine,opioid agonist analgesic
40,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p18,0,butorphanol,buprenorphine
41,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p19,1,butorphanol,opioid agonist analgesic
42,DDI-DrugBank.d637.s2,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",DDI-DrugBank.d637.s2.p20,1,buprenorphine,opioid agonist analgesic
0,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p0,0,Antacids,Myfortic
1,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p1,0,Antacids,magnesium
2,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p2,0,Antacids,aluminum
3,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p3,0,Antacids,antacids
4,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p4,0,Antacids,Myfortic
5,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p5,2,Myfortic,magnesium
6,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p6,2,Myfortic,aluminum
7,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p7,0,Myfortic,antacids
8,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p8,0,Myfortic,Myfortic
9,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p9,0,magnesium,aluminum
10,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p10,0,magnesium,antacids
11,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p11,0,magnesium,Myfortic
12,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p12,0,aluminum,antacids
13,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p13,0,aluminum,Myfortic
14,DDI-DrugBank.d700.s0,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",DDI-DrugBank.d700.s0.p14,0,antacids,Myfortic
15,DDI-DrugBank.d700.s1,It is recommended that Myfortic and antacids not be administered simultaneously. ,DDI-DrugBank.d700.s1.p0,1,Myfortic,antacids
16,DDI-DrugBank.d700.s2,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",DDI-DrugBank.d700.s2.p0,0,Cyclosporine,cyclosporine
17,DDI-DrugBank.d700.s2,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",DDI-DrugBank.d700.s2.p1,0,Cyclosporine,Myfortic
18,DDI-DrugBank.d700.s2,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",DDI-DrugBank.d700.s2.p2,0,cyclosporine,Myfortic
19,DDI-DrugBank.d700.s3,Acyclovir/Ganciclovir: may be taken with Myfortic; ,DDI-DrugBank.d700.s3.p0,0,Acyclovir,Ganciclovir
20,DDI-DrugBank.d700.s3,Acyclovir/Ganciclovir: may be taken with Myfortic; ,DDI-DrugBank.d700.s3.p1,0,Acyclovir,Myfortic
21,DDI-DrugBank.d700.s3,Acyclovir/Ganciclovir: may be taken with Myfortic; ,DDI-DrugBank.d700.s3.p2,0,Ganciclovir,Myfortic
22,DDI-DrugBank.d700.s5,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",DDI-DrugBank.d700.s5.p0,0,acyclovir,ganciclovir
23,DDI-DrugBank.d700.s5,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",DDI-DrugBank.d700.s5.p1,0,acyclovir,MPAG
24,DDI-DrugBank.d700.s5,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",DDI-DrugBank.d700.s5.p2,0,ganciclovir,MPAG
25,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p0,0,Azathioprine,Mycophenolate Mofetil
26,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p1,0,Azathioprine,azathioprine
27,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p2,0,Azathioprine,mycophenolate mofetil
28,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p3,0,Azathioprine,Myfortic
29,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p4,0,Azathioprine,azathioprine
30,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p5,0,Azathioprine,mycophenolate mofetil
31,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p6,0,Mycophenolate Mofetil,azathioprine
32,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p7,0,Mycophenolate Mofetil,mycophenolate mofetil
33,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p8,0,Mycophenolate Mofetil,Myfortic
34,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p9,0,Mycophenolate Mofetil,azathioprine
35,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p10,0,Mycophenolate Mofetil,mycophenolate mofetil
36,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p11,0,azathioprine,mycophenolate mofetil
37,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p12,0,azathioprine,Myfortic
38,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p13,0,azathioprine,azathioprine
39,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p14,0,azathioprine,mycophenolate mofetil
40,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p15,0,mycophenolate mofetil,Myfortic
41,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p16,0,mycophenolate mofetil,azathioprine
42,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p17,0,mycophenolate mofetil,mycophenolate mofetil
43,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p18,1,Myfortic,azathioprine
44,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p19,1,Myfortic,mycophenolate mofetil
45,DDI-DrugBank.d700.s6,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",DDI-DrugBank.d700.s6.p20,0,azathioprine,mycophenolate mofetil
46,DDI-DrugBank.d700.s7,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,DDI-DrugBank.d700.s7.p0,0,Cholestyramine,MPA
47,DDI-DrugBank.d700.s7,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,DDI-DrugBank.d700.s7.p1,0,Cholestyramine,mycophenolate mofetil
48,DDI-DrugBank.d700.s7,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,DDI-DrugBank.d700.s7.p2,0,MPA,mycophenolate mofetil
49,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p0,1,Myfortic,cholestyramine
50,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p1,1,Myfortic,activated charcoal
51,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p2,0,Myfortic,Myfortic
52,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p3,0,cholestyramine,activated charcoal
53,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p4,0,cholestyramine,Myfortic
54,DDI-DrugBank.d700.s8,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",DDI-DrugBank.d700.s8.p5,0,activated charcoal,Myfortic
55,DDI-DrugBank.d700.s9,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",DDI-DrugBank.d700.s9.p0,0,Contraceptives,Myfortic
56,DDI-DrugBank.d700.s9,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",DDI-DrugBank.d700.s9.p1,0,Contraceptives,contraceptives
57,DDI-DrugBank.d700.s9,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",DDI-DrugBank.d700.s9.p2,0,Myfortic,contraceptives
58,DDI-DrugBank.d700.s10,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",DDI-DrugBank.d700.s10.p0,2,levonorgesterol,mycophenolate mofetil
59,DDI-DrugBank.d700.s11,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",DDI-DrugBank.d700.s11.p0,1,contraceptives,Myfortic
60,DDI-DrugBank.d700.s12,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",DDI-DrugBank.d700.s12.p0,0,Live Vaccines,Myfortic
61,DDI-DrugBank.d700.s12,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",DDI-DrugBank.d700.s12.p1,0,Live Vaccines,live attenuated vaccines
62,DDI-DrugBank.d700.s12,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",DDI-DrugBank.d700.s12.p2,1,Myfortic,live attenuated vaccines
63,DDI-DrugBank.d700.s16,Interference of MPAG hydrolysis may lead to less MPA available for absorption.,DDI-DrugBank.d700.s16.p0,0,MPAG,MPA
0,DDI-DrugBank.d763.s1,"Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. ",DDI-DrugBank.d763.s1.p0,0,ondansetron,ondansetron
1,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p0,0,Phenytoin,Carbamazepine
2,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p1,0,Phenytoin,Rifampicin
3,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p2,0,Phenytoin,phenytoin
4,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p3,0,Phenytoin,carbamazepine
5,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p4,0,Phenytoin,rifampicin
6,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p5,0,Phenytoin,ondansetron
7,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p6,0,Phenytoin,ondansetron
8,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p7,0,Carbamazepine,Rifampicin
9,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p8,0,Carbamazepine,phenytoin
10,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p9,0,Carbamazepine,carbamazepine
11,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p10,0,Carbamazepine,rifampicin
12,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p11,0,Carbamazepine,ondansetron
13,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p12,0,Carbamazepine,ondansetron
14,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p13,0,Rifampicin,phenytoin
15,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p14,0,Rifampicin,carbamazepine
16,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p15,0,Rifampicin,rifampicin
17,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p16,0,Rifampicin,ondansetron
18,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p17,0,Rifampicin,ondansetron
19,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p18,0,phenytoin,carbamazepine
20,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p19,0,phenytoin,rifampicin
21,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p20,2,phenytoin,ondansetron
22,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p21,2,phenytoin,ondansetron
23,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p22,0,carbamazepine,rifampicin
24,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p23,2,carbamazepine,ondansetron
25,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p24,2,carbamazepine,ondansetron
26,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p25,2,rifampicin,ondansetron
27,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p26,2,rifampicin,ondansetron
28,DDI-DrugBank.d763.s3,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",DDI-DrugBank.d763.s3.p27,0,ondansetron,ondansetron
29,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p0,0,ondansetron,Tramadol
30,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p1,0,ondansetron,ondansetron
31,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p2,0,ondansetron,tramadol
32,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p3,0,ondansetron,ondansetron
33,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p4,0,ondansetron,tramadol
34,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p5,0,ondansetron,ondansetron
35,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p6,0,Tramadol,ondansetron
36,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p7,0,Tramadol,tramadol
37,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p8,0,Tramadol,ondansetron
38,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p9,0,Tramadol,tramadol
39,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p10,0,Tramadol,ondansetron
40,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p11,0,ondansetron,tramadol
41,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p12,0,ondansetron,ondansetron
42,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p13,0,ondansetron,tramadol
43,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p14,0,ondansetron,ondansetron
44,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p15,0,tramadol,ondansetron
45,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p16,0,tramadol,tramadol
46,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p17,0,tramadol,ondansetron
47,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p18,3,ondansetron,tramadol
48,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p19,0,ondansetron,ondansetron
49,DDI-DrugBank.d763.s4,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",DDI-DrugBank.d763.s4.p20,0,tramadol,ondansetron
50,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p0,0,carmustine,etoposide
51,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p1,0,carmustine,cisplatin
52,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p2,0,carmustine,ondansetron
53,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p3,0,etoposide,cisplatin
54,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p4,0,etoposide,ondansetron
55,DDI-DrugBank.d763.s5,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",DDI-DrugBank.d763.s5.p5,0,cisplatin,ondansetron
56,DDI-DrugBank.d763.s7,ondansetron did not increase blood levels of high-dose methotrexate.,DDI-DrugBank.d763.s7.p0,0,ondansetron,methotrexate
0,DDI-DrugBank.d611.s0,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,DDI-DrugBank.d611.s0.p0,1,beta adrenergic aerosol bronchodilators,Alupent
1,DDI-DrugBank.d611.s0,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,DDI-DrugBank.d611.s0.p1,1,beta adrenergic aerosol bronchodilators,metaproterenol sulfate
2,DDI-DrugBank.d611.s0,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,DDI-DrugBank.d611.s0.p2,0,Alupent,metaproterenol sulfate
3,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p0,1,Beta adrenergic agonists,monoamine oxidase inhibitors
4,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p1,1,Beta adrenergic agonists,tricyclic antidepressants
5,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p2,0,Beta adrenergic agonists,beta adrenergic agonists
6,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p3,0,monoamine oxidase inhibitors,tricyclic antidepressants
7,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p4,0,monoamine oxidase inhibitors,beta adrenergic agonists
8,DDI-DrugBank.d611.s1,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",DDI-DrugBank.d611.s1.p5,0,tricyclic antidepressants,beta adrenergic agonists
0,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p0,0,Alcohol,XENICAL
1,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p1,0,Alcohol,alcohol
2,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p2,0,Alcohol,alcohol
3,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p3,0,Alcohol,orlistat
4,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p4,0,Alcohol,orlistat
5,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p5,0,XENICAL,alcohol
6,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p6,0,XENICAL,alcohol
7,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p7,0,XENICAL,orlistat
8,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p8,0,XENICAL,orlistat
9,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p9,0,alcohol,alcohol
10,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p10,0,alcohol,orlistat
11,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p11,0,alcohol,orlistat
12,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p12,0,alcohol,orlistat
13,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p13,0,alcohol,orlistat
14,DDI-DrugBank.d761.s0,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",DDI-DrugBank.d761.s0.p14,0,orlistat,orlistat
15,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p0,0,Cyclosporine,XENICAL
16,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p1,0,Cyclosporine,cyclosporine
17,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p2,0,Cyclosporine,cyclosporine
18,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p3,0,Cyclosporine,XENICAL
19,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p4,0,Cyclosporine,cyclosporine
20,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p5,0,XENICAL,cyclosporine
21,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p6,0,XENICAL,cyclosporine
22,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p7,0,XENICAL,XENICAL
23,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p8,0,XENICAL,cyclosporine
24,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p9,0,cyclosporine,cyclosporine
25,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p10,0,cyclosporine,XENICAL
26,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p11,0,cyclosporine,cyclosporine
27,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p12,0,cyclosporine,XENICAL
28,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p13,0,cyclosporine,cyclosporine
29,DDI-DrugBank.d761.s1,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,DDI-DrugBank.d761.s1.p14,2,XENICAL,cyclosporine
30,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p0,0,Digoxin,XENICAL
31,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p1,0,Digoxin,XENICAL
32,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p2,0,Digoxin,digoxin
33,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p3,0,XENICAL,XENICAL
34,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p4,0,XENICAL,digoxin
35,DDI-DrugBank.d761.s2,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",DDI-DrugBank.d761.s2.p5,0,XENICAL,digoxin
36,DDI-DrugBank.d761.s3,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,DDI-DrugBank.d761.s3.p0,0,Fat-soluble Vitamin Supplements,beta-carotene
37,DDI-DrugBank.d761.s3,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,DDI-DrugBank.d761.s3.p1,0,Fat-soluble Vitamin Supplements,XENICAL
38,DDI-DrugBank.d761.s3,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,DDI-DrugBank.d761.s3.p2,2,beta-carotene,XENICAL
39,DDI-DrugBank.d761.s4,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,DDI-DrugBank.d761.s4.p0,2,XENICAL,vitamin E acetate
40,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p0,0,orlistat,vitamin D
41,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p1,0,orlistat,vitamin A
42,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p2,0,orlistat,vitamin K
43,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p3,0,vitamin D,vitamin A
44,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p4,0,vitamin D,vitamin K
45,DDI-DrugBank.d761.s5,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",DDI-DrugBank.d761.s5.p5,0,vitamin A,vitamin K
46,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p0,0,Glyburide,orlistat
47,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p1,0,Glyburide,orlistat
48,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p2,0,Glyburide,glyburide
49,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p3,0,orlistat,orlistat
50,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p4,0,orlistat,glyburide
51,DDI-DrugBank.d761.s6,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",DDI-DrugBank.d761.s6.p5,0,orlistat,glyburide
52,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p0,0,Nifedipine,XENICAL
53,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p1,0,Nifedipine,XENICAL
54,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p2,0,Nifedipine,nifedipine
55,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p3,0,XENICAL,XENICAL
56,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p4,0,XENICAL,nifedipine
57,DDI-DrugBank.d761.s7,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",DDI-DrugBank.d761.s7.p5,0,XENICAL,nifedipine
58,DDI-DrugBank.d761.s8,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",DDI-DrugBank.d761.s8.p0,0,Contraceptives,XENICAL
59,DDI-DrugBank.d761.s8,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",DDI-DrugBank.d761.s8.p1,0,Contraceptives,contraceptives
60,DDI-DrugBank.d761.s8,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",DDI-DrugBank.d761.s8.p2,0,XENICAL,contraceptives
61,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p0,0,Phenytoin,XENICAL
62,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p1,0,Phenytoin,XENICAL
63,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p2,0,Phenytoin,phenytoin
64,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p3,0,XENICAL,XENICAL
65,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p4,0,XENICAL,phenytoin
66,DDI-DrugBank.d761.s9,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",DDI-DrugBank.d761.s9.p5,0,XENICAL,phenytoin
67,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p0,0,Pravastatin,XENICAL
68,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p1,0,Pravastatin,XENICAL
69,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p2,0,Pravastatin,pravastatin
70,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p3,0,XENICAL,XENICAL
71,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p4,0,XENICAL,pravastatin
72,DDI-DrugBank.d761.s10,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",DDI-DrugBank.d761.s10.p5,0,XENICAL,pravastatin
73,DDI-DrugBank.d761.s11,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",DDI-DrugBank.d761.s11.p0,0,Warfarin,XENICAL
74,DDI-DrugBank.d761.s11,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",DDI-DrugBank.d761.s11.p1,0,Warfarin,warfarin
75,DDI-DrugBank.d761.s11,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",DDI-DrugBank.d761.s11.p2,0,XENICAL,warfarin
76,DDI-DrugBank.d761.s12,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. ",DDI-DrugBank.d761.s12.p0,0,XENICAL,XENICAL
77,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p0,2,vitamin K,XENICAL
78,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p1,0,vitamin K,warfarin
79,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p2,0,vitamin K,XENICAL
80,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p3,0,XENICAL,warfarin
81,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p4,0,XENICAL,XENICAL
82,DDI-DrugBank.d761.s13,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",DDI-DrugBank.d761.s13.p5,1,warfarin,XENICAL
0,DDI-DrugBank.d747.s0,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",DDI-DrugBank.d747.s0.p0,0,Tetracycline,antibiotic
1,DDI-DrugBank.d747.s0,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",DDI-DrugBank.d747.s0.p1,3,Tetracycline,penicillin
2,DDI-DrugBank.d747.s0,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",DDI-DrugBank.d747.s0.p2,0,antibiotic,penicillin
0,DDI-DrugBank.d728.s1,No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. ,DDI-DrugBank.d728.s1.p0,0,ELOXATIN,5-FU
1,DDI-DrugBank.d728.s2,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,DDI-DrugBank.d728.s2.p0,2,5-FU,ELOXATIN
0,DDI-DrugBank.d584.s0,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,DDI-DrugBank.d584.s0.p0,0,Anticoagulants,Anabolic steroids
1,DDI-DrugBank.d584.s0,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,DDI-DrugBank.d584.s0.p1,0,Anticoagulants,anticoagulants
2,DDI-DrugBank.d584.s0,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,DDI-DrugBank.d584.s0.p2,3,Anabolic steroids,anticoagulants
3,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p0,0,Warfarin,oxandrolone
4,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p1,0,Warfarin,warfarin
5,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p2,0,Warfarin,S-warfarin
6,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p3,0,Warfarin,R-warfarin
7,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p4,2,oxandrolone,warfarin
8,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p5,0,oxandrolone,S-warfarin
9,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p6,0,oxandrolone,R-warfarin
10,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p7,0,warfarin,S-warfarin
11,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p8,0,warfarin,R-warfarin
12,DDI-DrugBank.d584.s3,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",DDI-DrugBank.d584.s3.p9,0,S-warfarin,R-warfarin
13,DDI-DrugBank.d584.s5,"A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5. ",DDI-DrugBank.d584.s5.p0,0,warfarin,warfarin
14,DDI-DrugBank.d584.s6,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",DDI-DrugBank.d584.s6.p0,1,oxandrolone,warfarin
15,DDI-DrugBank.d584.s6,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",DDI-DrugBank.d584.s6.p1,0,oxandrolone,warfarin
16,DDI-DrugBank.d584.s6,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",DDI-DrugBank.d584.s6.p2,0,warfarin,warfarin
17,DDI-DrugBank.d584.s7,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",DDI-DrugBank.d584.s7.p0,1,warfarin,oxandrolone
18,DDI-DrugBank.d584.s9,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,DDI-DrugBank.d584.s9.p0,0,hypoglycemic agents,Oxandrolone
19,DDI-DrugBank.d584.s9,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,DDI-DrugBank.d584.s9.p1,0,hypoglycemic agents,hypoglycemic agents
20,DDI-DrugBank.d584.s9,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,DDI-DrugBank.d584.s9.p2,2,Oxandrolone,hypoglycemic agents
21,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p0,0,Adrenal steroids,ACTH
22,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p1,0,Adrenal steroids,adrenal cortical steroids
23,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p2,0,Adrenal steroids,ACTH
24,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p3,0,ACTH,adrenal cortical steroids
25,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p4,0,ACTH,ACTH
26,DDI-DrugBank.d584.s10,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",DDI-DrugBank.d584.s10.p5,0,adrenal cortical steroids,ACTH
0,DDI-DrugBank.d784.s0,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",DDI-DrugBank.d784.s0.p0,3,oxybutynin,anticholinergic drugs
1,DDI-DrugBank.d784.s3,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DDI-DrugBank.d784.s3.p0,0,oxybutynin chloride,DITROPAN XL
2,DDI-DrugBank.d784.s3,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DDI-DrugBank.d784.s3.p1,0,oxybutynin chloride,ketoconazole
3,DDI-DrugBank.d784.s3,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DDI-DrugBank.d784.s3.p2,2,DITROPAN XL,ketoconazole
4,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p0,0,antimycotic agents,itraconazole
5,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p1,0,antimycotic agents,miconazole
6,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p2,0,antimycotic agents,macrolide antibiotics
7,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p3,0,antimycotic agents,erythromycin
8,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p4,0,antimycotic agents,clarithromycin
9,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p5,2,antimycotic agents,oxybutynin
10,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p6,0,itraconazole,miconazole
11,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p7,0,itraconazole,macrolide antibiotics
12,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p8,0,itraconazole,erythromycin
13,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p9,0,itraconazole,clarithromycin
14,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p10,2,itraconazole,oxybutynin
15,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p11,0,miconazole,macrolide antibiotics
16,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p12,0,miconazole,erythromycin
17,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p13,0,miconazole,clarithromycin
18,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p14,2,miconazole,oxybutynin
19,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p15,0,macrolide antibiotics,erythromycin
20,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p16,0,macrolide antibiotics,clarithromycin
21,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p17,2,macrolide antibiotics,oxybutynin
22,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p18,0,erythromycin,clarithromycin
23,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p19,2,erythromycin,oxybutynin
24,DDI-DrugBank.d784.s4,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",DDI-DrugBank.d784.s4.p20,2,clarithromycin,oxybutynin
25,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p0,0,antacid,antacid
26,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p1,0,antacid,aluminum hydroxide
27,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p2,0,antacid,magnesium hydroxide
28,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p3,0,antacid,simethicone
29,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p4,0,antacid,oxybutynin
30,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p5,0,antacid,desethyloxybutynin
31,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p6,0,antacid,aluminum hydroxide
32,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p7,0,antacid,magnesium hydroxide
33,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p8,0,antacid,simethicone
34,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p9,0,antacid,oxybutynin
35,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p10,0,antacid,desethyloxybutynin
36,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p11,0,aluminum hydroxide,magnesium hydroxide
37,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p12,0,aluminum hydroxide,simethicone
38,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p13,0,aluminum hydroxide,oxybutynin
39,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p14,0,aluminum hydroxide,desethyloxybutynin
40,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p15,0,magnesium hydroxide,simethicone
41,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p16,0,magnesium hydroxide,oxybutynin
42,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p17,0,magnesium hydroxide,desethyloxybutynin
43,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p18,0,simethicone,oxybutynin
44,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p19,0,simethicone,desethyloxybutynin
45,DDI-DrugBank.d784.s7,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",DDI-DrugBank.d784.s7.p20,0,oxybutynin,desethyloxybutynin
0,DDI-DrugBank.d758.s0,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,DDI-DrugBank.d758.s0.p0,3,oxycodone hydrochloride,CNS depressants
0,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p0,0,CNS depressants,sedatives
1,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p1,0,CNS depressants,hypnotics
2,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p2,0,CNS depressants,tranquilizers
3,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p3,0,CNS depressants,anesthetics
4,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p4,0,CNS depressants,phenothiazines
5,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p5,0,CNS depressants,opioids
6,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p6,0,CNS depressants,tricyclic antidepressants
7,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p7,0,CNS depressants,monoamine oxidase (MAO) inhibitors
8,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p8,0,CNS depressants,alcohol
9,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p9,0,sedatives,hypnotics
10,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p10,0,sedatives,tranquilizers
11,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p11,0,sedatives,anesthetics
12,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p12,0,sedatives,phenothiazines
13,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p13,0,sedatives,opioids
14,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p14,0,sedatives,tricyclic antidepressants
15,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p15,0,sedatives,monoamine oxidase (MAO) inhibitors
16,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p16,0,sedatives,alcohol
17,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p17,0,hypnotics,tranquilizers
18,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p18,0,hypnotics,anesthetics
19,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p19,0,hypnotics,phenothiazines
20,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p20,0,hypnotics,opioids
21,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p21,0,hypnotics,tricyclic antidepressants
22,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p22,0,hypnotics,monoamine oxidase (MAO) inhibitors
23,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p23,0,hypnotics,alcohol
24,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p24,0,tranquilizers,anesthetics
25,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p25,0,tranquilizers,phenothiazines
26,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p26,0,tranquilizers,opioids
27,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p27,0,tranquilizers,tricyclic antidepressants
28,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p28,0,tranquilizers,monoamine oxidase (MAO) inhibitors
29,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p29,0,tranquilizers,alcohol
30,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p30,0,anesthetics,phenothiazines
31,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p31,0,anesthetics,opioids
32,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p32,0,anesthetics,tricyclic antidepressants
33,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p33,0,anesthetics,monoamine oxidase (MAO) inhibitors
34,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p34,0,anesthetics,alcohol
35,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p35,0,phenothiazines,opioids
36,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p36,0,phenothiazines,tricyclic antidepressants
37,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p37,0,phenothiazines,monoamine oxidase (MAO) inhibitors
38,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p38,0,phenothiazines,alcohol
39,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p39,0,opioids,tricyclic antidepressants
40,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p40,0,opioids,monoamine oxidase (MAO) inhibitors
41,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p41,0,opioids,alcohol
42,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p42,0,tricyclic antidepressants,monoamine oxidase (MAO) inhibitors
43,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p43,0,tricyclic antidepressants,alcohol
44,DDI-DrugBank.d753.s0,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",DDI-DrugBank.d753.s0.p44,0,monoamine oxidase (MAO) inhibitors,alcohol
45,DDI-DrugBank.d753.s2,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",DDI-DrugBank.d753.s2.p0,3,Anticholinergics,opioid analgesics
46,DDI-DrugBank.d753.s3,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,DDI-DrugBank.d753.s3.p0,3,oxymorphone,propofol
47,DDI-DrugBank.d753.s4,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",DDI-DrugBank.d753.s4.p0,3,cimetidine,opioid analgesics
0,DDI-DrugBank.d670.s0,Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ,DDI-DrugBank.d670.s0.p0,0,INVEGA,Paliperidone
1,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p0,0,paliperidone,INVEGA
2,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p1,1,paliperidone,centrally acting drugs
3,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p2,1,paliperidone,alcohol
4,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p3,1,INVEGA,centrally acting drugs
5,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p4,1,INVEGA,alcohol
6,DDI-DrugBank.d670.s6,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",DDI-DrugBank.d670.s6.p5,0,centrally acting drugs,alcohol
7,DDI-DrugBank.d670.s7,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,DDI-DrugBank.d670.s7.p0,3,Paliperidone,levodopa
8,DDI-DrugBank.d670.s7,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,DDI-DrugBank.d670.s7.p1,3,Paliperidone,dopamine agonists
9,DDI-DrugBank.d670.s7,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,DDI-DrugBank.d670.s7.p2,0,levodopa,dopamine agonists
10,DDI-DrugBank.d670.s9,"Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",DDI-DrugBank.d670.s9.p0,0,INVEGA,Paliperidone
0,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p0,0,pantoprazole,theophylline
1,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p1,0,pantoprazole,cisapride
2,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p2,0,pantoprazole,antipyrine
3,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p3,0,pantoprazole,caffeine
4,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p4,0,pantoprazole,carbamazepine
5,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p5,0,pantoprazole,diazepam
6,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p6,0,pantoprazole,desmethyldiazepam
7,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p7,0,pantoprazole,diclofenac
8,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p8,0,pantoprazole,naproxen
9,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p9,0,pantoprazole,piroxicam
10,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p10,0,pantoprazole,digoxin
11,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p11,0,pantoprazole,ethanol
12,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p12,0,pantoprazole,glyburide
13,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p13,0,pantoprazole,contraceptive
14,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p14,0,pantoprazole,levonorgestrel
15,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p15,0,pantoprazole,ethinyl estradiol
16,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p16,0,pantoprazole,metoprolol
17,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p17,0,pantoprazole,nifedipine
18,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p18,0,pantoprazole,phenytoin
19,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p19,0,pantoprazole,warfarin
20,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p20,0,pantoprazole,midazolam
21,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p21,0,pantoprazole,clarithromycin
22,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p22,0,pantoprazole,metronidazole
23,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p23,0,pantoprazole,amoxicillin
24,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p24,0,theophylline,cisapride
25,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p25,0,theophylline,antipyrine
26,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p26,0,theophylline,caffeine
27,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p27,0,theophylline,carbamazepine
28,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p28,0,theophylline,diazepam
29,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p29,0,theophylline,desmethyldiazepam
30,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p30,0,theophylline,diclofenac
31,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p31,0,theophylline,naproxen
32,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p32,0,theophylline,piroxicam
33,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p33,0,theophylline,digoxin
34,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p34,0,theophylline,ethanol
35,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p35,0,theophylline,glyburide
36,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p36,0,theophylline,contraceptive
37,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p37,0,theophylline,levonorgestrel
38,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p38,0,theophylline,ethinyl estradiol
39,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p39,0,theophylline,metoprolol
40,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p40,0,theophylline,nifedipine
41,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p41,0,theophylline,phenytoin
42,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p42,0,theophylline,warfarin
43,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p43,0,theophylline,midazolam
44,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p44,0,theophylline,clarithromycin
45,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p45,0,theophylline,metronidazole
46,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p46,0,theophylline,amoxicillin
47,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p47,0,cisapride,antipyrine
48,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p48,0,cisapride,caffeine
49,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p49,0,cisapride,carbamazepine
50,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p50,0,cisapride,diazepam
51,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p51,0,cisapride,desmethyldiazepam
52,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p52,0,cisapride,diclofenac
53,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p53,0,cisapride,naproxen
54,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p54,0,cisapride,piroxicam
55,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p55,0,cisapride,digoxin
56,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p56,0,cisapride,ethanol
57,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p57,0,cisapride,glyburide
58,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p58,0,cisapride,contraceptive
59,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p59,0,cisapride,levonorgestrel
60,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p60,0,cisapride,ethinyl estradiol
61,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p61,0,cisapride,metoprolol
62,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p62,0,cisapride,nifedipine
63,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p63,0,cisapride,phenytoin
64,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p64,0,cisapride,warfarin
65,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p65,0,cisapride,midazolam
66,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p66,0,cisapride,clarithromycin
67,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p67,0,cisapride,metronidazole
68,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p68,0,cisapride,amoxicillin
69,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p69,0,antipyrine,caffeine
70,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p70,0,antipyrine,carbamazepine
71,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p71,0,antipyrine,diazepam
72,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p72,0,antipyrine,desmethyldiazepam
73,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p73,0,antipyrine,diclofenac
74,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p74,0,antipyrine,naproxen
75,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p75,0,antipyrine,piroxicam
76,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p76,0,antipyrine,digoxin
77,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p77,0,antipyrine,ethanol
78,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p78,0,antipyrine,glyburide
79,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p79,0,antipyrine,contraceptive
80,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p80,0,antipyrine,levonorgestrel
81,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p81,0,antipyrine,ethinyl estradiol
82,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p82,0,antipyrine,metoprolol
83,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p83,0,antipyrine,nifedipine
84,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p84,0,antipyrine,phenytoin
85,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p85,0,antipyrine,warfarin
86,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p86,0,antipyrine,midazolam
87,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p87,0,antipyrine,clarithromycin
88,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p88,0,antipyrine,metronidazole
89,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p89,0,antipyrine,amoxicillin
90,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p90,0,caffeine,carbamazepine
91,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p91,0,caffeine,diazepam
92,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p92,0,caffeine,desmethyldiazepam
93,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p93,0,caffeine,diclofenac
94,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p94,0,caffeine,naproxen
95,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p95,0,caffeine,piroxicam
96,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p96,0,caffeine,digoxin
97,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p97,0,caffeine,ethanol
98,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p98,0,caffeine,glyburide
99,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p99,0,caffeine,contraceptive
100,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p100,0,caffeine,levonorgestrel
101,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p101,0,caffeine,ethinyl estradiol
102,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p102,0,caffeine,metoprolol
103,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p103,0,caffeine,nifedipine
104,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p104,0,caffeine,phenytoin
105,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p105,0,caffeine,warfarin
106,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p106,0,caffeine,midazolam
107,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p107,0,caffeine,clarithromycin
108,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p108,0,caffeine,metronidazole
109,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p109,0,caffeine,amoxicillin
110,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p110,0,carbamazepine,diazepam
111,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p111,0,carbamazepine,desmethyldiazepam
112,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p112,0,carbamazepine,diclofenac
113,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p113,0,carbamazepine,naproxen
114,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p114,0,carbamazepine,piroxicam
115,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p115,0,carbamazepine,digoxin
116,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p116,0,carbamazepine,ethanol
117,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p117,0,carbamazepine,glyburide
118,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p118,0,carbamazepine,contraceptive
119,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p119,0,carbamazepine,levonorgestrel
120,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p120,0,carbamazepine,ethinyl estradiol
121,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p121,0,carbamazepine,metoprolol
122,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p122,0,carbamazepine,nifedipine
123,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p123,0,carbamazepine,phenytoin
124,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p124,0,carbamazepine,warfarin
125,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p125,0,carbamazepine,midazolam
126,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p126,0,carbamazepine,clarithromycin
127,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p127,0,carbamazepine,metronidazole
128,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p128,0,carbamazepine,amoxicillin
129,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p129,0,diazepam,desmethyldiazepam
130,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p130,0,diazepam,diclofenac
131,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p131,0,diazepam,naproxen
132,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p132,0,diazepam,piroxicam
133,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p133,0,diazepam,digoxin
134,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p134,0,diazepam,ethanol
135,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p135,0,diazepam,glyburide
136,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p136,0,diazepam,contraceptive
137,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p137,0,diazepam,levonorgestrel
138,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p138,0,diazepam,ethinyl estradiol
139,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p139,0,diazepam,metoprolol
140,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p140,0,diazepam,nifedipine
141,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p141,0,diazepam,phenytoin
142,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p142,0,diazepam,warfarin
143,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p143,0,diazepam,midazolam
144,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p144,0,diazepam,clarithromycin
145,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p145,0,diazepam,metronidazole
146,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p146,0,diazepam,amoxicillin
147,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p147,0,desmethyldiazepam,diclofenac
148,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p148,0,desmethyldiazepam,naproxen
149,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p149,0,desmethyldiazepam,piroxicam
150,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p150,0,desmethyldiazepam,digoxin
151,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p151,0,desmethyldiazepam,ethanol
152,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p152,0,desmethyldiazepam,glyburide
153,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p153,0,desmethyldiazepam,contraceptive
154,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p154,0,desmethyldiazepam,levonorgestrel
155,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p155,0,desmethyldiazepam,ethinyl estradiol
156,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p156,0,desmethyldiazepam,metoprolol
157,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p157,0,desmethyldiazepam,nifedipine
158,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p158,0,desmethyldiazepam,phenytoin
159,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p159,0,desmethyldiazepam,warfarin
160,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p160,0,desmethyldiazepam,midazolam
161,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p161,0,desmethyldiazepam,clarithromycin
162,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p162,0,desmethyldiazepam,metronidazole
163,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p163,0,desmethyldiazepam,amoxicillin
164,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p164,0,diclofenac,naproxen
165,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p165,0,diclofenac,piroxicam
166,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p166,0,diclofenac,digoxin
167,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p167,0,diclofenac,ethanol
168,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p168,0,diclofenac,glyburide
169,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p169,0,diclofenac,contraceptive
170,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p170,0,diclofenac,levonorgestrel
171,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p171,0,diclofenac,ethinyl estradiol
172,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p172,0,diclofenac,metoprolol
173,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p173,0,diclofenac,nifedipine
174,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p174,0,diclofenac,phenytoin
175,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p175,0,diclofenac,warfarin
176,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p176,0,diclofenac,midazolam
177,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p177,0,diclofenac,clarithromycin
178,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p178,0,diclofenac,metronidazole
179,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p179,0,diclofenac,amoxicillin
180,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p180,0,naproxen,piroxicam
181,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p181,0,naproxen,digoxin
182,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p182,0,naproxen,ethanol
183,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p183,0,naproxen,glyburide
184,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p184,0,naproxen,contraceptive
185,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p185,0,naproxen,levonorgestrel
186,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p186,0,naproxen,ethinyl estradiol
187,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p187,0,naproxen,metoprolol
188,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p188,0,naproxen,nifedipine
189,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p189,0,naproxen,phenytoin
190,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p190,0,naproxen,warfarin
191,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p191,0,naproxen,midazolam
192,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p192,0,naproxen,clarithromycin
193,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p193,0,naproxen,metronidazole
194,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p194,0,naproxen,amoxicillin
195,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p195,0,piroxicam,digoxin
196,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p196,0,piroxicam,ethanol
197,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p197,0,piroxicam,glyburide
198,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p198,0,piroxicam,contraceptive
199,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p199,0,piroxicam,levonorgestrel
200,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p200,0,piroxicam,ethinyl estradiol
201,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p201,0,piroxicam,metoprolol
202,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p202,0,piroxicam,nifedipine
203,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p203,0,piroxicam,phenytoin
204,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p204,0,piroxicam,warfarin
205,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p205,0,piroxicam,midazolam
206,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p206,0,piroxicam,clarithromycin
207,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p207,0,piroxicam,metronidazole
208,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p208,0,piroxicam,amoxicillin
209,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p209,0,digoxin,ethanol
210,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p210,0,digoxin,glyburide
211,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p211,0,digoxin,contraceptive
212,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p212,0,digoxin,levonorgestrel
213,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p213,0,digoxin,ethinyl estradiol
214,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p214,0,digoxin,metoprolol
215,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p215,0,digoxin,nifedipine
216,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p216,0,digoxin,phenytoin
217,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p217,0,digoxin,warfarin
218,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p218,0,digoxin,midazolam
219,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p219,0,digoxin,clarithromycin
220,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p220,0,digoxin,metronidazole
221,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p221,0,digoxin,amoxicillin
222,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p222,0,ethanol,glyburide
223,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p223,0,ethanol,contraceptive
224,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p224,0,ethanol,levonorgestrel
225,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p225,0,ethanol,ethinyl estradiol
226,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p226,0,ethanol,metoprolol
227,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p227,0,ethanol,nifedipine
228,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p228,0,ethanol,phenytoin
229,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p229,0,ethanol,warfarin
230,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p230,0,ethanol,midazolam
231,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p231,0,ethanol,clarithromycin
232,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p232,0,ethanol,metronidazole
233,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p233,0,ethanol,amoxicillin
234,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p234,0,glyburide,contraceptive
235,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p235,0,glyburide,levonorgestrel
236,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p236,0,glyburide,ethinyl estradiol
237,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p237,0,glyburide,metoprolol
238,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p238,0,glyburide,nifedipine
239,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p239,0,glyburide,phenytoin
240,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p240,0,glyburide,warfarin
241,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p241,0,glyburide,midazolam
242,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p242,0,glyburide,clarithromycin
243,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p243,0,glyburide,metronidazole
244,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p244,0,glyburide,amoxicillin
245,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p245,0,contraceptive,levonorgestrel
246,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p246,0,contraceptive,ethinyl estradiol
247,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p247,0,contraceptive,metoprolol
248,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p248,0,contraceptive,nifedipine
249,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p249,0,contraceptive,phenytoin
250,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p250,0,contraceptive,warfarin
251,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p251,0,contraceptive,midazolam
252,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p252,0,contraceptive,clarithromycin
253,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p253,0,contraceptive,metronidazole
254,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p254,0,contraceptive,amoxicillin
255,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p255,0,levonorgestrel,ethinyl estradiol
256,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p256,0,levonorgestrel,metoprolol
257,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p257,0,levonorgestrel,nifedipine
258,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p258,0,levonorgestrel,phenytoin
259,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p259,0,levonorgestrel,warfarin
260,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p260,0,levonorgestrel,midazolam
261,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p261,0,levonorgestrel,clarithromycin
262,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p262,0,levonorgestrel,metronidazole
263,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p263,0,levonorgestrel,amoxicillin
264,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p264,0,ethinyl estradiol,metoprolol
265,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p265,0,ethinyl estradiol,nifedipine
266,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p266,0,ethinyl estradiol,phenytoin
267,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p267,0,ethinyl estradiol,warfarin
268,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p268,0,ethinyl estradiol,midazolam
269,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p269,0,ethinyl estradiol,clarithromycin
270,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p270,0,ethinyl estradiol,metronidazole
271,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p271,0,ethinyl estradiol,amoxicillin
272,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p272,0,metoprolol,nifedipine
273,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p273,0,metoprolol,phenytoin
274,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p274,0,metoprolol,warfarin
275,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p275,0,metoprolol,midazolam
276,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p276,0,metoprolol,clarithromycin
277,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p277,0,metoprolol,metronidazole
278,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p278,0,metoprolol,amoxicillin
279,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p279,0,nifedipine,phenytoin
280,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p280,0,nifedipine,warfarin
281,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p281,0,nifedipine,midazolam
282,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p282,0,nifedipine,clarithromycin
283,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p283,0,nifedipine,metronidazole
284,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p284,0,nifedipine,amoxicillin
285,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p285,0,phenytoin,warfarin
286,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p286,0,phenytoin,midazolam
287,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p287,0,phenytoin,clarithromycin
288,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p288,0,phenytoin,metronidazole
289,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p289,0,phenytoin,amoxicillin
290,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p290,0,warfarin,midazolam
291,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p291,0,warfarin,clarithromycin
292,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p292,0,warfarin,metronidazole
293,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p293,0,warfarin,amoxicillin
294,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p294,0,midazolam,clarithromycin
295,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p295,0,midazolam,metronidazole
296,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p296,0,midazolam,amoxicillin
297,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p297,0,clarithromycin,metronidazole
298,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p298,0,clarithromycin,amoxicillin
299,DDI-DrugBank.d680.s1,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",DDI-DrugBank.d680.s1.p299,0,metronidazole,amoxicillin
300,DDI-DrugBank.d680.s3,"Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. ",DDI-DrugBank.d680.s3.p0,0,pantoprazole,pantoprazole
301,DDI-DrugBank.d680.s5,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",DDI-DrugBank.d680.s5.p0,0,proton pump inhibitors,pantoprazole
302,DDI-DrugBank.d680.s5,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",DDI-DrugBank.d680.s5.p1,3,proton pump inhibitors,warfarin
303,DDI-DrugBank.d680.s5,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",DDI-DrugBank.d680.s5.p2,3,pantoprazole,warfarin
304,DDI-DrugBank.d680.s7,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,DDI-DrugBank.d680.s7.p0,1,proton pump inhibitors,warfarin
305,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p0,2,pantoprazole,ketoconazole
306,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p1,2,pantoprazole,ampicillin
307,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p2,2,pantoprazole,iron
308,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p3,0,ketoconazole,ampicillin
309,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p4,0,ketoconazole,iron
310,DDI-DrugBank.d680.s8,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",DDI-DrugBank.d680.s8.p5,0,ampicillin,iron
311,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p0,0,tetrahydrocannabinol,THC
312,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p1,0,tetrahydrocannabinol,proton pump inhibitors
313,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p2,0,tetrahydrocannabinol,pantoprazole
314,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p3,0,THC,proton pump inhibitors
315,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p4,0,THC,pantoprazole
316,DDI-DrugBank.d680.s9,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",DDI-DrugBank.d680.s9.p5,0,proton pump inhibitors,pantoprazole
0,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p0,2,ketoconazole,paricalcitol
1,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p1,0,ketoconazole,paricalcitol
2,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p2,0,ketoconazole,ketoconazole
3,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p3,0,ketoconazole,paricalcitol
4,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p4,0,ketoconazole,ketoconazole
5,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p5,0,ketoconazole,atazanavir
6,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p6,0,ketoconazole,clarithromycin
7,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p7,0,ketoconazole,indinavir
8,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p8,0,ketoconazole,itraconazole
9,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p9,0,ketoconazole,nefazodone
10,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p10,0,ketoconazole,nelfinavir
11,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p11,0,ketoconazole,ritonavir
12,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p12,0,ketoconazole,saquinavir
13,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p13,0,ketoconazole,telithromycin
14,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p14,0,ketoconazole,voriconazole
15,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p15,0,paricalcitol,paricalcitol
16,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p16,0,paricalcitol,ketoconazole
17,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p17,0,paricalcitol,paricalcitol
18,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p18,0,paricalcitol,ketoconazole
19,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p19,0,paricalcitol,atazanavir
20,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p20,0,paricalcitol,clarithromycin
21,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p21,0,paricalcitol,indinavir
22,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p22,0,paricalcitol,itraconazole
23,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p23,0,paricalcitol,nefazodone
24,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p24,0,paricalcitol,nelfinavir
25,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p25,0,paricalcitol,ritonavir
26,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p26,0,paricalcitol,saquinavir
27,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p27,0,paricalcitol,telithromycin
28,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p28,0,paricalcitol,voriconazole
29,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p29,0,paricalcitol,ketoconazole
30,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p30,0,paricalcitol,paricalcitol
31,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p31,0,paricalcitol,ketoconazole
32,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p32,0,paricalcitol,atazanavir
33,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p33,0,paricalcitol,clarithromycin
34,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p34,0,paricalcitol,indinavir
35,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p35,0,paricalcitol,itraconazole
36,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p36,0,paricalcitol,nefazodone
37,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p37,0,paricalcitol,nelfinavir
38,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p38,0,paricalcitol,ritonavir
39,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p39,0,paricalcitol,saquinavir
40,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p40,0,paricalcitol,telithromycin
41,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p41,0,paricalcitol,voriconazole
42,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p42,0,ketoconazole,paricalcitol
43,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p43,0,ketoconazole,ketoconazole
44,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p44,0,ketoconazole,atazanavir
45,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p45,0,ketoconazole,clarithromycin
46,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p46,0,ketoconazole,indinavir
47,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p47,0,ketoconazole,itraconazole
48,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p48,0,ketoconazole,nefazodone
49,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p49,0,ketoconazole,nelfinavir
50,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p50,0,ketoconazole,ritonavir
51,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p51,0,ketoconazole,saquinavir
52,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p52,0,ketoconazole,telithromycin
53,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p53,0,ketoconazole,voriconazole
54,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p54,1,paricalcitol,ketoconazole
55,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p55,1,paricalcitol,atazanavir
56,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p56,1,paricalcitol,clarithromycin
57,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p57,1,paricalcitol,indinavir
58,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p58,1,paricalcitol,itraconazole
59,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p59,1,paricalcitol,nefazodone
60,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p60,1,paricalcitol,nelfinavir
61,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p61,1,paricalcitol,ritonavir
62,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p62,1,paricalcitol,saquinavir
63,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p63,1,paricalcitol,telithromycin
64,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p64,1,paricalcitol,voriconazole
65,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p65,0,ketoconazole,atazanavir
66,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p66,0,ketoconazole,clarithromycin
67,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p67,0,ketoconazole,indinavir
68,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p68,0,ketoconazole,itraconazole
69,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p69,0,ketoconazole,nefazodone
70,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p70,0,ketoconazole,nelfinavir
71,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p71,0,ketoconazole,ritonavir
72,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p72,0,ketoconazole,saquinavir
73,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p73,0,ketoconazole,telithromycin
74,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p74,0,ketoconazole,voriconazole
75,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p75,0,atazanavir,clarithromycin
76,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p76,0,atazanavir,indinavir
77,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p77,0,atazanavir,itraconazole
78,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p78,0,atazanavir,nefazodone
79,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p79,0,atazanavir,nelfinavir
80,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p80,0,atazanavir,ritonavir
81,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p81,0,atazanavir,saquinavir
82,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p82,0,atazanavir,telithromycin
83,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p83,0,atazanavir,voriconazole
84,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p84,0,clarithromycin,indinavir
85,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p85,0,clarithromycin,itraconazole
86,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p86,0,clarithromycin,nefazodone
87,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p87,0,clarithromycin,nelfinavir
88,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p88,0,clarithromycin,ritonavir
89,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p89,0,clarithromycin,saquinavir
90,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p90,0,clarithromycin,telithromycin
91,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p91,0,clarithromycin,voriconazole
92,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p92,0,indinavir,itraconazole
93,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p93,0,indinavir,nefazodone
94,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p94,0,indinavir,nelfinavir
95,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p95,0,indinavir,ritonavir
96,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p96,0,indinavir,saquinavir
97,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p97,0,indinavir,telithromycin
98,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p98,0,indinavir,voriconazole
99,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p99,0,itraconazole,nefazodone
100,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p100,0,itraconazole,nelfinavir
101,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p101,0,itraconazole,ritonavir
102,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p102,0,itraconazole,saquinavir
103,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p103,0,itraconazole,telithromycin
104,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p104,0,itraconazole,voriconazole
105,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p105,0,nefazodone,nelfinavir
106,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p106,0,nefazodone,ritonavir
107,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p107,0,nefazodone,saquinavir
108,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p108,0,nefazodone,telithromycin
109,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p109,0,nefazodone,voriconazole
110,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p110,0,nelfinavir,ritonavir
111,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p111,0,nelfinavir,saquinavir
112,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p112,0,nelfinavir,telithromycin
113,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p113,0,nelfinavir,voriconazole
114,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p114,0,ritonavir,saquinavir
115,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p115,0,ritonavir,telithromycin
116,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p116,0,ritonavir,voriconazole
117,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p117,0,saquinavir,telithromycin
118,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p118,0,saquinavir,voriconazole
119,DDI-DrugBank.d726.s1,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",DDI-DrugBank.d726.s1.p119,0,telithromycin,voriconazole
120,DDI-DrugBank.d726.s2,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",DDI-DrugBank.d726.s2.p0,1,Zemplar,ketoconazole
121,DDI-DrugBank.d726.s3,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",DDI-DrugBank.d726.s3.p0,2,fat-soluble vitamins,cholestyramine
122,DDI-DrugBank.d726.s3,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",DDI-DrugBank.d726.s3.p1,0,fat-soluble vitamins,Zemplar
123,DDI-DrugBank.d726.s3,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",DDI-DrugBank.d726.s3.p2,2,cholestyramine,Zemplar
0,DDI-DrugBank.d581.s2,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,DDI-DrugBank.d581.s2.p0,1,lithium,Neulasta
0,DDI-DrugBank.d741.s0,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ",DDI-DrugBank.d741.s0.p0,2,methadone,PEG-Intron
1,DDI-DrugBank.d741.s0,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ",DDI-DrugBank.d741.s0.p1,0,methadone,methadone
2,DDI-DrugBank.d741.s0,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ",DDI-DrugBank.d741.s0.p2,0,PEG-Intron,methadone
0,DDI-DrugBank.d744.s0,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,DDI-DrugBank.d744.s0.p0,0,insulin,hypoglycemic
1,DDI-DrugBank.d744.s0,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,DDI-DrugBank.d744.s0.p1,1,insulin,SOMAVERT
2,DDI-DrugBank.d744.s0,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,DDI-DrugBank.d744.s0.p2,1,hypoglycemic,SOMAVERT
3,DDI-DrugBank.d744.s1,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",DDI-DrugBank.d744.s1.p0,2,opioids,pegvisomant
4,DDI-DrugBank.d744.s1,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",DDI-DrugBank.d744.s1.p1,0,opioids,opioids
5,DDI-DrugBank.d744.s1,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",DDI-DrugBank.d744.s1.p2,0,pegvisomant,opioids
0,DDI-DrugBank.d641.s2,"Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. ",DDI-DrugBank.d641.s2.p0,2,probenecid,ALIMTA
1,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p0,0,ibuprofen,ALIMTA
2,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p1,0,ibuprofen,ibuprofen
3,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p2,0,ibuprofen,ALIMTA
4,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p3,0,ALIMTA,ibuprofen
5,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p4,0,ALIMTA,ALIMTA
6,DDI-DrugBank.d641.s3,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",DDI-DrugBank.d641.s3.p5,1,ibuprofen,ALIMTA
7,DDI-DrugBank.d641.s4,"Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA. ",DDI-DrugBank.d641.s4.p0,1,NSAIDs,ALIMTA
8,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p0,0,ALIMTA,NSAIDs
9,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p1,0,ALIMTA,NSAIDs
10,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p2,0,ALIMTA,ALIMTA
11,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p3,0,NSAIDs,NSAIDs
12,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p4,0,NSAIDs,ALIMTA
13,DDI-DrugBank.d641.s5,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",DDI-DrugBank.d641.s5.p5,1,NSAIDs,ALIMTA
0,DDI-DrugBank.d671.s0,The interaction of CYLERT (pemoline) with other drugs has not been studied in humans. ,DDI-DrugBank.d671.s0.p0,0,CYLERT,pemoline
1,DDI-DrugBank.d671.s2,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,DDI-DrugBank.d671.s2.p0,3,CYLERT,antiepileptic medications
0,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p0,0,bacteriostatic antibiotics,erythromycin
1,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p1,0,bacteriostatic antibiotics,tetracycline
2,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p2,3,bacteriostatic antibiotics,penicillins
3,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p3,0,erythromycin,tetracycline
4,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p4,3,erythromycin,penicillins
5,DDI-DrugBank.d665.s0,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",DDI-DrugBank.d665.s0.p5,3,tetracycline,penicillins
6,DDI-DrugBank.d665.s6,Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. ,DDI-DrugBank.d665.s6.p0,2,Penicillin,probenecid
7,DDI-DrugBank.d665.s6,Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. ,DDI-DrugBank.d665.s6.p1,0,Penicillin,penicillins
8,DDI-DrugBank.d665.s6,Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. ,DDI-DrugBank.d665.s6.p2,0,probenecid,penicillins
9,DDI-DrugBank.d665.s7,Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.,DDI-DrugBank.d665.s7.p0,0,penicillin,penicillin
0,DDI-DrugBank.d757.s0,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",DDI-DrugBank.d757.s0.p0,0,Alcohol,alcohol
1,DDI-DrugBank.d757.s0,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",DDI-DrugBank.d757.s0.p1,0,Alcohol,pentazocine
2,DDI-DrugBank.d757.s0,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",DDI-DrugBank.d757.s0.p2,1,alcohol,pentazocine
0,DDI-DrugBank.d659.s0,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",DDI-DrugBank.d659.s0.p0,3,TRENTAL,anticoagulants
1,DDI-DrugBank.d659.s0,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",DDI-DrugBank.d659.s0.p1,3,TRENTAL,platelet aggregation inhibitors
2,DDI-DrugBank.d659.s0,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",DDI-DrugBank.d659.s0.p2,0,anticoagulants,platelet aggregation inhibitors
3,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p0,2,TRENTAL,theophylline
4,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p1,0,TRENTAL,theophylline
5,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p2,0,TRENTAL,theophylline
6,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p3,0,theophylline,theophylline
7,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p4,0,theophylline,theophylline
8,DDI-DrugBank.d659.s2,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,DDI-DrugBank.d659.s2.p5,0,theophylline,theophylline
9,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p0,0,TRENTAL,antihypertensive drugs
10,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p1,0,TRENTAL,beta blockers
11,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p2,0,TRENTAL,digitalis
12,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p3,0,TRENTAL,diuretics
13,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p4,0,TRENTAL,antidiabetic agents
14,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p5,0,TRENTAL,antiarrhythmics
15,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p6,0,antihypertensive drugs,beta blockers
16,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p7,0,antihypertensive drugs,digitalis
17,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p8,0,antihypertensive drugs,diuretics
18,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p9,0,antihypertensive drugs,antidiabetic agents
19,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p10,0,antihypertensive drugs,antiarrhythmics
20,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p11,0,beta blockers,digitalis
21,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p12,0,beta blockers,diuretics
22,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p13,0,beta blockers,antidiabetic agents
23,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p14,0,beta blockers,antiarrhythmics
24,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p15,0,digitalis,diuretics
25,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p16,0,digitalis,antidiabetic agents
26,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p17,0,digitalis,antiarrhythmics
27,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p18,0,diuretics,antidiabetic agents
28,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p19,0,diuretics,antiarrhythmics
29,DDI-DrugBank.d659.s4,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",DDI-DrugBank.d659.s4.p20,0,antidiabetic agents,antiarrhythmics
0,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p0,0,Dopamine antagonists,neuroleptics
1,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p1,0,Dopamine antagonists,phenothiazines
2,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p2,0,Dopamine antagonists,butyrophenones
3,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p3,0,Dopamine antagonists,thioxanthines
4,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p4,0,Dopamine antagonists,metoclopramide
5,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p5,1,Dopamine antagonists,Permax
6,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p6,0,Dopamine antagonists,dopamine agonist
7,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p7,0,neuroleptics,phenothiazines
8,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p8,0,neuroleptics,butyrophenones
9,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p9,0,neuroleptics,thioxanthines
10,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p10,0,neuroleptics,metoclopramide
11,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p11,1,neuroleptics,Permax
12,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p12,0,neuroleptics,dopamine agonist
13,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p13,0,phenothiazines,butyrophenones
14,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p14,0,phenothiazines,thioxanthines
15,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p15,0,phenothiazines,metoclopramide
16,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p16,1,phenothiazines,Permax
17,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p17,0,phenothiazines,dopamine agonist
18,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p18,0,butyrophenones,thioxanthines
19,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p19,0,butyrophenones,metoclopramide
20,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p20,1,butyrophenones,Permax
21,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p21,0,butyrophenones,dopamine agonist
22,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p22,0,thioxanthines,metoclopramide
23,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p23,1,thioxanthines,Permax
24,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p24,0,thioxanthines,dopamine agonist
25,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p25,1,metoclopramide,Permax
26,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p26,0,metoclopramide,dopamine agonist
27,DDI-DrugBank.d650.s0,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",DDI-DrugBank.d650.s0.p27,0,Permax,dopamine agonist
28,DDI-DrugBank.d650.s2,"Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.",DDI-DrugBank.d650.s2.p0,0,pergolide mesylate,pergolide mesylate
0,DDI-DrugBank.d781.s0,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",DDI-DrugBank.d781.s0.p0,0,Diuretics,diuretics
1,DDI-DrugBank.d781.s0,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",DDI-DrugBank.d781.s0.p1,0,Diuretics,ACEON
2,DDI-DrugBank.d781.s0,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",DDI-DrugBank.d781.s0.p2,3,diuretics,ACEON
3,DDI-DrugBank.d781.s1,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ,DDI-DrugBank.d781.s1.p0,3,diuretic,perindopril
4,DDI-DrugBank.d781.s2,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",DDI-DrugBank.d781.s2.p0,1,diuretics,ACEON
5,DDI-DrugBank.d781.s3,The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. ,DDI-DrugBank.d781.s3.p0,0,perindopril,diuretics
6,DDI-DrugBank.d781.s4,"The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition. ",DDI-DrugBank.d781.s4.p0,0,perindoprilat,diuretics
7,DDI-DrugBank.d781.s5,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,DDI-DrugBank.d781.s5.p0,0,Potassium,Potassium-Sparing Diuretics
8,DDI-DrugBank.d781.s5,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,DDI-DrugBank.d781.s5.p1,0,Potassium,ACEON
9,DDI-DrugBank.d781.s5,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,DDI-DrugBank.d781.s5.p2,0,Potassium-Sparing Diuretics,ACEON
10,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p0,0,potassium-sparing diuretics,spironolactone
11,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p1,0,potassium-sparing diuretics,amiloride
12,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p2,0,potassium-sparing diuretics,triamterene
13,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p3,0,potassium-sparing diuretics,potassium
14,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p4,0,potassium-sparing diuretics,indomethacin
15,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p5,0,potassium-sparing diuretics,heparin
16,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p6,0,potassium-sparing diuretics,cyclosporine
17,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p7,0,spironolactone,amiloride
18,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p8,0,spironolactone,triamterene
19,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p9,0,spironolactone,potassium
20,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p10,0,spironolactone,indomethacin
21,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p11,0,spironolactone,heparin
22,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p12,0,spironolactone,cyclosporine
23,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p13,0,amiloride,triamterene
24,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p14,0,amiloride,potassium
25,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p15,0,amiloride,indomethacin
26,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p16,0,amiloride,heparin
27,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p17,0,amiloride,cyclosporine
28,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p18,0,triamterene,potassium
29,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p19,0,triamterene,indomethacin
30,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p20,0,triamterene,heparin
31,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p21,0,triamterene,cyclosporine
32,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p22,0,potassium,indomethacin
33,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p23,0,potassium,heparin
34,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p24,0,potassium,cyclosporine
35,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p25,0,indomethacin,heparin
36,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p26,0,indomethacin,cyclosporine
37,DDI-DrugBank.d781.s6,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",DDI-DrugBank.d781.s6.p27,0,heparin,cyclosporine
38,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p0,0,Lithium,lithium
39,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p1,0,Lithium,lithium
40,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p2,0,Lithium,lithium
41,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p3,0,lithium,lithium
42,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p4,0,lithium,lithium
43,DDI-DrugBank.d781.s8,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,DDI-DrugBank.d781.s8.p5,0,lithium,lithium
44,DDI-DrugBank.d781.s10,Use of a diuretic may further increase the risk of lithium toxicity. ,DDI-DrugBank.d781.s10.p0,0,diuretic,lithium
45,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p0,0,Digoxin,digoxin
46,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p1,0,Digoxin,ACEON
47,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p2,0,Digoxin,digoxin
48,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p3,0,Digoxin,perindopril
49,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p4,0,Digoxin,perindoprilat
50,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p5,0,digoxin,ACEON
51,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p6,0,digoxin,digoxin
52,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p7,0,digoxin,perindopril
53,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p8,0,digoxin,perindoprilat
54,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p9,0,ACEON,digoxin
55,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p10,0,ACEON,perindopril
56,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p11,0,ACEON,perindoprilat
57,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p12,2,digoxin,perindopril
58,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p13,2,digoxin,perindoprilat
59,DDI-DrugBank.d781.s11,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",DDI-DrugBank.d781.s11.p14,0,perindopril,perindoprilat
60,DDI-DrugBank.d781.s12,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,DDI-DrugBank.d781.s12.p0,0,Gentamicin,perindopril
61,DDI-DrugBank.d781.s12,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,DDI-DrugBank.d781.s12.p1,0,Gentamicin,gentamicin
62,DDI-DrugBank.d781.s12,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,DDI-DrugBank.d781.s12.p2,4,perindopril,gentamicin
63,DDI-DrugBank.d781.s15,Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state. ,DDI-DrugBank.d781.s15.p0,0,ACEON,perindopril
64,DDI-DrugBank.d781.s16,"However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",DDI-DrugBank.d781.s16.p0,0,perindopril,perindoprilat
0,DDI-DrugBank.d750.s0,Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.,DDI-DrugBank.d750.s0.p0,4,alcohol,phentermine hydrochloride
0,DDI-DrugBank.d725.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d725.s0.p0,0,Vasopressors,metaraminol
1,DDI-DrugBank.d725.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d725.s0.p1,3,Vasopressors,halothane
2,DDI-DrugBank.d725.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d725.s0.p2,3,metaraminol,halothane
3,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p0,0,MAO Inhibitors,sympathomimetic pressor amines
4,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p1,0,MAO Inhibitors,monoamine oxidase inhibitors
5,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p2,0,MAO Inhibitors,MAOI
6,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p3,3,sympathomimetic pressor amines,monoamine oxidase inhibitors
7,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p4,3,sympathomimetic pressor amines,MAOI
8,DDI-DrugBank.d725.s1,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d725.s1.p5,0,monoamine oxidase inhibitors,MAOI
9,DDI-DrugBank.d725.s3,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,DDI-DrugBank.d725.s3.p0,3,adrenergic agents,tricyclic antidepressants
0,DDI-DrugBank.d689.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d689.s0.p0,0,Vasopressors,metaraminol
1,DDI-DrugBank.d689.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d689.s0.p1,3,Vasopressors,halothane
2,DDI-DrugBank.d689.s0,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",DDI-DrugBank.d689.s0.p2,3,metaraminol,halothane
3,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p0,0,MAO Inhibitors,sympathomimetic pressor amines
4,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p1,0,MAO Inhibitors,monoamine oxidase inhibitors
5,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p2,0,MAO Inhibitors,MAOI
6,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p3,3,sympathomimetic pressor amines,monoamine oxidase inhibitors
7,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p4,3,sympathomimetic pressor amines,MAOI
8,DDI-DrugBank.d689.s1,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,DDI-DrugBank.d689.s1.p5,0,monoamine oxidase inhibitors,MAOI
9,DDI-DrugBank.d689.s3,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,DDI-DrugBank.d689.s3.p0,3,adrenergic agents,tricyclic antidepressants
0,DDI-DrugBank.d627.s0,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,DDI-DrugBank.d627.s0.p0,1,Pilocarpine,beta adrenergic antagonists
1,DDI-DrugBank.d627.s3,"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). ",DDI-DrugBank.d627.s3.p0,0,atropine,ipratropium
2,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p0,0,acetylsalicylic acid,calcium
3,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p1,0,acetylsalicylic acid,conjugated estrogens
4,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p2,0,acetylsalicylic acid,hydroxychloroquine sulfate
5,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p3,0,acetylsalicylic acid,ibuprofen
6,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p4,0,acetylsalicylic acid,levothyroxine sodium
7,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p5,0,acetylsalicylic acid,medroxyprogesterone acetate
8,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p6,0,acetylsalicylic acid,methotrexate
9,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p7,0,acetylsalicylic acid,multivitamins
10,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p8,0,acetylsalicylic acid,naproxen
11,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p9,0,acetylsalicylic acid,omeprazole
12,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p10,0,acetylsalicylic acid,paracetamol
13,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p11,0,acetylsalicylic acid,prednisone
14,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p12,0,calcium,conjugated estrogens
15,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p13,0,calcium,hydroxychloroquine sulfate
16,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p14,0,calcium,ibuprofen
17,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p15,0,calcium,levothyroxine sodium
18,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p16,0,calcium,medroxyprogesterone acetate
19,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p17,0,calcium,methotrexate
20,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p18,0,calcium,multivitamins
21,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p19,0,calcium,naproxen
22,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p20,0,calcium,omeprazole
23,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p21,0,calcium,paracetamol
24,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p22,0,calcium,prednisone
25,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p23,0,conjugated estrogens,hydroxychloroquine sulfate
26,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p24,0,conjugated estrogens,ibuprofen
27,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p25,0,conjugated estrogens,levothyroxine sodium
28,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p26,0,conjugated estrogens,medroxyprogesterone acetate
29,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p27,0,conjugated estrogens,methotrexate
30,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p28,0,conjugated estrogens,multivitamins
31,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p29,0,conjugated estrogens,naproxen
32,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p30,0,conjugated estrogens,omeprazole
33,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p31,0,conjugated estrogens,paracetamol
34,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p32,0,conjugated estrogens,prednisone
35,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p33,0,hydroxychloroquine sulfate,ibuprofen
36,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p34,0,hydroxychloroquine sulfate,levothyroxine sodium
37,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p35,0,hydroxychloroquine sulfate,medroxyprogesterone acetate
38,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p36,0,hydroxychloroquine sulfate,methotrexate
39,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p37,0,hydroxychloroquine sulfate,multivitamins
40,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p38,0,hydroxychloroquine sulfate,naproxen
41,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p39,0,hydroxychloroquine sulfate,omeprazole
42,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p40,0,hydroxychloroquine sulfate,paracetamol
43,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p41,0,hydroxychloroquine sulfate,prednisone
44,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p42,0,ibuprofen,levothyroxine sodium
45,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p43,0,ibuprofen,medroxyprogesterone acetate
46,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p44,0,ibuprofen,methotrexate
47,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p45,0,ibuprofen,multivitamins
48,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p46,0,ibuprofen,naproxen
49,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p47,0,ibuprofen,omeprazole
50,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p48,0,ibuprofen,paracetamol
51,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p49,0,ibuprofen,prednisone
52,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p50,0,levothyroxine sodium,medroxyprogesterone acetate
53,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p51,0,levothyroxine sodium,methotrexate
54,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p52,0,levothyroxine sodium,multivitamins
55,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p53,0,levothyroxine sodium,naproxen
56,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p54,0,levothyroxine sodium,omeprazole
57,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p55,0,levothyroxine sodium,paracetamol
58,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p56,0,levothyroxine sodium,prednisone
59,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p57,0,medroxyprogesterone acetate,methotrexate
60,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p58,0,medroxyprogesterone acetate,multivitamins
61,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p59,0,medroxyprogesterone acetate,naproxen
62,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p60,0,medroxyprogesterone acetate,omeprazole
63,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p61,0,medroxyprogesterone acetate,paracetamol
64,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p62,0,medroxyprogesterone acetate,prednisone
65,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p63,0,methotrexate,multivitamins
66,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p64,0,methotrexate,naproxen
67,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p65,0,methotrexate,omeprazole
68,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p66,0,methotrexate,paracetamol
69,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p67,0,methotrexate,prednisone
70,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p68,0,multivitamins,naproxen
71,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p69,0,multivitamins,omeprazole
72,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p70,0,multivitamins,paracetamol
73,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p71,0,multivitamins,prednisone
74,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p72,0,naproxen,omeprazole
75,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p73,0,naproxen,paracetamol
76,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p74,0,naproxen,prednisone
77,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p75,0,omeprazole,paracetamol
78,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p76,0,omeprazole,prednisone
79,DDI-DrugBank.d627.s4,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",DDI-DrugBank.d627.s4.p77,0,paracetamol,prednisone
0,DDI-DrugBank.d666.s0,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",DDI-DrugBank.d666.s0.p0,3,reserpine,beta-blocking agents
1,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p0,0,Pindolol,antihypertensive agents
2,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p1,0,Pindolol,hydrochlorothiazide
3,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p2,0,Pindolol,hydralazine
4,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p3,0,Pindolol,guanethidine
5,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p4,0,antihypertensive agents,hydrochlorothiazide
6,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p5,0,antihypertensive agents,hydralazine
7,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p6,0,antihypertensive agents,guanethidine
8,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p7,0,hydrochlorothiazide,hydralazine
9,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p8,0,hydrochlorothiazide,guanethidine
10,DDI-DrugBank.d666.s2,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",DDI-DrugBank.d666.s2.p9,0,hydralazine,guanethidine
11,DDI-DrugBank.d666.s3,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,DDI-DrugBank.d666.s3.p0,2,Pindolol,thioridazine
0,DDI-DrugBank.d635.s0,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,DDI-DrugBank.d635.s0.p0,1,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER
0,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p0,0,coumarin-type anticoagulants,coumarin-type anticoagulants
1,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p1,0,coumarin-type anticoagulants,FELDENE
2,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p2,0,coumarin-type anticoagulants,FELDENE
3,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p3,0,coumarin-type anticoagulants,coumarin-type anticoagulants
4,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p4,4,coumarin-type anticoagulants,FELDENE
5,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p5,0,coumarin-type anticoagulants,FELDENE
6,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p6,0,coumarin-type anticoagulants,coumarin-type anticoagulants
7,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p7,0,FELDENE,FELDENE
8,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p8,0,FELDENE,coumarin-type anticoagulants
9,DDI-DrugBank.d656.s1,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",DDI-DrugBank.d656.s1.p9,1,FELDENE,coumarin-type anticoagulants
10,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p0,0,piroxicam,FELDENE
11,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p1,0,piroxicam,aspirin
12,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p2,0,piroxicam,antacids
13,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p3,0,piroxicam,piroxicam
14,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p4,0,piroxicam,Nonsteroidal anti-inflammatory agents
15,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p5,0,piroxicam,FELDENE
16,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p6,0,piroxicam,lithium
17,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p7,2,FELDENE,aspirin
18,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p8,0,FELDENE,antacids
19,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p9,0,FELDENE,piroxicam
20,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p10,0,FELDENE,Nonsteroidal anti-inflammatory agents
21,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p11,0,FELDENE,FELDENE
22,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p12,0,FELDENE,lithium
23,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p13,0,aspirin,antacids
24,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p14,0,aspirin,piroxicam
25,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p15,0,aspirin,Nonsteroidal anti-inflammatory agents
26,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p16,0,aspirin,FELDENE
27,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p17,0,aspirin,lithium
28,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p18,0,antacids,piroxicam
29,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p19,0,antacids,Nonsteroidal anti-inflammatory agents
30,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p20,0,antacids,FELDENE
31,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p21,0,antacids,lithium
32,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p22,0,piroxicam,Nonsteroidal anti-inflammatory agents
33,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p23,0,piroxicam,FELDENE
34,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p24,0,piroxicam,lithium
35,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p25,0,Nonsteroidal anti-inflammatory agents,FELDENE
36,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p26,2,Nonsteroidal anti-inflammatory agents,lithium
37,DDI-DrugBank.d656.s2,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",DDI-DrugBank.d656.s2.p27,2,FELDENE,lithium
38,DDI-DrugBank.d656.s3,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",DDI-DrugBank.d656.s3.p0,1,lithium,FELDENE
0,DDI-DrugBank.d622.s0,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",DDI-DrugBank.d622.s0.p0,3,atropine,pralidoxime
1,DDI-DrugBank.d622.s0,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",DDI-DrugBank.d622.s0.p1,0,atropine,atropine
2,DDI-DrugBank.d622.s0,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",DDI-DrugBank.d622.s0.p2,0,pralidoxime,atropine
3,DDI-DrugBank.d622.s1,This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. ,DDI-DrugBank.d622.s1.p0,0,atropine,pralidoxime
4,DDI-DrugBank.d622.s2,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",DDI-DrugBank.d622.s2.p0,0,pralidoxime,barbiturates
5,DDI-DrugBank.d622.s2,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",DDI-DrugBank.d622.s2.p1,0,pralidoxime,anticholinesterases
6,DDI-DrugBank.d622.s2,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",DDI-DrugBank.d622.s2.p2,3,barbiturates,anticholinesterases
7,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p0,0,morphine,theophylline
8,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p1,0,morphine,aminophylline
9,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p2,0,morphine,succinylcholine
10,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p3,0,morphine,reserpine
11,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p4,0,morphine,phenothiazine-type tranquilizers
12,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p5,0,theophylline,aminophylline
13,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p6,0,theophylline,succinylcholine
14,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p7,0,theophylline,reserpine
15,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p8,0,theophylline,phenothiazine-type tranquilizers
16,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p9,0,aminophylline,succinylcholine
17,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p10,0,aminophylline,reserpine
18,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p11,0,aminophylline,phenothiazine-type tranquilizers
19,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p12,0,succinylcholine,reserpine
20,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p13,0,succinylcholine,phenothiazine-type tranquilizers
21,DDI-DrugBank.d622.s3,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",DDI-DrugBank.d622.s3.p14,0,reserpine,phenothiazine-type tranquilizers
0,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p0,0,Carbidopa,Levodopa
1,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p1,0,Carbidopa,Carbidopa
2,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p2,0,Carbidopa,Levodopa
3,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p3,0,Carbidopa,pramipexole
4,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p4,0,Levodopa,Carbidopa
5,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p5,0,Levodopa,Levodopa
6,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p6,0,Levodopa,pramipexole
7,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p7,0,Carbidopa,Levodopa
8,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p8,0,Carbidopa,pramipexole
9,DDI-DrugBank.d737.s0,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,DDI-DrugBank.d737.s0.p9,0,Levodopa,pramipexole
10,DDI-DrugBank.d737.s2,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",DDI-DrugBank.d737.s2.p0,0,Selegiline,selegiline
11,DDI-DrugBank.d737.s2,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",DDI-DrugBank.d737.s2.p1,0,Selegiline,pramipexole
12,DDI-DrugBank.d737.s2,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",DDI-DrugBank.d737.s2.p2,0,selegiline,pramipexole
13,DDI-DrugBank.d737.s3,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,DDI-DrugBank.d737.s3.p0,0,Amantadine,amantadine
14,DDI-DrugBank.d737.s3,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,DDI-DrugBank.d737.s3.p1,0,Amantadine,pramipexole
15,DDI-DrugBank.d737.s3,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,DDI-DrugBank.d737.s3.p2,0,amantadine,pramipexole
16,DDI-DrugBank.d737.s4,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",DDI-DrugBank.d737.s4.p0,0,Cimetidine,Cimetidine
17,DDI-DrugBank.d737.s4,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",DDI-DrugBank.d737.s4.p1,0,Cimetidine,pramipexole
18,DDI-DrugBank.d737.s4,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",DDI-DrugBank.d737.s4.p2,2,Cimetidine,pramipexole
19,DDI-DrugBank.d737.s5,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",DDI-DrugBank.d737.s5.p0,0,Probenecid,Probenecid
20,DDI-DrugBank.d737.s5,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",DDI-DrugBank.d737.s5.p1,0,Probenecid,pramipexole
21,DDI-DrugBank.d737.s5,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",DDI-DrugBank.d737.s5.p2,0,Probenecid,pramipexole
22,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p0,0,cimetidine,ranitidine
23,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p1,0,cimetidine,diltiazem
24,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p2,0,cimetidine,triamterene
25,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p3,0,cimetidine,verapamil
26,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p4,0,cimetidine,quinidine
27,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p5,0,cimetidine,quinine
28,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p6,2,cimetidine,pramipexole
29,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p7,0,cimetidine,cephalosporins
30,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p8,0,cimetidine,penicillins
31,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p9,0,cimetidine,indomethacin
32,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p10,0,cimetidine,hydrochlorothiazide
33,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p11,0,cimetidine,chlorpropamide
34,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p12,0,cimetidine,pramipexole
35,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p13,0,ranitidine,diltiazem
36,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p14,0,ranitidine,triamterene
37,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p15,0,ranitidine,verapamil
38,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p16,0,ranitidine,quinidine
39,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p17,0,ranitidine,quinine
40,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p18,2,ranitidine,pramipexole
41,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p19,0,ranitidine,cephalosporins
42,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p20,0,ranitidine,penicillins
43,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p21,0,ranitidine,indomethacin
44,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p22,0,ranitidine,hydrochlorothiazide
45,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p23,0,ranitidine,chlorpropamide
46,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p24,0,ranitidine,pramipexole
47,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p25,0,diltiazem,triamterene
48,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p26,0,diltiazem,verapamil
49,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p27,0,diltiazem,quinidine
50,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p28,0,diltiazem,quinine
51,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p29,2,diltiazem,pramipexole
52,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p30,0,diltiazem,cephalosporins
53,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p31,0,diltiazem,penicillins
54,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p32,0,diltiazem,indomethacin
55,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p33,0,diltiazem,hydrochlorothiazide
56,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p34,0,diltiazem,chlorpropamide
57,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p35,0,diltiazem,pramipexole
58,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p36,0,triamterene,verapamil
59,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p37,0,triamterene,quinidine
60,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p38,0,triamterene,quinine
61,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p39,2,triamterene,pramipexole
62,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p40,0,triamterene,cephalosporins
63,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p41,0,triamterene,penicillins
64,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p42,0,triamterene,indomethacin
65,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p43,0,triamterene,hydrochlorothiazide
66,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p44,0,triamterene,chlorpropamide
67,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p45,0,triamterene,pramipexole
68,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p46,0,verapamil,quinidine
69,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p47,0,verapamil,quinine
70,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p48,2,verapamil,pramipexole
71,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p49,0,verapamil,cephalosporins
72,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p50,0,verapamil,penicillins
73,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p51,0,verapamil,indomethacin
74,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p52,0,verapamil,hydrochlorothiazide
75,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p53,0,verapamil,chlorpropamide
76,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p54,0,verapamil,pramipexole
77,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p55,0,quinidine,quinine
78,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p56,2,quinidine,pramipexole
79,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p57,0,quinidine,cephalosporins
80,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p58,0,quinidine,penicillins
81,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p59,0,quinidine,indomethacin
82,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p60,0,quinidine,hydrochlorothiazide
83,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p61,0,quinidine,chlorpropamide
84,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p62,0,quinidine,pramipexole
85,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p63,2,quinine,pramipexole
86,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p64,0,quinine,cephalosporins
87,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p65,0,quinine,penicillins
88,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p66,0,quinine,indomethacin
89,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p67,0,quinine,hydrochlorothiazide
90,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p68,0,quinine,chlorpropamide
91,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p69,0,quinine,pramipexole
92,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p70,0,pramipexole,cephalosporins
93,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p71,0,pramipexole,penicillins
94,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p72,0,pramipexole,indomethacin
95,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p73,0,pramipexole,hydrochlorothiazide
96,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p74,0,pramipexole,chlorpropamide
97,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p75,0,pramipexole,pramipexole
98,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p76,0,cephalosporins,penicillins
99,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p77,0,cephalosporins,indomethacin
100,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p78,0,cephalosporins,hydrochlorothiazide
101,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p79,0,cephalosporins,chlorpropamide
102,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p80,2,cephalosporins,pramipexole
103,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p81,0,penicillins,indomethacin
104,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p82,0,penicillins,hydrochlorothiazide
105,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p83,0,penicillins,chlorpropamide
106,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p84,2,penicillins,pramipexole
107,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p85,0,indomethacin,hydrochlorothiazide
108,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p86,0,indomethacin,chlorpropamide
109,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p87,2,indomethacin,pramipexole
110,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p88,0,hydrochlorothiazide,chlorpropamide
111,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p89,2,hydrochlorothiazide,pramipexole
112,DDI-DrugBank.d737.s6,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",DDI-DrugBank.d737.s6.p90,2,chlorpropamide,pramipexole
113,DDI-DrugBank.d737.s7,CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. ,DDI-DrugBank.d737.s7.p0,0,pramipexole,pramipexole
114,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p0,0,Dopamine antagonists,pramipexole
115,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p1,0,Dopamine antagonists,dopamine agonist
116,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p2,0,Dopamine antagonists,dopamine antagonists
117,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p3,0,Dopamine antagonists,neuroleptics
118,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p4,0,Dopamine antagonists,phenothiazines
119,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p5,0,Dopamine antagonists,butyrophenones
120,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p6,0,Dopamine antagonists,thioxanthenes
121,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p7,0,Dopamine antagonists,metoclopramide
122,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p8,0,Dopamine antagonists,MIRAPEX
123,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p9,0,pramipexole,dopamine agonist
124,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p10,0,pramipexole,dopamine antagonists
125,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p11,0,pramipexole,neuroleptics
126,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p12,0,pramipexole,phenothiazines
127,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p13,0,pramipexole,butyrophenones
128,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p14,0,pramipexole,thioxanthenes
129,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p15,0,pramipexole,metoclopramide
130,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p16,0,pramipexole,MIRAPEX
131,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p17,0,dopamine agonist,dopamine antagonists
132,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p18,0,dopamine agonist,neuroleptics
133,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p19,0,dopamine agonist,phenothiazines
134,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p20,0,dopamine agonist,butyrophenones
135,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p21,0,dopamine agonist,thioxanthenes
136,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p22,0,dopamine agonist,metoclopramide
137,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p23,0,dopamine agonist,MIRAPEX
138,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p24,0,dopamine antagonists,neuroleptics
139,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p25,0,dopamine antagonists,phenothiazines
140,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p26,0,dopamine antagonists,butyrophenones
141,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p27,0,dopamine antagonists,thioxanthenes
142,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p28,0,dopamine antagonists,metoclopramide
143,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p29,3,dopamine antagonists,MIRAPEX
144,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p30,0,neuroleptics,phenothiazines
145,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p31,0,neuroleptics,butyrophenones
146,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p32,0,neuroleptics,thioxanthenes
147,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p33,0,neuroleptics,metoclopramide
148,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p34,3,neuroleptics,MIRAPEX
149,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p35,0,phenothiazines,butyrophenones
150,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p36,0,phenothiazines,thioxanthenes
151,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p37,0,phenothiazines,metoclopramide
152,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p38,3,phenothiazines,MIRAPEX
153,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p39,0,butyrophenones,thioxanthenes
154,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p40,0,butyrophenones,metoclopramide
155,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p41,3,butyrophenones,MIRAPEX
156,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p42,0,thioxanthenes,metoclopramide
157,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p43,3,thioxanthenes,MIRAPEX
158,DDI-DrugBank.d737.s10,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",DDI-DrugBank.d737.s10.p44,3,metoclopramide,MIRAPEX
0,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p0,1,SYMLIN,anticholinergic agents
1,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p1,1,SYMLIN,atropine
2,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p2,1,SYMLIN,alpha glucosidase inhibitors
3,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p3,0,anticholinergic agents,atropine
4,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p4,0,anticholinergic agents,alpha glucosidase inhibitors
5,DDI-DrugBank.d632.s0,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",DDI-DrugBank.d632.s0.p5,0,atropine,alpha glucosidase inhibitors
6,DDI-DrugBank.d632.s3,"When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection. ",DDI-DrugBank.d632.s3.p0,1,analgesics,SYMLIN
7,DDI-DrugBank.d632.s4,"In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. ",DDI-DrugBank.d632.s4.p0,0,sulfonylureas,biguanides
8,DDI-DrugBank.d632.s4,"In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. ",DDI-DrugBank.d632.s4.p1,0,sulfonylureas,SYMLIN
9,DDI-DrugBank.d632.s4,"In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. ",DDI-DrugBank.d632.s4.p2,0,biguanides,SYMLIN
10,DDI-DrugBank.d632.s5,No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents. ,DDI-DrugBank.d632.s5.p0,0,SYMLIN,antidiabetic agents
11,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p0,0,SYMLIN,Insulin
12,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p1,0,SYMLIN,SYMLIN
13,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p2,0,SYMLIN,human insulin
14,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p3,0,Insulin,SYMLIN
15,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p4,0,Insulin,human insulin
16,DDI-DrugBank.d632.s6,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",DDI-DrugBank.d632.s6.p5,2,SYMLIN,human insulin
17,DDI-DrugBank.d632.s7,"Thus, SYMLIN and insulin should not be mixed and must be administered separately.",DDI-DrugBank.d632.s7.p0,0,SYMLIN,insulin
0,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p0,0,phenobarbital,phenytoin
1,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p1,0,phenobarbital,rifampin
2,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p2,2,phenobarbital,corticosteroids
3,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p3,2,phenobarbital,corticosteroid
4,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p4,0,phenytoin,rifampin
5,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p5,2,phenytoin,corticosteroids
6,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p6,2,phenytoin,corticosteroid
7,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p7,2,rifampin,corticosteroids
8,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p8,2,rifampin,corticosteroid
9,DDI-DrugBank.d653.s1,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",DDI-DrugBank.d653.s1.p9,0,corticosteroids,corticosteroid
10,DDI-DrugBank.d653.s2,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,DDI-DrugBank.d653.s2.p0,0,troleandomycin,ketoconazole
11,DDI-DrugBank.d653.s2,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,DDI-DrugBank.d653.s2.p1,2,troleandomycin,corticosteroids
12,DDI-DrugBank.d653.s2,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,DDI-DrugBank.d653.s2.p2,2,ketoconazole,corticosteroids
13,DDI-DrugBank.d653.s4,Corticosteroids may increase the clearance of chronic high dose aspirin. ,DDI-DrugBank.d653.s4.p0,2,Corticosteroids,aspirin
14,DDI-DrugBank.d653.s5,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,DDI-DrugBank.d653.s5.p0,0,salicylate,salicylate
15,DDI-DrugBank.d653.s5,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,DDI-DrugBank.d653.s5.p1,0,salicylate,corticosteroid
16,DDI-DrugBank.d653.s5,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,DDI-DrugBank.d653.s5.p2,3,salicylate,corticosteroid
17,DDI-DrugBank.d653.s6,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,DDI-DrugBank.d653.s6.p0,1,Aspirin,corticosteroids
18,DDI-DrugBank.d653.s7,The effect of corticosteroids on oral anticoagulants is variable. ,DDI-DrugBank.d653.s7.p0,3,corticosteroids,anticoagulants
19,DDI-DrugBank.d653.s8,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ,DDI-DrugBank.d653.s8.p0,3,anticoagulants,corticosteroids
0,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p0,0,Anticholinesterases,procaine hydrochloride
1,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p1,0,Anticholinesterases,anticholinesterase agents
2,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p2,0,Anticholinesterases,anticholinesterases
3,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p3,0,Anticholinesterases,procaine hydrochloride
4,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p4,3,procaine hydrochloride,anticholinesterase agents
5,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p5,0,procaine hydrochloride,anticholinesterases
6,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p6,0,procaine hydrochloride,procaine hydrochloride
7,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p7,0,anticholinesterase agents,anticholinesterases
8,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p8,0,anticholinesterase agents,procaine hydrochloride
9,DDI-DrugBank.d780.s0,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,DDI-DrugBank.d780.s0.p9,2,anticholinesterases,procaine hydrochloride
10,DDI-DrugBank.d780.s4,CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ,DDI-DrugBank.d780.s4.p0,0,CNS depressant,procaine hydrochloride
11,DDI-DrugBank.d780.s4,CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ,DDI-DrugBank.d780.s4.p1,0,CNS depressant,CNS depressant medications
12,DDI-DrugBank.d780.s4,CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ,DDI-DrugBank.d780.s4.p2,3,procaine hydrochloride,CNS depressant medications
13,DDI-DrugBank.d780.s5,"Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",DDI-DrugBank.d780.s5.p0,0,Hyaluronidase,Hyaluronidase
14,DDI-DrugBank.d780.s5,"Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",DDI-DrugBank.d780.s5.p1,0,Hyaluronidase,procaine hydrochloride
15,DDI-DrugBank.d780.s5,"Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",DDI-DrugBank.d780.s5.p2,2,Hyaluronidase,procaine hydrochloride
16,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p0,0,Neuromuscular blocking agents,suxamethonium chloride
17,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p1,0,Neuromuscular blocking agents,procaine hydrochloride
18,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p2,0,Neuromuscular blocking agents,neuromuscular blocking agents
19,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p3,0,suxamethonium chloride,procaine hydrochloride
20,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p4,0,suxamethonium chloride,neuromuscular blocking agents
21,DDI-DrugBank.d780.s6,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,DDI-DrugBank.d780.s6.p5,3,procaine hydrochloride,neuromuscular blocking agents
22,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p0,0,Sulfonamides,procaine hydrochloride
23,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p1,0,Sulfonamides,sulfonamides
24,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p2,0,Sulfonamides,sulfonamide
25,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p3,3,procaine hydrochloride,sulfonamides
26,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p4,0,procaine hydrochloride,sulfonamide
27,DDI-DrugBank.d780.s7,Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,DDI-DrugBank.d780.s7.p5,0,sulfonamides,sulfonamide
28,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p0,0,Acetazolamide,acetazolamide
29,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p1,0,Acetazolamide,procaine hydrochloride
30,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p2,0,Acetazolamide,procaine
31,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p3,2,acetazolamide,procaine hydrochloride
32,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p4,0,acetazolamide,procaine
33,DDI-DrugBank.d780.s8,Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.,DDI-DrugBank.d780.s8.p5,0,procaine hydrochloride,procaine
0,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p0,0,barbiturates,antihistamines
1,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p1,0,barbiturates,narcotics
2,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p2,0,barbiturates,hypotensive agents
3,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p3,0,barbiturates,phenothiazines
4,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p4,0,antihistamines,narcotics
5,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p5,0,antihistamines,hypotensive agents
6,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p6,0,antihistamines,phenothiazines
7,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p7,0,narcotics,hypotensive agents
8,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p8,0,narcotics,phenothiazines
9,DDI-DrugBank.d676.s0,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ",DDI-DrugBank.d676.s0.p9,0,hypotensive agents,phenothiazines
10,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p0,1,Matulane,sympathomimetic drugs
11,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p1,1,Matulane,tricyclic antidepressant
12,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p2,1,Matulane,amitriptyline HCl
13,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p3,1,Matulane,imipramine HCl
14,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p4,1,Matulane,tyramine
15,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p5,0,sympathomimetic drugs,tricyclic antidepressant
16,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p6,0,sympathomimetic drugs,amitriptyline HCl
17,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p7,0,sympathomimetic drugs,imipramine HCl
18,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p8,0,sympathomimetic drugs,tyramine
19,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p9,0,tricyclic antidepressant,amitriptyline HCl
20,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p10,0,tricyclic antidepressant,imipramine HCl
21,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p11,0,tricyclic antidepressant,tyramine
22,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p12,0,amitriptyline HCl,imipramine HCl
23,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p13,0,amitriptyline HCl,tyramine
24,DDI-DrugBank.d676.s2,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",DDI-DrugBank.d676.s2.p14,0,imipramine HCl,tyramine
25,DDI-DrugBank.d676.s4,"No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.",DDI-DrugBank.d676.s4.p0,0,chemotherapeutic agents,steroids
0,DDI-DrugBank.d734.s0,Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ,DDI-DrugBank.d734.s0.p0,3,Thiazide diuretics,phenothiazines
1,DDI-DrugBank.d734.s1,Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ,DDI-DrugBank.d734.s1.p0,3,guanethidine,phenothiazines
2,DDI-DrugBank.d734.s2,Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.,DDI-DrugBank.d734.s2.p0,2,propranolol,phenothiazines
0,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p0,3,DIPRIVAN,narcotics
1,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p1,3,DIPRIVAN,morphine
2,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p2,3,DIPRIVAN,meperidine
3,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p3,3,DIPRIVAN,fentanyl
4,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p4,0,narcotics,morphine
5,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p5,0,narcotics,meperidine
6,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p6,0,narcotics,fentanyl
7,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p7,0,morphine,meperidine
8,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p8,0,morphine,fentanyl
9,DDI-DrugBank.d628.s0,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DDI-DrugBank.d628.s0.p9,0,meperidine,fentanyl
10,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p0,0,opioids,sedatives
11,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p1,0,opioids,benzodiazepines
12,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p2,0,opioids,barbiturates
13,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p3,0,opioids,chloral hydrate
14,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p4,0,opioids,droperidol
15,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p5,0,sedatives,benzodiazepines
16,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p6,0,sedatives,barbiturates
17,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p7,0,sedatives,chloral hydrate
18,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p8,0,sedatives,droperidol
19,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p9,0,benzodiazepines,barbiturates
20,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p10,0,benzodiazepines,chloral hydrate
21,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p11,0,benzodiazepines,droperidol
22,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p12,0,barbiturates,chloral hydrate
23,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p13,0,barbiturates,droperidol
24,DDI-DrugBank.d628.s1,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",DDI-DrugBank.d628.s1.p14,0,chloral hydrate,droperidol
25,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p0,1,DIPRIVAN,analgesic agents
26,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p1,1,DIPRIVAN,nitrous oxide
27,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p2,1,DIPRIVAN,opioids
28,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p3,0,analgesic agents,nitrous oxide
29,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p4,0,analgesic agents,opioids
30,DDI-DrugBank.d628.s3,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DDI-DrugBank.d628.s3.p5,0,nitrous oxide,opioids
31,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p0,0,isoflurane,enflurane
32,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p1,0,isoflurane,halothane
33,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p2,0,isoflurane,DIPRIVAN
34,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p3,0,enflurane,halothane
35,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p4,0,enflurane,DIPRIVAN
36,DDI-DrugBank.d628.s4,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",DDI-DrugBank.d628.s4.p5,0,halothane,DIPRIVAN
37,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p0,0,DIPRIVAN,neuromuscular blocking agents
38,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p1,0,DIPRIVAN,succinylcholine
39,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p2,0,DIPRIVAN,nondepolarizing muscle relaxants
40,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p3,0,neuromuscular blocking agents,succinylcholine
41,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p4,0,neuromuscular blocking agents,nondepolarizing muscle relaxants
42,DDI-DrugBank.d628.s6,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DDI-DrugBank.d628.s6.p5,0,succinylcholine,nondepolarizing muscle relaxants
43,DDI-DrugBank.d628.s7,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",DDI-DrugBank.d628.s7.p0,0,muscle relaxants,analgesic agents
44,DDI-DrugBank.d628.s7,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",DDI-DrugBank.d628.s7.p1,0,muscle relaxants,anesthetic agents
45,DDI-DrugBank.d628.s7,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",DDI-DrugBank.d628.s7.p2,0,analgesic agents,anesthetic agents
0,DDI-DrugBank.d690.s0,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",DDI-DrugBank.d690.s0.p0,3,propoxyphene,CNS depressants
1,DDI-DrugBank.d690.s0,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",DDI-DrugBank.d690.s0.p1,3,propoxyphene,alcohol
2,DDI-DrugBank.d690.s0,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",DDI-DrugBank.d690.s0.p2,0,CNS depressants,alcohol
3,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p0,0,propoxyphene,antidepressants
4,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p1,0,propoxyphene,anticonvulsants
5,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p2,0,propoxyphene,warfarin
6,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p3,0,antidepressants,anticonvulsants
7,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p4,0,antidepressants,warfarin
8,DDI-DrugBank.d690.s3,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",DDI-DrugBank.d690.s3.p5,0,anticonvulsants,warfarin
0,DDI-DrugBank.d606.s0,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,DDI-DrugBank.d606.s0.p0,0,MAO inhibitors,beta adrenergic blockers
1,DDI-DrugBank.d606.s0,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,DDI-DrugBank.d606.s0.p1,3,MAO inhibitors,pseudoephedrine
2,DDI-DrugBank.d606.s0,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,DDI-DrugBank.d606.s0.p2,3,beta adrenergic blockers,pseudoephedrine
3,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p0,3,Sympathomimetics,methyldopa
4,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p1,3,Sympathomimetics,mecamylamine
5,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p2,3,Sympathomimetics,reserpine
6,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p3,3,Sympathomimetics,veratrum alkaloids
7,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p4,0,methyldopa,mecamylamine
8,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p5,0,methyldopa,reserpine
9,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p6,0,methyldopa,veratrum alkaloids
10,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p7,0,mecamylamine,reserpine
11,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p8,0,mecamylamine,veratrum alkaloids
12,DDI-DrugBank.d606.s1,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",DDI-DrugBank.d606.s1.p9,0,reserpine,veratrum alkaloids
0,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p0,0,Pyrimethamine,sulfonamides
1,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p1,0,Pyrimethamine,quinine
2,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p2,0,Pyrimethamine,antimalarials
3,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p3,0,Pyrimethamine,antibiotics
4,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p4,0,sulfonamides,quinine
5,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p5,0,sulfonamides,antimalarials
6,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p6,0,sulfonamides,antibiotics
7,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p7,0,quinine,antimalarials
8,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p8,0,quinine,antibiotics
9,DDI-DrugBank.d631.s0,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",DDI-DrugBank.d631.s0.p9,0,antimalarials,antibiotics
10,DDI-DrugBank.d631.s2,Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. ,DDI-DrugBank.d631.s2.p0,0,Folinic acid,leucovorin
11,DDI-DrugBank.d631.s3,Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.,DDI-DrugBank.d631.s3.p0,3,lorazepam,pyrimethamine
0,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p0,0,Cholestyramine,Cholestyramine
1,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p1,0,Cholestyramine,raloxifene
2,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p2,0,Cholestyramine,EVISTA
3,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p3,2,Cholestyramine,raloxifene
4,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p4,1,Cholestyramine,EVISTA
5,DDI-DrugBank.d648.s0,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,DDI-DrugBank.d648.s0.p5,0,raloxifene,EVISTA
6,DDI-DrugBank.d648.s1,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,DDI-DrugBank.d648.s1.p0,0,Warfarin,EVISTA
7,DDI-DrugBank.d648.s1,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,DDI-DrugBank.d648.s1.p1,0,Warfarin,warfarin
8,DDI-DrugBank.d648.s1,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,DDI-DrugBank.d648.s1.p2,0,EVISTA,warfarin
9,DDI-DrugBank.d648.s3,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",DDI-DrugBank.d648.s3.p0,1,EVISTA,warfarin
10,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p0,0,raloxifene,warfarin
11,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p1,0,raloxifene,phenytoin
12,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p2,0,raloxifene,tamoxifen
13,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p3,0,warfarin,phenytoin
14,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p4,0,warfarin,tamoxifen
15,DDI-DrugBank.d648.s5,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",DDI-DrugBank.d648.s5.p5,0,phenytoin,tamoxifen
16,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p0,1,EVISTA,clofibrate
17,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p1,1,EVISTA,indomethacin
18,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p2,1,EVISTA,naproxen
19,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p3,1,EVISTA,ibuprofen
20,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p4,1,EVISTA,diazepam
21,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p5,1,EVISTA,diazoxide
22,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p6,0,clofibrate,indomethacin
23,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p7,0,clofibrate,naproxen
24,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p8,0,clofibrate,ibuprofen
25,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p9,0,clofibrate,diazepam
26,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p10,0,clofibrate,diazoxide
27,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p11,0,indomethacin,naproxen
28,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p12,0,indomethacin,ibuprofen
29,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p13,0,indomethacin,diazepam
30,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p14,0,indomethacin,diazoxide
31,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p15,0,naproxen,ibuprofen
32,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p16,0,naproxen,diazepam
33,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p17,0,naproxen,diazoxide
34,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p18,0,ibuprofen,diazepam
35,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p19,0,ibuprofen,diazoxide
36,DDI-DrugBank.d648.s6,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",DDI-DrugBank.d648.s6.p20,0,diazepam,diazoxide
0,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p0,2,TRITEC,clarithromycin
1,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p1,0,TRITEC,ranitidine
2,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p2,0,TRITEC,14- hydroxy- clarithromycin
3,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p3,0,clarithromycin,ranitidine
4,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p4,0,clarithromycin,14- hydroxy- clarithromycin
5,DDI-DrugBank.d590.s0,"Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",DDI-DrugBank.d590.s0.p5,0,ranitidine,14- hydroxy- clarithromycin
6,DDI-DrugBank.d590.s1,Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant. ,DDI-DrugBank.d590.s1.p0,0,aspirin,salicylate
7,DDI-DrugBank.d590.s2,Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. ,DDI-DrugBank.d590.s2.p0,2,antacid,ranitidine
8,DDI-DrugBank.d590.s2,Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. ,DDI-DrugBank.d590.s2.p1,2,antacid,TRITEC
9,DDI-DrugBank.d590.s2,Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. ,DDI-DrugBank.d590.s2.p2,0,ranitidine,TRITEC
10,DDI-DrugBank.d590.s4,"For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.",DDI-DrugBank.d590.s4.p0,0,ranitidine,ZANTAC
0,DDI-DrugBank.d654.s0,"Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ",DDI-DrugBank.d654.s0.p0,0,ketoconazole,retapamulin
1,DDI-DrugBank.d654.s0,"Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ",DDI-DrugBank.d654.s0.p1,2,ketoconazole,retapamulin
2,DDI-DrugBank.d654.s0,"Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ",DDI-DrugBank.d654.s0.p2,0,retapamulin,retapamulin
3,DDI-DrugBank.d654.s1,"Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ",DDI-DrugBank.d654.s1.p0,0,retapamulin,retapamulin
4,DDI-DrugBank.d654.s1,"Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ",DDI-DrugBank.d654.s1.p1,0,retapamulin,ketoconazole
5,DDI-DrugBank.d654.s1,"Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ",DDI-DrugBank.d654.s1.p2,0,retapamulin,ketoconazole
6,DDI-DrugBank.d654.s2,"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates. ",DDI-DrugBank.d654.s2.p0,0,ALTABAX,retapamulin
0,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p0,0,heparin,vitamin K antagonists
1,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p1,0,heparin,aspirin
2,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p2,0,heparin,dipyridamole
3,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p3,0,heparin,abciximab
4,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p4,3,heparin,Retavase
5,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p5,0,vitamin K antagonists,aspirin
6,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p6,0,vitamin K antagonists,dipyridamole
7,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p7,0,vitamin K antagonists,abciximab
8,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p8,3,vitamin K antagonists,Retavase
9,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p9,0,aspirin,dipyridamole
10,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p10,0,aspirin,abciximab
11,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p11,3,aspirin,Retavase
12,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p12,0,dipyridamole,abciximab
13,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p13,3,dipyridamole,Retavase
14,DDI-DrugBank.d618.s1,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",DDI-DrugBank.d618.s1.p14,3,abciximab,Retavase
0,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p0,0,Vitamin B2,Riboflavin
1,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p1,0,Vitamin B2,Alcohol
2,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p2,0,Vitamin B2,riboflavin
3,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p3,0,Riboflavin,Alcohol
4,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p4,0,Riboflavin,riboflavin
5,DDI-DrugBank.d698.s0,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,DDI-DrugBank.d698.s0.p5,2,Alcohol,riboflavin
6,DDI-DrugBank.d698.s1,Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ,DDI-DrugBank.d698.s1.p0,2,Probenecid,riboflavin
7,DDI-DrugBank.d698.s2,requirements for riboflavin may be increased in patients receiving probenecid.,DDI-DrugBank.d698.s2.p0,3,riboflavin,probenecid
0,DDI-DrugBank.d710.s0,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,DDI-DrugBank.d710.s0.p0,0,Cimetidine,cimetidine
1,DDI-DrugBank.d710.s0,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,DDI-DrugBank.d710.s0.p1,0,Cimetidine,rimantadine
2,DDI-DrugBank.d710.s0,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,DDI-DrugBank.d710.s0.p2,0,cimetidine,rimantadine
3,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p0,2,rimantadine HCl,Cimetidine
4,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p1,0,rimantadine HCl,rimantadine
5,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p2,0,rimantadine HCl,rimantadine
6,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p3,0,rimantadine HCl,cimetidine
7,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p4,0,Cimetidine,rimantadine
8,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p5,0,Cimetidine,rimantadine
9,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p6,0,Cimetidine,cimetidine
10,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p7,0,rimantadine,rimantadine
11,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p8,0,rimantadine,cimetidine
12,DDI-DrugBank.d710.s1,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",DDI-DrugBank.d710.s1.p9,0,rimantadine,cimetidine
13,DDI-DrugBank.d710.s2,"Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",DDI-DrugBank.d710.s2.p0,0,Acetaminophen,Rimantadine HCl
14,DDI-DrugBank.d710.s5,Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ,DDI-DrugBank.d710.s5.p0,2,acetaminophen,rimantadine
15,DDI-DrugBank.d710.s6,"Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",DDI-DrugBank.d710.s6.p0,0,Aspirin,Rimantadine HCl
16,DDI-DrugBank.d710.s9,Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.,DDI-DrugBank.d710.s9.p0,2,rimantadine,aspirin
0,DDI-DrugBank.d596.s0,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,DDI-DrugBank.d596.s0.p0,0,Exelon,rivastigmine tartrate
1,DDI-DrugBank.d596.s0,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,DDI-DrugBank.d596.s0.p1,0,Exelon,Rivastigmine
2,DDI-DrugBank.d596.s0,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,DDI-DrugBank.d596.s0.p2,0,rivastigmine tartrate,Rivastigmine
3,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p0,0,rivastigmine,digoxin
4,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p1,0,rivastigmine,warfarin
5,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p2,0,rivastigmine,diazepam
6,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p3,0,rivastigmine,fluoxetine
7,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p4,0,digoxin,warfarin
8,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p5,0,digoxin,diazepam
9,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p6,0,digoxin,fluoxetine
10,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p7,0,warfarin,diazepam
11,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p8,0,warfarin,fluoxetine
12,DDI-DrugBank.d596.s3,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",DDI-DrugBank.d596.s3.p9,0,diazepam,fluoxetine
13,DDI-DrugBank.d596.s4,The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon. ,DDI-DrugBank.d596.s4.p0,0,warfarin,Exelon
14,DDI-DrugBank.d596.s5,Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. ,DDI-DrugBank.d596.s5.p0,0,Exelon,rivastigmine
15,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p0,0,rivastigmine,digoxin
16,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p1,0,rivastigmine,warfarin
17,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p2,0,rivastigmine,diazepam
18,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p3,0,rivastigmine,fluoxetine
19,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p4,0,digoxin,warfarin
20,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p5,0,digoxin,diazepam
21,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p6,0,digoxin,fluoxetine
22,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p7,0,warfarin,diazepam
23,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p8,0,warfarin,fluoxetine
24,DDI-DrugBank.d596.s6,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",DDI-DrugBank.d596.s6.p9,0,diazepam,fluoxetine
25,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p0,0,rivastigmine,antacids
26,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p1,0,rivastigmine,antihypertensives
27,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p2,0,rivastigmine,calcium channel blockers
28,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p3,0,rivastigmine,antidiabetics
29,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p4,0,rivastigmine,nonsteroidal anti-inflammatory drugs
30,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p5,0,rivastigmine,estrogens
31,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p6,0,rivastigmine,salicylate analgesics
32,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p7,0,rivastigmine,antianginals
33,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p8,0,rivastigmine,antihistamines
34,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p9,0,antacids,antihypertensives
35,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p10,0,antacids,calcium channel blockers
36,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p11,0,antacids,antidiabetics
37,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p12,0,antacids,nonsteroidal anti-inflammatory drugs
38,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p13,0,antacids,estrogens
39,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p14,0,antacids,salicylate analgesics
40,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p15,0,antacids,antianginals
41,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p16,0,antacids,antihistamines
42,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p17,0,antihypertensives,calcium channel blockers
43,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p18,0,antihypertensives,antidiabetics
44,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p19,0,antihypertensives,nonsteroidal anti-inflammatory drugs
45,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p20,0,antihypertensives,estrogens
46,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p21,0,antihypertensives,salicylate analgesics
47,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p22,0,antihypertensives,antianginals
48,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p23,0,antihypertensives,antihistamines
49,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p24,0,calcium channel blockers,antidiabetics
50,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p25,0,calcium channel blockers,nonsteroidal anti-inflammatory drugs
51,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p26,0,calcium channel blockers,estrogens
52,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p27,0,calcium channel blockers,salicylate analgesics
53,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p28,0,calcium channel blockers,antianginals
54,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p29,0,calcium channel blockers,antihistamines
55,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p30,0,antidiabetics,nonsteroidal anti-inflammatory drugs
56,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p31,0,antidiabetics,estrogens
57,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p32,0,antidiabetics,salicylate analgesics
58,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p33,0,antidiabetics,antianginals
59,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p34,0,antidiabetics,antihistamines
60,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p35,0,nonsteroidal anti-inflammatory drugs,estrogens
61,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p36,0,nonsteroidal anti-inflammatory drugs,salicylate analgesics
62,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p37,0,nonsteroidal anti-inflammatory drugs,antianginals
63,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p38,0,nonsteroidal anti-inflammatory drugs,antihistamines
64,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p39,0,estrogens,salicylate analgesics
65,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p40,0,estrogens,antianginals
66,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p41,0,estrogens,antihistamines
67,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p42,0,salicylate analgesics,antianginals
68,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p43,0,salicylate analgesics,antihistamines
69,DDI-DrugBank.d596.s7,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",DDI-DrugBank.d596.s7.p44,0,antianginals,antihistamines
70,DDI-DrugBank.d596.s8,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",DDI-DrugBank.d596.s8.p0,0,Anticholinergics,cholinesterase inhibitors
71,DDI-DrugBank.d596.s8,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",DDI-DrugBank.d596.s8.p1,0,Anticholinergics,anticholinergic medications
72,DDI-DrugBank.d596.s8,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",DDI-DrugBank.d596.s8.p2,4,cholinesterase inhibitors,anticholinergic medications
73,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p0,0,Cholinomimetics,Cholinesterase Inhibitors
74,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p1,0,Cholinomimetics,cholinesterase inhibitors
75,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p2,0,Cholinomimetics,succinylcholine
76,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p3,0,Cholinomimetics,neuromuscular blocking agents
77,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p4,0,Cholinomimetics,cholinergic agonists
78,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p5,0,Cholinomimetics,bethanechol
79,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p6,0,Cholinesterase Inhibitors,cholinesterase inhibitors
80,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p7,0,Cholinesterase Inhibitors,succinylcholine
81,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p8,0,Cholinesterase Inhibitors,neuromuscular blocking agents
82,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p9,0,Cholinesterase Inhibitors,cholinergic agonists
83,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p10,0,Cholinesterase Inhibitors,bethanechol
84,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p11,3,cholinesterase inhibitors,succinylcholine
85,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p12,3,cholinesterase inhibitors,neuromuscular blocking agents
86,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p13,3,cholinesterase inhibitors,cholinergic agonists
87,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p14,3,cholinesterase inhibitors,bethanechol
88,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p15,0,succinylcholine,neuromuscular blocking agents
89,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p16,0,succinylcholine,cholinergic agonists
90,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p17,0,succinylcholine,bethanechol
91,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p18,0,neuromuscular blocking agents,cholinergic agonists
92,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p19,0,neuromuscular blocking agents,bethanechol
93,DDI-DrugBank.d596.s9,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",DDI-DrugBank.d596.s9.p20,0,cholinergic agonists,bethanechol
0,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p0,0,ZEMURON,rocuronium bromide
1,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p1,0,ZEMURON,succinylcholine
2,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p2,0,ZEMURON,succinylcholine
3,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p3,0,rocuronium bromide,succinylcholine
4,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p4,0,rocuronium bromide,succinylcholine
5,DDI-DrugBank.d661.s0,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",DDI-DrugBank.d661.s0.p5,0,succinylcholine,succinylcholine
6,DDI-DrugBank.d661.s1,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",DDI-DrugBank.d661.s1.p0,1,ZEMURON,succinylcholine
7,DDI-DrugBank.d661.s1,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",DDI-DrugBank.d661.s1.p1,0,ZEMURON,succinylcholine
8,DDI-DrugBank.d661.s1,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",DDI-DrugBank.d661.s1.p2,0,succinylcholine,succinylcholine
9,DDI-DrugBank.d661.s2,"The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",DDI-DrugBank.d661.s2.p0,0,ZEMURON,succinylcholine
10,DDI-DrugBank.d661.s4,There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants. ,DDI-DrugBank.d661.s4.p0,0,ZEMURON,nondepolarizing muscle relaxants
0,DDI-DrugBank.d591.s0,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",DDI-DrugBank.d591.s0.p0,1,Ropivacaine,anesthetics
1,DDI-DrugBank.d591.s0,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",DDI-DrugBank.d591.s0.p1,0,Ropivacaine,amide-type local anesthetics
2,DDI-DrugBank.d591.s0,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",DDI-DrugBank.d591.s0.p2,0,anesthetics,amide-type local anesthetics
3,DDI-DrugBank.d591.s2,"In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",DDI-DrugBank.d591.s2.p0,2,ropivacaine,fluvoxamine
4,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p0,4,fluvoxamine,Ropivacaine
5,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p1,0,fluvoxamine,Ropivacaine
6,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p2,0,fluvoxamine,ropivacaine
7,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p3,0,Ropivacaine,Ropivacaine
8,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p4,0,Ropivacaine,ropivacaine
9,DDI-DrugBank.d591.s3,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",DDI-DrugBank.d591.s3.p5,0,Ropivacaine,ropivacaine
10,DDI-DrugBank.d591.s5,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. ,DDI-DrugBank.d591.s5.p0,0,theophylline,imipramine
11,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p0,0,ketoconazole,ropivacaine
12,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p1,0,ketoconazole,ketoconazole
13,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p2,2,ketoconazole,ropivacaine
14,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p3,0,ropivacaine,ketoconazole
15,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p4,0,ropivacaine,ropivacaine
16,DDI-DrugBank.d591.s6,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",DDI-DrugBank.d591.s6.p5,0,ketoconazole,ropivacaine
0,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p0,2,gemfibrozil,rosiglitazone
1,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p1,0,gemfibrozil,rifampin
2,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p2,0,gemfibrozil,rosiglitazone
3,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p3,0,rosiglitazone,rifampin
4,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p4,0,rosiglitazone,rosiglitazone
5,DDI-DrugBank.d609.s0,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,DDI-DrugBank.d609.s0.p5,2,rifampin,rosiglitazone
0,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p0,0,Terfenadine,astemizole
1,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p1,0,Terfenadine,macrolides
2,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p2,0,Terfenadine,terfenadine
3,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p3,0,Terfenadine,astemizole
4,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p4,0,astemizole,macrolides
5,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p5,0,astemizole,terfenadine
6,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p6,0,astemizole,astemizole
7,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p7,4,macrolides,terfenadine
8,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p8,4,macrolides,astemizole
9,DDI-DrugBank.d709.s1,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,DDI-DrugBank.d709.s1.p9,0,terfenadine,astemizole
10,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p0,0,roxithromycin,roxithromycin
11,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p1,0,roxithromycin,terfenadine
12,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p2,0,roxithromycin,astemizole
13,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p3,1,roxithromycin,terfenadine
14,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p4,1,roxithromycin,astemizole
15,DDI-DrugBank.d709.s3,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",DDI-DrugBank.d709.s3.p5,0,terfenadine,astemizole
16,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p0,0,Cisapride,pimozide
17,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p1,0,Cisapride,cisapride
18,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p2,0,Cisapride,pimozide
19,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p3,0,Cisapride,macrolide antibacterials
20,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p4,0,pimozide,cisapride
21,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p5,0,pimozide,pimozide
22,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p6,2,pimozide,macrolide antibacterials
23,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p7,0,cisapride,pimozide
24,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p8,2,cisapride,macrolide antibacterials
25,DDI-DrugBank.d709.s4,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",DDI-DrugBank.d709.s4.p9,0,pimozide,macrolide antibacterials
26,DDI-DrugBank.d709.s5,"Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.",DDI-DrugBank.d709.s5.p0,0,roxithromycin,roxithromycin
0,DDI-DrugBank.d770.s4,"however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",DDI-DrugBank.d770.s4.p0,3,diphosphonate,Calcitonin (salmon)
0,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p0,0,ASPIRIN,SALICYLATE DRUGS
1,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p1,3,ASPIRIN,DISALCID
2,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p2,0,ASPIRIN,SALICYLIC ACID
3,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p3,3,SALICYLATE DRUGS,DISALCID
4,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p4,0,SALICYLATE DRUGS,SALICYLIC ACID
5,DDI-DrugBank.d576.s1,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DDI-DrugBank.d576.s1.p5,0,DISALCID,SALICYLIC ACID
6,DDI-DrugBank.d576.s4,Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ,DDI-DrugBank.d576.s4.p0,3,Salicylates,anticoagulant drugs
7,DDI-DrugBank.d576.s5,Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ,DDI-DrugBank.d576.s5.p0,3,Salicylates,antidiabetic drugs
8,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p0,2,Salicylate,penicillin
9,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p1,2,Salicylate,thiopental
10,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p2,2,Salicylate,thyroxine
11,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p3,2,Salicylate,triiodothyronine
12,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p4,2,Salicylate,phenytoin
13,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p5,2,Salicylate,sulfinpyrazone
14,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p6,2,Salicylate,naproxen
15,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p7,2,Salicylate,warfarin
16,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p8,2,Salicylate,methotrexate
17,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p9,2,Salicylate,corticosteroids
18,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p10,0,penicillin,thiopental
19,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p11,0,penicillin,thyroxine
20,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p12,0,penicillin,triiodothyronine
21,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p13,0,penicillin,phenytoin
22,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p14,0,penicillin,sulfinpyrazone
23,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p15,0,penicillin,naproxen
24,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p16,0,penicillin,warfarin
25,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p17,0,penicillin,methotrexate
26,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p18,0,penicillin,corticosteroids
27,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p19,0,thiopental,thyroxine
28,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p20,0,thiopental,triiodothyronine
29,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p21,0,thiopental,phenytoin
30,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p22,0,thiopental,sulfinpyrazone
31,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p23,0,thiopental,naproxen
32,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p24,0,thiopental,warfarin
33,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p25,0,thiopental,methotrexate
34,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p26,0,thiopental,corticosteroids
35,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p27,0,thyroxine,triiodothyronine
36,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p28,0,thyroxine,phenytoin
37,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p29,0,thyroxine,sulfinpyrazone
38,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p30,0,thyroxine,naproxen
39,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p31,0,thyroxine,warfarin
40,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p32,0,thyroxine,methotrexate
41,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p33,0,thyroxine,corticosteroids
42,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p34,0,triiodothyronine,phenytoin
43,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p35,0,triiodothyronine,sulfinpyrazone
44,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p36,0,triiodothyronine,naproxen
45,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p37,0,triiodothyronine,warfarin
46,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p38,0,triiodothyronine,methotrexate
47,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p39,0,triiodothyronine,corticosteroids
48,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p40,0,phenytoin,sulfinpyrazone
49,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p41,0,phenytoin,naproxen
50,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p42,0,phenytoin,warfarin
51,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p43,0,phenytoin,methotrexate
52,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p44,0,phenytoin,corticosteroids
53,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p45,0,sulfinpyrazone,naproxen
54,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p46,0,sulfinpyrazone,warfarin
55,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p47,0,sulfinpyrazone,methotrexate
56,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p48,0,sulfinpyrazone,corticosteroids
57,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p49,0,naproxen,warfarin
58,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p50,0,naproxen,methotrexate
59,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p51,0,naproxen,corticosteroids
60,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p52,0,warfarin,methotrexate
61,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p53,0,warfarin,corticosteroids
62,DDI-DrugBank.d576.s6,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",DDI-DrugBank.d576.s6.p54,0,methotrexate,corticosteroids
0,DDI-DrugBank.d607.s1,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",DDI-DrugBank.d607.s1.p0,3,Leukine,lithium
1,DDI-DrugBank.d607.s1,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",DDI-DrugBank.d607.s1.p1,3,Leukine,corticosteroids
2,DDI-DrugBank.d607.s1,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",DDI-DrugBank.d607.s1.p2,0,lithium,corticosteroids
0,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p0,1,Scopolamine,sedatives
1,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p1,1,Scopolamine,tranquilizers
2,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p2,1,Scopolamine,alcohol
3,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p3,0,sedatives,tranquilizers
4,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p4,0,sedatives,alcohol
5,DDI-DrugBank.d771.s1,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ",DDI-DrugBank.d771.s1.p5,0,tranquilizers,alcohol
6,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p0,0,belladonna alkaloids,antihistamines
7,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p1,0,belladonna alkaloids,meclizine
8,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p2,0,belladonna alkaloids,tricyclic antidepressants
9,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p3,0,belladonna alkaloids,muscle relaxants
10,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p4,0,antihistamines,meclizine
11,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p5,0,antihistamines,tricyclic antidepressants
12,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p6,0,antihistamines,muscle relaxants
13,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p7,0,meclizine,tricyclic antidepressants
14,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p8,0,meclizine,muscle relaxants
15,DDI-DrugBank.d771.s3,"e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ",DDI-DrugBank.d771.s3.p9,0,tricyclic antidepressants,muscle relaxants
0,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p0,4,Barbiturates,contraceptives
1,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p1,4,Barbiturates,antibiotics
2,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p2,4,Barbiturates,quinidine
3,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p3,4,Barbiturates,theophylline
4,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p4,4,Barbiturates,corticosteroids
5,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p5,4,Barbiturates,anticoagulants
6,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p6,4,Barbiturates,beta blockers
7,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p7,0,contraceptives,antibiotics
8,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p8,0,contraceptives,quinidine
9,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p9,0,contraceptives,theophylline
10,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p10,0,contraceptives,corticosteroids
11,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p11,0,contraceptives,anticoagulants
12,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p12,0,contraceptives,beta blockers
13,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p13,0,antibiotics,quinidine
14,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p14,0,antibiotics,theophylline
15,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p15,0,antibiotics,corticosteroids
16,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p16,0,antibiotics,anticoagulants
17,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p17,0,antibiotics,beta blockers
18,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p18,0,quinidine,theophylline
19,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p19,0,quinidine,corticosteroids
20,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p20,0,quinidine,anticoagulants
21,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p21,0,quinidine,beta blockers
22,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p22,0,theophylline,corticosteroids
23,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p23,0,theophylline,anticoagulants
24,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p24,0,theophylline,beta blockers
25,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p25,0,corticosteroids,anticoagulants
26,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p26,0,corticosteroids,beta blockers
27,DDI-DrugBank.d601.s0,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",DDI-DrugBank.d601.s0.p27,0,anticoagulants,beta blockers
0,DDI-DrugBank.d619.s0,"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. ",DDI-DrugBank.d619.s0.p0,3,selegiline,meperidine
1,DDI-DrugBank.d619.s2,This is typical of the interaction of meperidine and MAOIs. ,DDI-DrugBank.d619.s2.p0,4,meperidine,MAOIs
2,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p0,3,tricyclic antidepressants,ELDEPRYL
3,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p1,0,tricyclic antidepressants,selective serotonin reuptake inhibitors
4,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p2,0,tricyclic antidepressants,ELDEPRYL
5,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p3,0,ELDEPRYL,selective serotonin reuptake inhibitors
6,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p4,0,ELDEPRYL,ELDEPRYL
7,DDI-DrugBank.d619.s4,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ,DDI-DrugBank.d619.s4.p5,3,selective serotonin reuptake inhibitors,ELDEPRYL
8,DDI-DrugBank.d619.s5,One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).,DDI-DrugBank.d619.s5.p0,3,selegiline,sympathomimetic medication
9,DDI-DrugBank.d619.s5,One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).,DDI-DrugBank.d619.s5.p1,3,selegiline,ephedrine
10,DDI-DrugBank.d619.s5,One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).,DDI-DrugBank.d619.s5.p2,0,sympathomimetic medication,ephedrine
0,DDI-DrugBank.d694.s0,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",DDI-DrugBank.d694.s0.p0,0,Digoxin,digoxin
1,DDI-DrugBank.d694.s0,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",DDI-DrugBank.d694.s0.p1,0,Digoxin,sitagliptin
2,DDI-DrugBank.d694.s0,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",DDI-DrugBank.d694.s0.p2,2,digoxin,sitagliptin
3,DDI-DrugBank.d694.s2,No dosage adjustment of digoxin or JANUVIA is recommended.,DDI-DrugBank.d694.s2.p0,0,digoxin,JANUVIA
0,DDI-DrugBank.d595.s1,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,DDI-DrugBank.d595.s1.p0,0,norepinephrine,dobutamine
1,DDI-DrugBank.d595.s1,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,DDI-DrugBank.d595.s1.p1,4,norepinephrine,sodium bicarbonate
2,DDI-DrugBank.d595.s1,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,DDI-DrugBank.d595.s1.p2,4,dobutamine,sodium bicarbonate
3,DDI-DrugBank.d595.s2,"The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. ",DDI-DrugBank.d595.s2.p0,0,sodium bicarbonate,calcium
0,DDI-DrugBank.d738.s0,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,DDI-DrugBank.d738.s0.p0,1,VESIcare,ketoconazole
1,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p0,0,solifenacin,solifenacin
2,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p1,0,solifenacin,solifenacin
3,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p2,0,solifenacin,moxifloxacin
4,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p3,0,solifenacin,solifenacin
5,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p4,0,solifenacin,moxifloxacin
6,DDI-DrugBank.d738.s1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",DDI-DrugBank.d738.s1.p5,0,solifenacin,moxifloxacin
0,DDI-DrugBank.d599.s4,"If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. ",DDI-DrugBank.d599.s4.p0,0,glucocorticoid,glucocorticoid
1,DDI-DrugBank.d599.s6,Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ,DDI-DrugBank.d599.s6.p0,2,GH,antipyrine
2,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p0,2,GH,corticosteroids
3,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p1,2,GH,sex steroids
4,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p2,2,GH,anticonvulsants
5,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p3,2,GH,cyclosporin
6,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p4,0,corticosteroids,sex steroids
7,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p5,0,corticosteroids,anticonvulsants
8,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p6,0,corticosteroids,cyclosporin
9,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p7,0,sex steroids,anticonvulsants
10,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p8,0,sex steroids,cyclosporin
11,DDI-DrugBank.d599.s7,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",DDI-DrugBank.d599.s7.p9,0,anticonvulsants,cyclosporin
0,DDI-DrugBank.d602.s0,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,DDI-DrugBank.d602.s0.p0,1,NEXAVAR,irinotecan
1,DDI-DrugBank.d602.s1,Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ,DDI-DrugBank.d602.s1.p0,2,NEXAVAR,doxorubicin
2,DDI-DrugBank.d602.s2,Caution is recommended when administering doxorubicin with NEXAVAR. ,DDI-DrugBank.d602.s2.p0,1,doxorubicin,NEXAVAR
0,DDI-DrugBank.d727.s0,Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ,DDI-DrugBank.d727.s0.p0,3,Zidovudine,stavudine
1,DDI-DrugBank.d727.s1,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",DDI-DrugBank.d727.s1.p0,1,zidovudine,ZERIT
2,DDI-DrugBank.d727.s2,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,DDI-DrugBank.d727.s2.p0,3,stavudine,doxorubicin
3,DDI-DrugBank.d727.s2,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,DDI-DrugBank.d727.s2.p1,3,stavudine,ribavirin
4,DDI-DrugBank.d727.s2,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,DDI-DrugBank.d727.s2.p2,0,doxorubicin,ribavirin
0,DDI-DrugBank.d777.s0,"The interaction of Streptase, Streptokinase, with other drugs has not been well studied. ",DDI-DrugBank.d777.s0.p0,0,Streptase,Streptokinase
1,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p0,0,Anticoagulants,Antiplatelet Agents
2,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p1,0,Anticoagulants,Streptase
3,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p2,0,Anticoagulants,Streptokinase
4,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p3,0,Anticoagulants,antiplatelet agents
5,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p4,0,Anticoagulants,anticoagulants
6,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p5,0,Antiplatelet Agents,Streptase
7,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p6,0,Antiplatelet Agents,Streptokinase
8,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p7,0,Antiplatelet Agents,antiplatelet agents
9,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p8,0,Antiplatelet Agents,anticoagulants
10,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p9,0,Streptase,Streptokinase
11,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p10,3,Streptase,antiplatelet agents
12,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p11,3,Streptase,anticoagulants
13,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p12,3,Streptokinase,antiplatelet agents
14,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p13,3,Streptokinase,anticoagulants
15,DDI-DrugBank.d777.s1,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",DDI-DrugBank.d777.s1.p14,0,antiplatelet agents,anticoagulants
16,DDI-DrugBank.d777.s3,"In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ). ",DDI-DrugBank.d777.s3.p0,0,aspirin,Streptokinase
17,DDI-DrugBank.d777.s4,"Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke. ",DDI-DrugBank.d777.s4.p0,0,Antiplatelets,aspirin
18,DDI-DrugBank.d777.s5,"The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",DDI-DrugBank.d777.s5.p0,3,aspirin,Streptokinase
0,DDI-DrugBank.d647.s1,Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ,DDI-DrugBank.d647.s1.p0,2,Streptozocin,doxorubicin
1,DDI-DrugBank.d647.s2,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,DDI-DrugBank.d647.s2.p0,1,doxorubicin,ZANOSAR
2,DDI-DrugBank.d647.s3,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,DDI-DrugBank.d647.s3.p0,3,streptozocin,phenytoin
3,DDI-DrugBank.d647.s3,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,DDI-DrugBank.d647.s3.p1,0,streptozocin,streptozocin
4,DDI-DrugBank.d647.s3,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,DDI-DrugBank.d647.s3.p2,0,phenytoin,streptozocin
0,DDI-DrugBank.d732.s0,CHEMET is not known to interact with other drugs including iron supplements; ,DDI-DrugBank.d732.s0.p0,0,CHEMET,iron
1,DDI-DrugBank.d732.s2,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",DDI-DrugBank.d732.s2.p0,1,CHEMET,CaNa 2 EDTA
0,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p0,3,Sulfamethizole,barbiturates
1,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p1,3,Sulfamethizole,tolbutamide
2,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p2,3,Sulfamethizole,uricosurics
3,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p3,0,barbiturates,tolbutamide
4,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p4,0,barbiturates,uricosurics
5,DDI-DrugBank.d649.s0,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d649.s0.p5,0,tolbutamide,uricosurics
6,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p0,0,thiazides,cyclosporine
7,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p1,0,thiazides,sulfonylurea agents
8,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p2,0,thiazides,warfarin
9,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p3,0,thiazides,methotrexate
10,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p4,0,thiazides,methotrexate
11,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p5,0,thiazides,phenytoin
12,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p6,0,thiazides,phenytoin
13,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p7,0,cyclosporine,sulfonylurea agents
14,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p8,0,cyclosporine,warfarin
15,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p9,0,cyclosporine,methotrexate
16,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p10,0,cyclosporine,methotrexate
17,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p11,0,cyclosporine,phenytoin
18,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p12,0,cyclosporine,phenytoin
19,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p13,0,sulfonylurea agents,warfarin
20,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p14,0,sulfonylurea agents,methotrexate
21,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p15,0,sulfonylurea agents,methotrexate
22,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p16,0,sulfonylurea agents,phenytoin
23,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p17,0,sulfonylurea agents,phenytoin
24,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p18,0,warfarin,methotrexate
25,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p19,0,warfarin,methotrexate
26,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p20,0,warfarin,phenytoin
27,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p21,0,warfarin,phenytoin
28,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p22,0,methotrexate,methotrexate
29,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p23,0,methotrexate,phenytoin
30,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p24,0,methotrexate,phenytoin
31,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p25,0,methotrexate,phenytoin
32,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p26,0,methotrexate,phenytoin
33,DDI-DrugBank.d649.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d649.s1.p27,0,phenytoin,phenytoin
0,DDI-DrugBank.d577.s0,"In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported. ",DDI-DrugBank.d577.s0.p0,0,diuretics,thiazides
1,DDI-DrugBank.d577.s1,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,DDI-DrugBank.d577.s1.p0,0,sulfamethoxazole,anticoagulant
2,DDI-DrugBank.d577.s1,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,DDI-DrugBank.d577.s1.p1,3,sulfamethoxazole,warfarin
3,DDI-DrugBank.d577.s1,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,DDI-DrugBank.d577.s1.p2,0,anticoagulant,warfarin
4,DDI-DrugBank.d577.s3,Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ,DDI-DrugBank.d577.s3.p0,2,Sulfamethoxazole,phenytoin
5,DDI-DrugBank.d577.s4,"At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ",DDI-DrugBank.d577.s4.p0,2,sulfamethoxazole,phenytoin
6,DDI-DrugBank.d577.s6,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",DDI-DrugBank.d577.s6.p0,2,Sulfonamides,methotrexate
7,DDI-DrugBank.d577.s6,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",DDI-DrugBank.d577.s6.p1,0,Sulfonamides,methotrexate
8,DDI-DrugBank.d577.s6,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",DDI-DrugBank.d577.s6.p2,0,methotrexate,methotrexate
0,DDI-DrugBank.d693.s0,Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ,DDI-DrugBank.d693.s0.p0,0,folic acid,digoxin
1,DDI-DrugBank.d693.s0,Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ,DDI-DrugBank.d693.s0.p1,2,folic acid,sulfasalazine
2,DDI-DrugBank.d693.s0,Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ,DDI-DrugBank.d693.s0.p2,2,digoxin,sulfasalazine
3,DDI-DrugBank.d693.s1,"When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. ",DDI-DrugBank.d693.s1.p0,0,sulfasalazine,methotrexate
4,DDI-DrugBank.d693.s2,Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ,DDI-DrugBank.d693.s2.p0,0,sulfasalazine,methotrexate
0,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p0,3,Sulfoxone,barbiturates
1,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p1,3,Sulfoxone,tolbutamide
2,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p2,3,Sulfoxone,uricosurics
3,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p3,0,barbiturates,tolbutamide
4,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p4,0,barbiturates,uricosurics
5,DDI-DrugBank.d682.s0,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",DDI-DrugBank.d682.s0.p5,0,tolbutamide,uricosurics
6,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p0,0,thiazides,cyclosporine
7,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p1,0,thiazides,sulfonylurea agents
8,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p2,0,thiazides,warfarin
9,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p3,0,thiazides,methotrexate
10,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p4,0,thiazides,methotrexate
11,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p5,0,thiazides,phenytoin
12,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p6,0,thiazides,phenytoin
13,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p7,0,cyclosporine,sulfonylurea agents
14,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p8,0,cyclosporine,warfarin
15,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p9,0,cyclosporine,methotrexate
16,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p10,0,cyclosporine,methotrexate
17,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p11,0,cyclosporine,phenytoin
18,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p12,0,cyclosporine,phenytoin
19,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p13,0,sulfonylurea agents,warfarin
20,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p14,0,sulfonylurea agents,methotrexate
21,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p15,0,sulfonylurea agents,methotrexate
22,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p16,0,sulfonylurea agents,phenytoin
23,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p17,0,sulfonylurea agents,phenytoin
24,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p18,0,warfarin,methotrexate
25,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p19,0,warfarin,methotrexate
26,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p20,0,warfarin,phenytoin
27,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p21,0,warfarin,phenytoin
28,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p22,0,methotrexate,methotrexate
29,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p23,0,methotrexate,phenytoin
30,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p24,0,methotrexate,phenytoin
31,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p25,0,methotrexate,phenytoin
32,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p26,0,methotrexate,phenytoin
33,DDI-DrugBank.d682.s1,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",DDI-DrugBank.d682.s1.p27,0,phenytoin,phenytoin
0,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p0,0,ergotamine,ergot-type medications
1,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p1,0,ergotamine,dihydroergotamine
2,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p2,0,ergotamine,methysergide
3,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p3,1,ergotamine,sumatriptan
4,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p4,0,ergot-type medications,dihydroergotamine
5,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p5,0,ergot-type medications,methysergide
6,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p6,1,ergot-type medications,sumatriptan
7,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p7,0,dihydroergotamine,methysergide
8,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p8,1,dihydroergotamine,sumatriptan
9,DDI-DrugBank.d720.s1,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",DDI-DrugBank.d720.s1.p9,1,methysergide,sumatriptan
10,DDI-DrugBank.d720.s2,"MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. ",DDI-DrugBank.d720.s2.p0,2,MAO-A inhibitors,sumatriptan
11,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p0,1,sumatriptan succinate,MAO-A inhibitors
12,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p1,0,sumatriptan succinate,Selective serotonin reuptake inhibitors
13,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p2,0,sumatriptan succinate,SSRIs
14,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p3,0,sumatriptan succinate,fluoxetine
15,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p4,0,sumatriptan succinate,fluvoxamine
16,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p5,0,sumatriptan succinate,paroxetine
17,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p6,0,sumatriptan succinate,sertraline
18,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p7,0,sumatriptan succinate,sumatriptan
19,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p8,0,MAO-A inhibitors,Selective serotonin reuptake inhibitors
20,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p9,0,MAO-A inhibitors,SSRIs
21,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p10,0,MAO-A inhibitors,fluoxetine
22,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p11,0,MAO-A inhibitors,fluvoxamine
23,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p12,0,MAO-A inhibitors,paroxetine
24,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p13,0,MAO-A inhibitors,sertraline
25,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p14,0,MAO-A inhibitors,sumatriptan
26,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p15,0,Selective serotonin reuptake inhibitors,SSRIs
27,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p16,0,Selective serotonin reuptake inhibitors,fluoxetine
28,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p17,0,Selective serotonin reuptake inhibitors,fluvoxamine
29,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p18,0,Selective serotonin reuptake inhibitors,paroxetine
30,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p19,0,Selective serotonin reuptake inhibitors,sertraline
31,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p20,3,Selective serotonin reuptake inhibitors,sumatriptan
32,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p21,0,SSRIs,fluoxetine
33,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p22,0,SSRIs,fluvoxamine
34,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p23,0,SSRIs,paroxetine
35,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p24,0,SSRIs,sertraline
36,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p25,3,SSRIs,sumatriptan
37,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p26,0,fluoxetine,fluvoxamine
38,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p27,0,fluoxetine,paroxetine
39,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p28,0,fluoxetine,sertraline
40,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p29,3,fluoxetine,sumatriptan
41,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p30,0,fluvoxamine,paroxetine
42,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p31,0,fluvoxamine,sertraline
43,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p32,3,fluvoxamine,sumatriptan
44,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p33,0,paroxetine,sertraline
45,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p34,3,paroxetine,sumatriptan
46,DDI-DrugBank.d720.s3,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",DDI-DrugBank.d720.s3.p35,3,sertraline,sumatriptan
47,DDI-DrugBank.d720.s4,"If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",DDI-DrugBank.d720.s4.p0,1,sumatriptan,SSRI
0,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p0,2,SUTENT,ketoconazole
1,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p1,2,SUTENT,itraconazole
2,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p2,2,SUTENT,clarithromycin
3,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p3,2,SUTENT,atazanavir
4,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p4,2,SUTENT,indinavir
5,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p5,2,SUTENT,nefazodone
6,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p6,2,SUTENT,nelfinavir
7,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p7,2,SUTENT,ritonavir
8,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p8,2,SUTENT,saquinavir
9,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p9,2,SUTENT,telithromycin
10,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p10,2,SUTENT,voriconizole
11,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p11,0,SUTENT,sunitinib
12,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p12,0,ketoconazole,itraconazole
13,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p13,0,ketoconazole,clarithromycin
14,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p14,0,ketoconazole,atazanavir
15,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p15,0,ketoconazole,indinavir
16,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p16,0,ketoconazole,nefazodone
17,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p17,0,ketoconazole,nelfinavir
18,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p18,0,ketoconazole,ritonavir
19,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p19,0,ketoconazole,saquinavir
20,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p20,0,ketoconazole,telithromycin
21,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p21,0,ketoconazole,voriconizole
22,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p22,0,ketoconazole,sunitinib
23,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p23,0,itraconazole,clarithromycin
24,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p24,0,itraconazole,atazanavir
25,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p25,0,itraconazole,indinavir
26,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p26,0,itraconazole,nefazodone
27,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p27,0,itraconazole,nelfinavir
28,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p28,0,itraconazole,ritonavir
29,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p29,0,itraconazole,saquinavir
30,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p30,0,itraconazole,telithromycin
31,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p31,0,itraconazole,voriconizole
32,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p32,0,itraconazole,sunitinib
33,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p33,0,clarithromycin,atazanavir
34,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p34,0,clarithromycin,indinavir
35,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p35,0,clarithromycin,nefazodone
36,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p36,0,clarithromycin,nelfinavir
37,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p37,0,clarithromycin,ritonavir
38,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p38,0,clarithromycin,saquinavir
39,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p39,0,clarithromycin,telithromycin
40,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p40,0,clarithromycin,voriconizole
41,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p41,0,clarithromycin,sunitinib
42,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p42,0,atazanavir,indinavir
43,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p43,0,atazanavir,nefazodone
44,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p44,0,atazanavir,nelfinavir
45,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p45,0,atazanavir,ritonavir
46,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p46,0,atazanavir,saquinavir
47,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p47,0,atazanavir,telithromycin
48,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p48,0,atazanavir,voriconizole
49,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p49,0,atazanavir,sunitinib
50,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p50,0,indinavir,nefazodone
51,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p51,0,indinavir,nelfinavir
52,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p52,0,indinavir,ritonavir
53,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p53,0,indinavir,saquinavir
54,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p54,0,indinavir,telithromycin
55,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p55,0,indinavir,voriconizole
56,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p56,0,indinavir,sunitinib
57,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p57,0,nefazodone,nelfinavir
58,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p58,0,nefazodone,ritonavir
59,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p59,0,nefazodone,saquinavir
60,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p60,0,nefazodone,telithromycin
61,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p61,0,nefazodone,voriconizole
62,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p62,0,nefazodone,sunitinib
63,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p63,0,nelfinavir,ritonavir
64,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p64,0,nelfinavir,saquinavir
65,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p65,0,nelfinavir,telithromycin
66,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p66,0,nelfinavir,voriconizole
67,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p67,0,nelfinavir,sunitinib
68,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p68,0,ritonavir,saquinavir
69,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p69,0,ritonavir,telithromycin
70,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p70,0,ritonavir,voriconizole
71,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p71,0,ritonavir,sunitinib
72,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p72,0,saquinavir,telithromycin
73,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p73,0,saquinavir,voriconizole
74,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p74,0,saquinavir,sunitinib
75,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p75,0,telithromycin,voriconizole
76,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p76,0,telithromycin,sunitinib
77,DDI-DrugBank.d639.s0,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",DDI-DrugBank.d639.s0.p77,0,voriconizole,sunitinib
78,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p0,2,SUTENT,dexamethasone
79,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p1,2,SUTENT,phenytoin
80,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p2,2,SUTENT,carbamazepine
81,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p3,2,SUTENT,rifampin
82,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p4,2,SUTENT,rifabutin
83,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p5,2,SUTENT,rifapentin
84,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p6,2,SUTENT,phenobarbital
85,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p7,0,SUTENT,sunitinib
86,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p8,0,dexamethasone,phenytoin
87,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p9,0,dexamethasone,carbamazepine
88,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p10,0,dexamethasone,rifampin
89,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p11,0,dexamethasone,rifabutin
90,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p12,0,dexamethasone,rifapentin
91,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p13,0,dexamethasone,phenobarbital
92,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p14,0,dexamethasone,sunitinib
93,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p15,0,phenytoin,carbamazepine
94,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p16,0,phenytoin,rifampin
95,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p17,0,phenytoin,rifabutin
96,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p18,0,phenytoin,rifapentin
97,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p19,0,phenytoin,phenobarbital
98,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p20,0,phenytoin,sunitinib
99,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p21,0,carbamazepine,rifampin
100,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p22,0,carbamazepine,rifabutin
101,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p23,0,carbamazepine,rifapentin
102,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p24,0,carbamazepine,phenobarbital
103,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p25,0,carbamazepine,sunitinib
104,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p26,0,rifampin,rifabutin
105,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p27,0,rifampin,rifapentin
106,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p28,0,rifampin,phenobarbital
107,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p29,0,rifampin,sunitinib
108,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p30,0,rifabutin,rifapentin
109,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p31,0,rifabutin,phenobarbital
110,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p32,0,rifabutin,sunitinib
111,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p33,0,rifapentin,phenobarbital
112,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p34,0,rifapentin,sunitinib
113,DDI-DrugBank.d639.s2,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",DDI-DrugBank.d639.s2.p35,0,phenobarbital,sunitinib
0,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p0,0,acetylcholine chloride,Miochol
1,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p1,0,acetylcholine chloride,carbachol
2,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p2,0,acetylcholine chloride,Carboptic
3,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p3,0,acetylcholine chloride,Isopto Carbachol
4,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p4,3,acetylcholine chloride,suprofen
5,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p5,0,Miochol,carbachol
6,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p6,0,Miochol,Carboptic
7,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p7,0,Miochol,Isopto Carbachol
8,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p8,3,Miochol,suprofen
9,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p9,0,carbachol,Carboptic
10,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p10,0,carbachol,Isopto Carbachol
11,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p11,3,carbachol,suprofen
12,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p12,0,Carboptic,Isopto Carbachol
13,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p13,3,Carboptic,suprofen
14,DDI-DrugBank.d723.s0,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",DDI-DrugBank.d723.s0.p14,3,Isopto Carbachol,suprofen
0,DDI-DrugBank.d704.s0,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. ,DDI-DrugBank.d704.s0.p0,0,FLOMAX,alpha-adrenergic blocking agents
1,DDI-DrugBank.d704.s1,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",DDI-DrugBank.d704.s1.p0,1,FLOMAX,alpha-adrenergic blocking agents
2,DDI-DrugBank.d704.s2,The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated. ,DDI-DrugBank.d704.s2.p0,0,cimetidine,FLOMAX
3,DDI-DrugBank.d704.s4,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",DDI-DrugBank.d704.s4.p0,1,FLOMAX,cimetidine
4,DDI-DrugBank.d704.s5,Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive. ,DDI-DrugBank.d704.s5.p0,0,tamsulosin HCI,warfarin
5,DDI-DrugBank.d704.s6,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",DDI-DrugBank.d704.s6.p0,1,warfarin,FLOMAX
0,DDI-DrugBank.d687.s0,Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ,DDI-DrugBank.d687.s0.p0,2,valproic acid,temozolomide
0,DDI-DrugBank.d773.s1,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,DDI-DrugBank.d773.s1.p0,0,TNKase,heparin
1,DDI-DrugBank.d773.s1,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,DDI-DrugBank.d773.s1.p1,0,TNKase,aspirin
2,DDI-DrugBank.d773.s1,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,DDI-DrugBank.d773.s1.p2,0,heparin,aspirin
3,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p0,0,Anticoagulants,heparin
4,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p1,0,Anticoagulants,vitamin K antagonists
5,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p2,0,Anticoagulants,acetylsalicylic acid
6,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p3,0,Anticoagulants,dipyridamole
7,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p4,3,Anticoagulants,TNKase
8,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p5,0,heparin,vitamin K antagonists
9,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p6,0,heparin,acetylsalicylic acid
10,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p7,0,heparin,dipyridamole
11,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p8,3,heparin,TNKase
12,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p9,0,vitamin K antagonists,acetylsalicylic acid
13,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p10,0,vitamin K antagonists,dipyridamole
14,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p11,3,vitamin K antagonists,TNKase
15,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p12,0,acetylsalicylic acid,dipyridamole
16,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p13,3,acetylsalicylic acid,TNKase
17,DDI-DrugBank.d773.s2,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",DDI-DrugBank.d773.s2.p14,3,dipyridamole,TNKase
0,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p0,0,tolbutamide,sodium salicylate
1,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p1,0,tolbutamide,sulfamethizole
2,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p2,2,tolbutamide,teniposide
3,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p3,0,sodium salicylate,sulfamethizole
4,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p4,2,sodium salicylate,teniposide
5,DDI-DrugBank.d575.s0,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",DDI-DrugBank.d575.s0.p5,2,sulfamethizole,teniposide
6,DDI-DrugBank.d575.s2,"Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. ",DDI-DrugBank.d575.s2.p0,0,VUMON,teniposide
7,DDI-DrugBank.d575.s3,There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. ,DDI-DrugBank.d575.s3.p0,0,teniposide,methotrexate
8,DDI-DrugBank.d575.s5,An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.,DDI-DrugBank.d575.s5.p0,2,methotrexate,teniposide
0,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p0,0,terbinafine,tolbutamide
1,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p1,0,terbinafine,ethinylestradiol
2,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p2,0,terbinafine,ethoxycoumarin
3,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p3,0,terbinafine,cyclosporine
4,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p4,0,tolbutamide,ethinylestradiol
5,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p5,0,tolbutamide,ethoxycoumarin
6,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p6,0,tolbutamide,cyclosporine
7,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p7,0,ethinylestradiol,ethoxycoumarin
8,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p8,0,ethinylestradiol,cyclosporine
9,DDI-DrugBank.d645.s0,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",DDI-DrugBank.d645.s0.p9,0,ethoxycoumarin,cyclosporine
10,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p0,0,tricyclic antidepressants,selective serotonin reuptake inhibitors
11,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p1,0,tricyclic antidepressants,SSRIs
12,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p2,0,tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B
13,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p3,0,selective serotonin reuptake inhibitors,SSRIs
14,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p4,0,selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B
15,DDI-DrugBank.d645.s2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",DDI-DrugBank.d645.s2.p5,0,SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B
16,DDI-DrugBank.d645.s3,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,DDI-DrugBank.d645.s3.p0,0,terbinafine,antipyrine
17,DDI-DrugBank.d645.s3,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,DDI-DrugBank.d645.s3.p1,0,terbinafine,digoxin
18,DDI-DrugBank.d645.s3,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,DDI-DrugBank.d645.s3.p2,0,antipyrine,digoxin
19,DDI-DrugBank.d645.s4,Terbinafine decreases the clearance of caffeine by 19%. ,DDI-DrugBank.d645.s4.p0,2,Terbinafine,caffeine
20,DDI-DrugBank.d645.s5,Terbinafine increases the clearance of cyclosporine by 15%. ,DDI-DrugBank.d645.s5.p0,2,Terbinafine,cyclosporine
21,DDI-DrugBank.d645.s6,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",DDI-DrugBank.d645.s6.p0,3,terbinafine,warfarin
22,DDI-DrugBank.d645.s6,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",DDI-DrugBank.d645.s6.p1,0,terbinafine,LAMISIL
23,DDI-DrugBank.d645.s6,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",DDI-DrugBank.d645.s6.p2,0,warfarin,LAMISIL
24,DDI-DrugBank.d645.s7,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",DDI-DrugBank.d645.s7.p0,2,Terbinafine,rifampin
25,DDI-DrugBank.d645.s7,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",DDI-DrugBank.d645.s7.p1,2,Terbinafine,cimetidine
26,DDI-DrugBank.d645.s7,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",DDI-DrugBank.d645.s7.p2,0,rifampin,cimetidine
27,DDI-DrugBank.d645.s8,Terbinafine clearance is unaffected by cyclosporine. ,DDI-DrugBank.d645.s8.p0,0,Terbinafine,cyclosporine
28,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p0,0,contraceptives,hypoglycemics
29,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p1,0,contraceptives,theophyllines
30,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p2,0,contraceptives,phenytoins
31,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p3,0,contraceptives,thiazide diuretics
32,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p4,0,contraceptives,beta blockers
33,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p5,0,contraceptives,calcium channel blockers
34,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p6,0,hypoglycemics,theophyllines
35,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p7,0,hypoglycemics,phenytoins
36,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p8,0,hypoglycemics,thiazide diuretics
37,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p9,0,hypoglycemics,beta blockers
38,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p10,0,hypoglycemics,calcium channel blockers
39,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p11,0,theophyllines,phenytoins
40,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p12,0,theophyllines,thiazide diuretics
41,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p13,0,theophyllines,beta blockers
42,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p14,0,theophyllines,calcium channel blockers
43,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p15,0,phenytoins,thiazide diuretics
44,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p16,0,phenytoins,beta blockers
45,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p17,0,phenytoins,calcium channel blockers
46,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p18,0,thiazide diuretics,beta blockers
47,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p19,0,thiazide diuretics,calcium channel blockers
48,DDI-DrugBank.d645.s9,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",DDI-DrugBank.d645.s9.p20,0,beta blockers,calcium channel blockers
0,DDI-DrugBank.d743.s0,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",DDI-DrugBank.d743.s0.p0,0,Ketoconazole,ketoconazole
1,DDI-DrugBank.d743.s0,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",DDI-DrugBank.d743.s0.p1,0,Ketoconazole,terfenadine
2,DDI-DrugBank.d743.s0,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",DDI-DrugBank.d743.s0.p2,3,ketoconazole,terfenadine
3,DDI-DrugBank.d743.s2,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",DDI-DrugBank.d743.s2.p0,2,ketoconazole,terfenadine
4,DDI-DrugBank.d743.s2,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",DDI-DrugBank.d743.s2.p1,0,ketoconazole,terfenadine
5,DDI-DrugBank.d743.s2,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",DDI-DrugBank.d743.s2.p2,0,terfenadine,terfenadine
6,DDI-DrugBank.d743.s4,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,DDI-DrugBank.d743.s4.p0,1,ketoconazole,terfenadine
7,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p0,0,Itraconazole,terfenadine
8,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p1,0,Itraconazole,terfenadine
9,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p2,0,Itraconazole,itraconazole
10,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p3,0,Itraconazole,itraconazole
11,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p4,0,terfenadine,terfenadine
12,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p5,0,terfenadine,itraconazole
13,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p6,0,terfenadine,itraconazole
14,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p7,2,terfenadine,itraconazole
15,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p8,0,terfenadine,itraconazole
16,DDI-DrugBank.d743.s5,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,DDI-DrugBank.d743.s5.p9,0,itraconazole,itraconazole
17,DDI-DrugBank.d743.s7,Concomitant administration of itraconazole and terfenadine is contraindicated. ,DDI-DrugBank.d743.s7.p0,1,itraconazole,terfenadine
18,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p0,0,azole-type antifungal agents,fluconazole
19,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p1,0,azole-type antifungal agents,metronidazole
20,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p2,0,azole-type antifungal agents,miconazole
21,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p3,0,azole-type antifungal agents,ketoconazole
22,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p4,0,azole-type antifungal agents,itraconazole
23,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p5,1,azole-type antifungal agents,terfenadine
24,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p6,0,fluconazole,metronidazole
25,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p7,0,fluconazole,miconazole
26,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p8,0,fluconazole,ketoconazole
27,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p9,0,fluconazole,itraconazole
28,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p10,1,fluconazole,terfenadine
29,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p11,0,metronidazole,miconazole
30,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p12,0,metronidazole,ketoconazole
31,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p13,0,metronidazole,itraconazole
32,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p14,1,metronidazole,terfenadine
33,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p15,0,miconazole,ketoconazole
34,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p16,0,miconazole,itraconazole
35,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p17,1,miconazole,terfenadine
36,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p18,0,ketoconazole,itraconazole
37,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p19,0,ketoconazole,terfenadine
38,DDI-DrugBank.d743.s8,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",DDI-DrugBank.d743.s8.p20,0,itraconazole,terfenadine
39,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p0,0,Macrolides,erythromycin
40,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p1,0,Macrolides,clarithromycin
41,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p2,0,Macrolides,terfenadine
42,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p3,0,Macrolides,ketoconazole
43,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p4,0,erythromycin,clarithromycin
44,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p5,2,erythromycin,terfenadine
45,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p6,0,erythromycin,ketoconazole
46,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p7,2,clarithromycin,terfenadine
47,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p8,0,clarithromycin,ketoconazole
48,DDI-DrugBank.d743.s9,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",DDI-DrugBank.d743.s9.p9,0,terfenadine,ketoconazole
49,DDI-DrugBank.d743.s11,"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin. ",DDI-DrugBank.d743.s11.p0,0,erythromycin,troleandomycin
50,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p0,1,terfenadine,clarithromycin
51,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p1,1,terfenadine,erythromycin
52,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p2,1,terfenadine,troleandomycin
53,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p3,0,terfenadine,terfenadine
54,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p4,0,terfenadine,macrolide antibiotics
55,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p5,0,terfenadine,azithromycin
56,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p6,0,clarithromycin,erythromycin
57,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p7,0,clarithromycin,troleandomycin
58,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p8,0,clarithromycin,terfenadine
59,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p9,0,clarithromycin,macrolide antibiotics
60,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p10,0,clarithromycin,azithromycin
61,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p11,0,erythromycin,troleandomycin
62,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p12,0,erythromycin,terfenadine
63,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p13,0,erythromycin,macrolide antibiotics
64,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p14,0,erythromycin,azithromycin
65,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p15,0,troleandomycin,terfenadine
66,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p16,0,troleandomycin,macrolide antibiotics
67,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p17,0,troleandomycin,azithromycin
68,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p18,1,terfenadine,macrolide antibiotics
69,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p19,1,terfenadine,azithromycin
70,DDI-DrugBank.d743.s12,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",DDI-DrugBank.d743.s12.p20,0,macrolide antibiotics,azithromycin
71,DDI-DrugBank.d743.s13,Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.,DDI-DrugBank.d743.s13.p0,0,terfenadine,azithromycin
0,DDI-DrugBank.d658.s0,"When administered concurrently, testolactone may increase the effects of oral anticoagulants; ",DDI-DrugBank.d658.s0.p0,3,testolactone,anticoagulants
0,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p0,3,Thalidomide,barbiturates
1,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p1,0,Thalidomide,alcohol
2,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p2,0,Thalidomide,chlorpromazine
3,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p3,0,Thalidomide,reserpine
4,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p4,0,barbiturates,alcohol
5,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p5,0,barbiturates,chlorpromazine
6,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p6,0,barbiturates,reserpine
7,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p7,0,alcohol,chlorpromazine
8,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p8,0,alcohol,reserpine
9,DDI-DrugBank.d604.s0,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",DDI-DrugBank.d604.s0.p9,0,chlorpromazine,reserpine
10,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p0,0,Contraceptives,norethindrone
11,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p1,0,Contraceptives,ethinyl estradiol
12,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p2,0,Contraceptives,norethindrone acetate
13,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p3,0,Contraceptives,ethinyl estradiol
14,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p4,0,norethindrone,ethinyl estradiol
15,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p5,0,norethindrone,norethindrone acetate
16,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p6,0,norethindrone,ethinyl estradiol
17,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p7,0,ethinyl estradiol,norethindrone acetate
18,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p8,0,ethinyl estradiol,ethinyl estradiol
19,DDI-DrugBank.d604.s2,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",DDI-DrugBank.d604.s2.p9,0,norethindrone acetate,ethinyl estradiol
20,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p0,0,Thalidomide,Hormonal Contraceptives
21,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p1,0,Thalidomide,HIV-protease inhibitors
22,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p2,0,Thalidomide,griseofulvin
23,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p3,0,Thalidomide,modafinil
24,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p4,0,Thalidomide,penicillins
25,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p5,0,Thalidomide,rifampin
26,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p6,0,Thalidomide,rifabutin
27,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p7,0,Thalidomide,phenytoin
28,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p8,0,Thalidomide,carbamazepine
29,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p9,0,Hormonal Contraceptives,HIV-protease inhibitors
30,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p10,0,Hormonal Contraceptives,griseofulvin
31,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p11,0,Hormonal Contraceptives,modafinil
32,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p12,0,Hormonal Contraceptives,penicillins
33,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p13,0,Hormonal Contraceptives,rifampin
34,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p14,0,Hormonal Contraceptives,rifabutin
35,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p15,0,Hormonal Contraceptives,phenytoin
36,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p16,0,Hormonal Contraceptives,carbamazepine
37,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p17,0,HIV-protease inhibitors,griseofulvin
38,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p18,0,HIV-protease inhibitors,modafinil
39,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p19,0,HIV-protease inhibitors,penicillins
40,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p20,0,HIV-protease inhibitors,rifampin
41,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p21,0,HIV-protease inhibitors,rifabutin
42,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p22,0,HIV-protease inhibitors,phenytoin
43,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p23,0,HIV-protease inhibitors,carbamazepine
44,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p24,0,griseofulvin,modafinil
45,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p25,0,griseofulvin,penicillins
46,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p26,0,griseofulvin,rifampin
47,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p27,0,griseofulvin,rifabutin
48,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p28,0,griseofulvin,phenytoin
49,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p29,0,griseofulvin,carbamazepine
50,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p30,0,modafinil,penicillins
51,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p31,0,modafinil,rifampin
52,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p32,0,modafinil,rifabutin
53,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p33,0,modafinil,phenytoin
54,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p34,0,modafinil,carbamazepine
55,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p35,0,penicillins,rifampin
56,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p36,0,penicillins,rifabutin
57,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p37,0,penicillins,phenytoin
58,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p38,0,penicillins,carbamazepine
59,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p39,0,rifampin,rifabutin
60,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p40,0,rifampin,phenytoin
61,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p41,0,rifampin,carbamazepine
62,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p42,0,rifabutin,phenytoin
63,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p43,0,rifabutin,carbamazepine
64,DDI-DrugBank.d604.s4,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",DDI-DrugBank.d604.s4.p44,0,phenytoin,carbamazepine
65,DDI-DrugBank.d604.s5,John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,DDI-DrugBank.d604.s5.p0,3,John's Wort,hormonal contraceptive agents
0,DDI-DrugBank.d686.s0,"Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",DDI-DrugBank.d686.s0.p0,2,Thiabendazole,theophylline
1,DDI-DrugBank.d686.s1,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",DDI-DrugBank.d686.s1.p0,1,thiabendazole,xanthine derivatives
0,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p0,0,Vitamin B1,Thiamine
1,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p1,4,Vitamin B1,Loop Diuretics
2,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p2,4,Vitamin B1,Contraceptives
3,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p3,4,Vitamin B1,Stavudine
4,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p4,4,Vitamin B1,Tricyclic Antidepressants
5,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p5,4,Thiamine,Loop Diuretics
6,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p6,4,Thiamine,Contraceptives
7,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p7,4,Thiamine,Stavudine
8,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p8,4,Thiamine,Tricyclic Antidepressants
9,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p9,0,Loop Diuretics,Contraceptives
10,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p10,0,Loop Diuretics,Stavudine
11,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p11,0,Loop Diuretics,Tricyclic Antidepressants
12,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p12,0,Contraceptives,Stavudine
13,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p13,0,Contraceptives,Tricyclic Antidepressants
14,DDI-DrugBank.d697.s0,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",DDI-DrugBank.d697.s0.p14,0,Stavudine,Tricyclic Antidepressants
0,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p0,3,Phenothiazines,CNS depressants
1,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p1,3,Phenothiazines,barbiturates
2,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p2,3,Phenothiazines,anesthetics
3,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p3,3,Phenothiazines,opiates
4,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p4,3,Phenothiazines,alcohol
5,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p5,0,CNS depressants,barbiturates
6,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p6,0,CNS depressants,anesthetics
7,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p7,0,CNS depressants,opiates
8,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p8,0,CNS depressants,alcohol
9,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p9,0,barbiturates,anesthetics
10,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p10,0,barbiturates,opiates
11,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p11,0,barbiturates,alcohol
12,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p12,0,anesthetics,opiates
13,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p13,0,anesthetics,alcohol
14,DDI-DrugBank.d677.s0,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",DDI-DrugBank.d677.s0.p14,0,opiates,alcohol
15,DDI-DrugBank.d677.s1,as well as atropine and phosphorous insecticides.,DDI-DrugBank.d677.s1.p0,0,atropine,phosphorous insecticides
0,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p0,0,PURINETHOL,mercaptopurine
1,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p1,3,PURINETHOL,TABLOID
2,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p2,3,PURINETHOL,Thioguanine
3,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p3,3,mercaptopurine,TABLOID
4,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p4,3,mercaptopurine,Thioguanine
5,DDI-DrugBank.d722.s0,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,DDI-DrugBank.d722.s0.p5,0,TABLOID,Thioguanine
6,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p0,0,aminosalicylate derivatives,olsalazine
7,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p1,0,aminosalicylate derivatives,mesalazine
8,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p2,0,aminosalicylate derivatives,sulphasalazine
9,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p3,2,aminosalicylate derivatives,thioguanine
10,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p4,0,olsalazine,mesalazine
11,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p5,0,olsalazine,sulphasalazine
12,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p6,2,olsalazine,thioguanine
13,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p7,0,mesalazine,sulphasalazine
14,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p8,2,mesalazine,thioguanine
15,DDI-DrugBank.d722.s1,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",DDI-DrugBank.d722.s1.p9,2,sulphasalazine,thioguanine
0,DDI-DrugBank.d616.s1,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,DDI-DrugBank.d616.s1.p0,1,ZADAXIN,immunomodulating drugs
0,DDI-DrugBank.d642.s0,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,DDI-DrugBank.d642.s0.p0,1,tigecycline,warfarin
1,DDI-DrugBank.d642.s1,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,DDI-DrugBank.d642.s1.p0,3,antibacterial drugs,contraceptives
2,DDI-DrugBank.d642.s1,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,DDI-DrugBank.d642.s1.p1,0,antibacterial drugs,contraceptives
3,DDI-DrugBank.d642.s1,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,DDI-DrugBank.d642.s1.p2,0,contraceptives,contraceptives
0,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p0,2,SKELID,calcium
1,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p1,0,SKELID,calcium
2,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p2,0,SKELID,SKELID
3,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p3,0,SKELID,aluminum
4,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p4,0,SKELID,magnesium
5,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p5,0,SKELID,antacids
6,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p6,0,SKELID,SKELID
7,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p7,0,calcium,calcium
8,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p8,0,calcium,SKELID
9,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p9,0,calcium,aluminum
10,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p10,0,calcium,magnesium
11,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p11,0,calcium,antacids
12,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p12,0,calcium,SKELID
13,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p13,0,calcium,SKELID
14,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p14,0,calcium,aluminum
15,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p15,0,calcium,magnesium
16,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p16,0,calcium,antacids
17,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p17,0,calcium,SKELID
18,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p18,0,SKELID,aluminum
19,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p19,0,SKELID,magnesium
20,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p20,0,SKELID,antacids
21,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p21,0,SKELID,SKELID
22,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p22,0,aluminum,magnesium
23,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p23,0,aluminum,antacids
24,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p24,2,aluminum,SKELID
25,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p25,0,magnesium,antacids
26,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p26,2,magnesium,SKELID
27,DDI-DrugBank.d721.s0,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",DDI-DrugBank.d721.s0.p27,0,antacids,SKELID
28,DDI-DrugBank.d721.s1,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,DDI-DrugBank.d721.s1.p0,2,Aspirin,SKELID
29,DDI-DrugBank.d721.s1,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,DDI-DrugBank.d721.s1.p1,0,Aspirin,SKELID
30,DDI-DrugBank.d721.s1,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,DDI-DrugBank.d721.s1.p2,0,SKELID,SKELID
31,DDI-DrugBank.d721.s2,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,DDI-DrugBank.d721.s2.p0,2,SKELID,indomethacin
32,DDI-DrugBank.d721.s2,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,DDI-DrugBank.d721.s2.p1,0,SKELID,diclofenac
33,DDI-DrugBank.d721.s2,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,DDI-DrugBank.d721.s2.p2,0,indomethacin,diclofenac
34,DDI-DrugBank.d721.s3,The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration. ,DDI-DrugBank.d721.s3.p0,0,digoxin,SKELID
35,DDI-DrugBank.d721.s4,In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.,DDI-DrugBank.d721.s4.p0,0,tiludronate,warfarin
0,DDI-DrugBank.d702.s1,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",DDI-DrugBank.d702.s1.p0,0,sympathomimetic bronchodilators,methylxanthines
1,DDI-DrugBank.d702.s1,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",DDI-DrugBank.d702.s1.p1,0,sympathomimetic bronchodilators,steroids
2,DDI-DrugBank.d702.s1,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",DDI-DrugBank.d702.s1.p2,0,methylxanthines,steroids
3,DDI-DrugBank.d702.s2,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",DDI-DrugBank.d702.s2.p0,1,SPIRIVA,anticholinergic
4,DDI-DrugBank.d702.s2,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",DDI-DrugBank.d702.s2.p1,1,SPIRIVA,ipratropium
5,DDI-DrugBank.d702.s2,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",DDI-DrugBank.d702.s2.p2,0,anticholinergic,ipratropium
0,DDI-DrugBank.d751.s0,AGGRASTAT has been studied on a background of aspirin and heparin. ,DDI-DrugBank.d751.s0.p0,0,AGGRASTAT,aspirin
1,DDI-DrugBank.d751.s0,AGGRASTAT has been studied on a background of aspirin and heparin. ,DDI-DrugBank.d751.s0.p1,0,AGGRASTAT,heparin
2,DDI-DrugBank.d751.s0,AGGRASTAT has been studied on a background of aspirin and heparin. ,DDI-DrugBank.d751.s0.p2,0,aspirin,heparin
3,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p0,3,AGGRASTAT,heparin
4,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p1,3,AGGRASTAT,aspirin
5,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p2,0,AGGRASTAT,heparin
6,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p3,0,AGGRASTAT,aspirin
7,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p4,0,heparin,aspirin
8,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p5,0,heparin,heparin
9,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p6,0,heparin,aspirin
10,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p7,0,aspirin,heparin
11,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p8,0,aspirin,aspirin
12,DDI-DrugBank.d751.s1,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",DDI-DrugBank.d751.s1.p9,0,heparin,aspirin
0,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p0,0,TOBI,TOBI
1,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p1,0,TOBI,dornase alfa
2,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p2,0,TOBI,PULMOZYME
3,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p3,0,TOBI,(beta)-agonists
4,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p4,0,TOBI,corticosteroids
5,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p5,0,TOBI,anti-pseudomonal antibiotics
6,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p6,0,TOBI,aminoglycosides
7,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p7,3,TOBI,dornase alfa
8,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p8,3,TOBI,PULMOZYME
9,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p9,3,TOBI,(beta)-agonists
10,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p10,3,TOBI,corticosteroids
11,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p11,3,TOBI,anti-pseudomonal antibiotics
12,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p12,3,TOBI,aminoglycosides
13,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p13,0,dornase alfa,PULMOZYME
14,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p14,0,dornase alfa,(beta)-agonists
15,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p15,0,dornase alfa,corticosteroids
16,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p16,0,dornase alfa,anti-pseudomonal antibiotics
17,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p17,0,dornase alfa,aminoglycosides
18,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p18,0,PULMOZYME,(beta)-agonists
19,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p19,0,PULMOZYME,corticosteroids
20,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p20,0,PULMOZYME,anti-pseudomonal antibiotics
21,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p21,0,PULMOZYME,aminoglycosides
22,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p22,0,(beta)-agonists,corticosteroids
23,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p23,0,(beta)-agonists,anti-pseudomonal antibiotics
24,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p24,0,(beta)-agonists,aminoglycosides
25,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p25,0,corticosteroids,anti-pseudomonal antibiotics
26,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p26,0,corticosteroids,aminoglycosides
27,DDI-DrugBank.d624.s0,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",DDI-DrugBank.d624.s0.p27,0,anti-pseudomonal antibiotics,aminoglycosides
28,DDI-DrugBank.d624.s2,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,DDI-DrugBank.d624.s2.p0,3,diuretics,aminoglycoside
29,DDI-DrugBank.d624.s2,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,DDI-DrugBank.d624.s2.p1,0,diuretics,antibiotic
30,DDI-DrugBank.d624.s2,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,DDI-DrugBank.d624.s2.p2,0,aminoglycoside,antibiotic
31,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p0,1,TOBI,ethacrynic acid
32,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p1,1,TOBI,furosemide
33,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p2,1,TOBI,urea
34,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p3,1,TOBI,mannitol
35,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p4,0,ethacrynic acid,furosemide
36,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p5,0,ethacrynic acid,urea
37,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p6,0,ethacrynic acid,mannitol
38,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p7,0,furosemide,urea
39,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p8,0,furosemide,mannitol
40,DDI-DrugBank.d624.s3,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",DDI-DrugBank.d624.s3.p9,0,urea,mannitol
0,DDI-DrugBank.d608.s0,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",DDI-DrugBank.d608.s0.p0,0,warfarin,tolmetin
1,DDI-DrugBank.d608.s0,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",DDI-DrugBank.d608.s0.p1,0,warfarin,tolmetin
2,DDI-DrugBank.d608.s0,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",DDI-DrugBank.d608.s0.p2,0,tolmetin,tolmetin
3,DDI-DrugBank.d608.s1,"However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ",DDI-DrugBank.d608.s1.p0,3,TOLECTIN,warfarin
4,DDI-DrugBank.d608.s2,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",DDI-DrugBank.d608.s2.p0,1,TOLECTIN,anticoagulants
5,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p0,0,sulfonylureas,insulin
6,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p1,0,sulfonylureas,TOLECTIN
7,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p2,0,sulfonylureas,hypoglycemic agents
8,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p3,0,insulin,TOLECTIN
9,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p4,0,insulin,hypoglycemic agents
10,DDI-DrugBank.d608.s3,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,DDI-DrugBank.d608.s3.p5,0,TOLECTIN,hypoglycemic agents
11,DDI-DrugBank.d608.s4,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,DDI-DrugBank.d608.s4.p0,1,TOLECTIN,methotrexate
12,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p0,0,TOLECTIN,nonsteroidal anti-inflammatory drugs
13,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p1,2,TOLECTIN,methotrexate
14,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p2,0,TOLECTIN,methotrexate
15,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p3,2,nonsteroidal anti-inflammatory drugs,methotrexate
16,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p4,0,nonsteroidal anti-inflammatory drugs,methotrexate
17,DDI-DrugBank.d608.s5,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",DDI-DrugBank.d608.s5.p5,0,methotrexate,methotrexate
0,DDI-DrugBank.d765.s0,"CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",DDI-DrugBank.d765.s0.p0,2,Ketoconazole,tolterodine
1,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p0,0,ketoconazole,azole antifungals
2,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p1,0,ketoconazole,itraconazole
3,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p2,0,ketoconazole,miconazole
4,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p3,0,ketoconazole,macrolide antibiotics
5,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p4,0,ketoconazole,erythromycin
6,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p5,0,ketoconazole,clarithromycin
7,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p6,0,ketoconazole,cyclosporine
8,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p7,0,ketoconazole,vinblastine
9,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p8,1,ketoconazole,DETROL LA
10,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p9,0,azole antifungals,itraconazole
11,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p10,0,azole antifungals,miconazole
12,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p11,0,azole antifungals,macrolide antibiotics
13,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p12,0,azole antifungals,erythromycin
14,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p13,0,azole antifungals,clarithromycin
15,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p14,0,azole antifungals,cyclosporine
16,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p15,0,azole antifungals,vinblastine
17,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p16,1,azole antifungals,DETROL LA
18,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p17,0,itraconazole,miconazole
19,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p18,0,itraconazole,macrolide antibiotics
20,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p19,0,itraconazole,erythromycin
21,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p20,0,itraconazole,clarithromycin
22,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p21,0,itraconazole,cyclosporine
23,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p22,0,itraconazole,vinblastine
24,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p23,1,itraconazole,DETROL LA
25,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p24,0,miconazole,macrolide antibiotics
26,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p25,0,miconazole,erythromycin
27,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p26,0,miconazole,clarithromycin
28,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p27,0,miconazole,cyclosporine
29,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p28,0,miconazole,vinblastine
30,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p29,1,miconazole,DETROL LA
31,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p30,0,macrolide antibiotics,erythromycin
32,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p31,0,macrolide antibiotics,clarithromycin
33,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p32,0,macrolide antibiotics,cyclosporine
34,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p33,0,macrolide antibiotics,vinblastine
35,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p34,1,macrolide antibiotics,DETROL LA
36,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p35,0,erythromycin,clarithromycin
37,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p36,0,erythromycin,cyclosporine
38,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p37,0,erythromycin,vinblastine
39,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p38,1,erythromycin,DETROL LA
40,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p39,0,clarithromycin,cyclosporine
41,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p40,0,clarithromycin,vinblastine
42,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p41,1,clarithromycin,DETROL LA
43,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p42,0,cyclosporine,vinblastine
44,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p43,1,cyclosporine,DETROL LA
45,DDI-DrugBank.d765.s1,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",DDI-DrugBank.d765.s1.p44,1,vinblastine,DETROL LA
0,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p0,2,paclitaxel,HERCEPTIN
1,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p1,0,paclitaxel,HERCEPTIN
2,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p2,0,paclitaxel,HERCEPTIN
3,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p3,0,HERCEPTIN,HERCEPTIN
4,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p4,0,HERCEPTIN,HERCEPTIN
5,DDI-DrugBank.d712.s1,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,DDI-DrugBank.d712.s1.p5,0,HERCEPTIN,HERCEPTIN
0,DDI-DrugBank.d774.s0,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,DDI-DrugBank.d774.s0.p0,4,Trilostane,aminoglutethimide
1,DDI-DrugBank.d774.s0,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,DDI-DrugBank.d774.s0.p1,4,Trilostane,mitotane
2,DDI-DrugBank.d774.s0,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,DDI-DrugBank.d774.s0.p2,0,aminoglutethimide,mitotane
0,DDI-DrugBank.d598.s0,Trimethoprim may inhibit the hepatic metabolism of phenytoin. ,DDI-DrugBank.d598.s0.p0,2,Trimethoprim,phenytoin
1,DDI-DrugBank.d598.s1,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",DDI-DrugBank.d598.s1.p0,2,Trimethoprim,phenytoin
2,DDI-DrugBank.d598.s1,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",DDI-DrugBank.d598.s1.p1,2,Trimethoprim,phenytoin
3,DDI-DrugBank.d598.s1,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",DDI-DrugBank.d598.s1.p2,0,phenytoin,phenytoin
0,DDI-DrugBank.d766.s0,"Since trimetrexate is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations. ",DDI-DrugBank.d766.s0.p0,0,trimetrexate,trimetrexate
1,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p0,3,trimetrexate,erythromycin
2,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p1,3,trimetrexate,rifampin
3,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p2,3,trimetrexate,rifabutin
4,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p3,3,trimetrexate,ketoconazole
5,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p4,3,trimetrexate,fluconazole
6,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p5,0,erythromycin,rifampin
7,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p6,0,erythromycin,rifabutin
8,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p7,0,erythromycin,ketoconazole
9,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p8,0,erythromycin,fluconazole
10,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p9,0,rifampin,rifabutin
11,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p10,0,rifampin,ketoconazole
12,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p11,0,rifampin,fluconazole
13,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p12,0,rifabutin,ketoconazole
14,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p13,0,rifabutin,fluconazole
15,DDI-DrugBank.d766.s1,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ",DDI-DrugBank.d766.s1.p14,0,ketoconazole,fluconazole
16,DDI-DrugBank.d766.s2,In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,DDI-DrugBank.d766.s2.p0,2,cimetidine,trimetrexate
17,DDI-DrugBank.d766.s2,In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,DDI-DrugBank.d766.s2.p1,0,cimetidine,acetaminophen
18,DDI-DrugBank.d766.s2,In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,DDI-DrugBank.d766.s2.p2,0,trimetrexate,acetaminophen
19,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p0,0,imidazole drugs,clotrimazole
20,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p1,0,imidazole drugs,ketoconazole
21,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p2,0,imidazole drugs,miconazole
22,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p3,2,imidazole drugs,trimetrexate
23,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p4,0,clotrimazole,ketoconazole
24,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p5,0,clotrimazole,miconazole
25,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p6,2,clotrimazole,trimetrexate
26,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p7,0,ketoconazole,miconazole
27,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p8,2,ketoconazole,trimetrexate
28,DDI-DrugBank.d766.s3,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",DDI-DrugBank.d766.s3.p9,2,miconazole,trimetrexate
0,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p0,3,Triprolidine,central nervous system depressants
1,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p1,3,Triprolidine,alcohol
2,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p2,3,Triprolidine,barbiturates
3,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p3,3,Triprolidine,hypnotics
4,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p4,3,Triprolidine,narcotic analgesics
5,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p5,3,Triprolidine,sedatives
6,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p6,3,Triprolidine,tranquillisers
7,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p7,0,central nervous system depressants,alcohol
8,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p8,0,central nervous system depressants,barbiturates
9,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p9,0,central nervous system depressants,hypnotics
10,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p10,0,central nervous system depressants,narcotic analgesics
11,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p11,0,central nervous system depressants,sedatives
12,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p12,0,central nervous system depressants,tranquillisers
13,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p13,0,alcohol,barbiturates
14,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p14,0,alcohol,hypnotics
15,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p15,0,alcohol,narcotic analgesics
16,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p16,0,alcohol,sedatives
17,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p17,0,alcohol,tranquillisers
18,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p18,0,barbiturates,hypnotics
19,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p19,0,barbiturates,narcotic analgesics
20,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p20,0,barbiturates,sedatives
21,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p21,0,barbiturates,tranquillisers
22,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p22,0,hypnotics,narcotic analgesics
23,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p23,0,hypnotics,sedatives
24,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p24,0,hypnotics,tranquillisers
25,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p25,0,narcotic analgesics,sedatives
26,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p26,0,narcotic analgesics,tranquillisers
27,DDI-DrugBank.d615.s0,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",DDI-DrugBank.d615.s0.p27,0,sedatives,tranquillisers
28,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p0,0,anticholinergic drugs,atropine
29,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p1,0,anticholinergic drugs,tricyclic antidepressants
30,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p2,3,anticholinergic drugs,triprolidine
31,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p3,0,atropine,tricyclic antidepressants
32,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p4,3,atropine,triprolidine
33,DDI-DrugBank.d615.s1,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",DDI-DrugBank.d615.s1.p5,3,tricyclic antidepressants,triprolidine
0,DDI-DrugBank.d713.s0,"The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",DDI-DrugBank.d713.s0.p0,3,Sanctura,anticholinergic agents
1,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p0,0,Sanctura,Sanctura
2,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p1,0,Sanctura,digoxin
3,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p2,0,Sanctura,procainamide
4,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p3,0,Sanctura,pancuronium
5,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p4,0,Sanctura,morphine
6,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p5,0,Sanctura,vancomycin
7,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p6,0,Sanctura,metformin
8,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p7,0,Sanctura,tenofovir
9,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p8,2,Sanctura,digoxin
10,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p9,2,Sanctura,procainamide
11,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p10,2,Sanctura,pancuronium
12,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p11,2,Sanctura,morphine
13,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p12,2,Sanctura,vancomycin
14,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p13,2,Sanctura,metformin
15,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p14,2,Sanctura,tenofovir
16,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p15,0,digoxin,procainamide
17,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p16,0,digoxin,pancuronium
18,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p17,0,digoxin,morphine
19,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p18,0,digoxin,vancomycin
20,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p19,0,digoxin,metformin
21,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p20,0,digoxin,tenofovir
22,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p21,0,procainamide,pancuronium
23,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p22,0,procainamide,morphine
24,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p23,0,procainamide,vancomycin
25,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p24,0,procainamide,metformin
26,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p25,0,procainamide,tenofovir
27,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p26,0,pancuronium,morphine
28,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p27,0,pancuronium,vancomycin
29,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p28,0,pancuronium,metformin
30,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p29,0,pancuronium,tenofovir
31,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p30,0,morphine,vancomycin
32,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p31,0,morphine,metformin
33,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p32,0,morphine,tenofovir
34,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p33,0,vancomycin,metformin
35,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p34,0,vancomycin,tenofovir
36,DDI-DrugBank.d713.s2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",DDI-DrugBank.d713.s2.p35,0,metformin,tenofovir
37,DDI-DrugBank.d713.s3,Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. ,DDI-DrugBank.d713.s3.p0,0,Sanctura,Sanctura
0,DDI-DrugBank.d669.s0,Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,DDI-DrugBank.d669.s0.p0,3,vancomycin,anesthetic agents
1,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p0,0,amphotericin B,aminoglycosides
2,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p1,0,amphotericin B,bacitracin
3,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p2,0,amphotericin B,polymyxin B
4,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p3,0,amphotericin B,colistin
5,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p4,0,amphotericin B,viomycin
6,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p5,0,amphotericin B,cisplatin
7,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p6,0,aminoglycosides,bacitracin
8,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p7,0,aminoglycosides,polymyxin B
9,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p8,0,aminoglycosides,colistin
10,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p9,0,aminoglycosides,viomycin
11,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p10,0,aminoglycosides,cisplatin
12,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p11,0,bacitracin,polymyxin B
13,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p12,0,bacitracin,colistin
14,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p13,0,bacitracin,viomycin
15,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p14,0,bacitracin,cisplatin
16,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p15,0,polymyxin B,colistin
17,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p16,0,polymyxin B,viomycin
18,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p17,0,polymyxin B,cisplatin
19,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p18,0,colistin,viomycin
20,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p19,0,colistin,cisplatin
21,DDI-DrugBank.d669.s1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",DDI-DrugBank.d669.s1.p20,0,viomycin,cisplatin
0,DDI-DrugBank.d613.s0,A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ,DDI-DrugBank.d613.s0.p0,2,vigabatrin,carbamazepine
1,DDI-DrugBank.d613.s1,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",DDI-DrugBank.d613.s1.p0,2,vigabatrin,phenytoin
2,DDI-DrugBank.d613.s1,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",DDI-DrugBank.d613.s1.p1,0,vigabatrin,phenytoin
3,DDI-DrugBank.d613.s1,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",DDI-DrugBank.d613.s1.p2,0,phenytoin,phenytoin
0,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p0,4,Vindesine,Phenytoin
1,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p1,4,Vindesine,Live virus vaccines
2,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p2,0,Vindesine,vaccine
3,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p3,4,Vindesine,Mitomycin-C
4,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p4,4,Vindesine,Killed virus vaccines
5,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p5,0,Vindesine,vaccine
6,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p6,0,Phenytoin,Live virus vaccines
7,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p7,0,Phenytoin,vaccine
8,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p8,0,Phenytoin,Mitomycin-C
9,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p9,0,Phenytoin,Killed virus vaccines
10,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p10,0,Phenytoin,vaccine
11,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p11,0,Live virus vaccines,vaccine
12,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p12,0,Live virus vaccines,Mitomycin-C
13,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p13,0,Live virus vaccines,Killed virus vaccines
14,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p14,0,Live virus vaccines,vaccine
15,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p15,0,vaccine,Mitomycin-C
16,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p16,0,vaccine,Killed virus vaccines
17,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p17,0,vaccine,vaccine
18,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p18,0,Mitomycin-C,Killed virus vaccines
19,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p19,0,Mitomycin-C,vaccine
20,DDI-DrugBank.d782.s0,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",DDI-DrugBank.d782.s0.p20,0,Killed virus vaccines,vaccine
0,DDI-DrugBank.d651.s0,Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.,DDI-DrugBank.d651.s0.p0,2,contraceptives,vitamin A
0,DDI-DrugBank.d759.s0,Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.,DDI-DrugBank.d759.s0.p0,2,ascorbic acid,bishydroxycoumarin
0,DDI-DrugBank.d769.s0,Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. ,DDI-DrugBank.d769.s0.p0,0,Coumarin-Derivative Anticoagulants,ZOLINZA
1,DDI-DrugBank.d769.s0,Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. ,DDI-DrugBank.d769.s0.p1,0,Coumarin-Derivative Anticoagulants,coumarin-derivative anticoagulants
2,DDI-DrugBank.d769.s0,Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. ,DDI-DrugBank.d769.s0.p2,3,ZOLINZA,coumarin-derivative anticoagulants
3,DDI-DrugBank.d769.s1,Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives. ,DDI-DrugBank.d769.s1.p0,1,ZOLINZA,coumarin derivatives
4,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p0,0,HDAC Inhibitors,ZOLINZA
5,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p1,0,HDAC Inhibitors,HDAC inhibitors
6,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p2,0,HDAC Inhibitors,valproic acid
7,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p3,3,ZOLINZA,HDAC inhibitors
8,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p4,3,ZOLINZA,valproic acid
9,DDI-DrugBank.d769.s2,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ",DDI-DrugBank.d769.s2.p5,0,HDAC inhibitors,valproic acid
